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Abstract 
O’Connor, P.L. The Effect Of Acute And Chronic Exercise On Circulating Microparticles 
Microparticles (MPs) are small membrane vesicles shed from plasma membranes 
following cell activation or apoptosis.  They are released from a variety of cells 
including endothelial cells, smooth muscle cells, platelets, leukocytes, and 
erythrocytes.  MPs are produced in a healthy state, however changes in the number 
and composition of MPs are associated with many disease states, including 
cardiovascular disease (CVD), venous thrombosis, diabetes mellitus, rheumatic disease 
and other inflammatory states.  MPs may be used as a marker of dysfunction in many 
of these disease states.  Exercise has been shown to have a positive effect on many of 
these disease states with MPs a possible biomarker of improvement. 
Study 1: This study examined the effect of isocaloric bouts of exercise at 60%, 70% and 
80%   O2max on circulating levels of MPs in healthy young men.  There was a 
significant increase in mean numbers of circulating endothelial MPs (EMPs) 6 h 
following each bout.  Compared to baseline circulating platelet MPs (PMPs) did not 
increase during any of the acute bouts of exercise. 
Study 2: This study examined the effect of 14 consecutive days of aerobic exercise on 
circulating MPs.  There was no difference in circulating EMPs before exercise, 
immediately after exercise and 13 h following exercise on day 1, 3, 7, 10 and 14 of the 
training program.  Circulating EMPs were significantly decreased 13 h following 
training compared to immediately post training.  There were no changes in platelet MP 
numbers.  There was no correlation between aerobic fitness and circulating MP 
numbers 
Study 3: This study examined the effect of 4 weeks of low-volume, short duration high-
intensity interval training (LS-HIIT) and cardiac rehabilitation on circulating MPs in 
individuals with CVD.  There were no changes in MP numbers in either group following 
the exercise intervention.  Flow-mediated dilation was significantly higher in the LS-
HIIT group than the cardiac rehabilitation group following the exercise intervention 
Conclusions:  EMPs increase following an acute bout of isocaloric exercise at 60%, 70% 
and 80%   O2max in healthy young trained men.  Aerobic exercise training for 14 
consecutive days elicits a significant increase in aerobic fitness. Circulating EMPs 
decrease 13 h following training.  Endothelial function is significantly improved and 
circulating MPs are unchanged in men and women with CVD following 8 sessions of LS-
HIIT.  There were no changes in circulating PMP numbers in response to acute or 
chronic exercise.   
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Chapter I 
Introduction 
Microparticles (MPs) are submicron vesicles shed from the plasma membrane 
of a variety of cells in response to a number of conditions including cell activation, 
injury, and/or apoptosis.1  They were initially identified as membrane fragments from 
platelets and called ‘platelet dust’.  It was discovered that this ‘dust’ had procoagulant 
activity similar to the platelets from which they formed.2  Since then it has become 
apparent that MPs are released from many cell types including endothelial cells, 
monocytes, red blood cells and granulocytes.3  Remodelling of the plasma lipid 
membrane during their formation results in MPs containing glycoproteins, 
phospholipids and cytoplasmic components from their parental cell.4   
Circulating MPs from a variety of cells are present in healthy individuals but 
their number and composition change in various disease states.  Increased circulating 
MP numbers have been found in individuals with diabetes, kidney disease, 
inflammatory diseases and, in particular, cardiovascular disease (CVD).5  Furthermore, 
increased endothelial MPs (EMPs) and platelets MPs (PMPs) are linked to 
hypertension, hypercholesterolemia, obesity, coronary artery disease, peripheral 
artery disease, acute coronary syndromes and CVD.6  MPs have recently been 
proposed as a novel biomarker of cardiovascular disease and have been linked to 
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established biomarkers.  A number of studies have found a significant relation 
between circulating MPs and IL-6, adhesion molecules and blood pressure.7-9 
Acute and chronic exercise has many well documented positive effects on 
processes associated with CVD such as aerobic fitness, obesity, hypertension, 
inflammation, coagulation and endothelial function.10,11  To date, relatively few studies 
have evaluated the effect of acute or chronic exercise on circulating MP numbers. 
Furthermore, no studies have evaluated the relation between MPs and endothelial 
function in men and women with CVD. 
Purpose 
The purpose of the following series of studies is to determine the acute and 
chronic effects of exercise on circulating MP numbers, and evaluate the relation 
between endothelial function and circulating MPs before and after training in men and 
women with CVD. 
Objectives 
1. To determine the acute effects of isocaloric bouts of exercise at different 
intensities on circulating MP formation in young healthy men 
2. To determine the effects of exercise training on circulating MP numbers in young 
healthy men  
3 
 
3. To examine the relation between circulating MPs and aerobic fitness and 
endothelial function before and after training in men and women with CVD 
Null Hypotheses 
1. There will be no significant difference in circulating levels of MPs following 
isocaloric bouts of exercise at 60%, 70%, and 80%   O2max in healthy young 
physically active men 
2. There will be no difference in circulating MP numbers pre-exercise, immediately 
following 1 h of exercise at 80%   O2peak and 13 h following exercise on days 1, 3, 
7, 10 and 14 of a 14 day training program 
3. Circulating levels of MPs will not change significantly following 4 weeks of LS-HIIT 
or CR in individuals with CVD and there will be no relation between MPs and 
endothelial function before or after training 
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Chapter II 
Review of Literature 
Microparticles 
Microparticles (MPs) are small membrane vesicles ranging in size from 0.2 µm 
to 1.0 µm that are shed from plasma membranes following cell activation or apoptosis.  
They are released from a variety of cells including endothelial cells, smooth muscle 
cells, platelets, leukocytes, lymphocytes and erythrocytes.2  Originally considered as 
‘cell dust’ MPs are now known to play a significant role in cellular activity.12  Although 
MPs are produced in a healthy state changes in their number and composition are 
associated with a number of disease states, including cardiovascular disease (CVD), 
venous thrombosis, diabetes mellitus, sickle cell disease, rheumatic disease and other 
inflammatory states. 1,2,13,14 
Microparticle Formation 
Triggers for cell activation and apoptosis include chemical stimuli, cytokines 
such as TNF-α and IL-6, thrombin and endotoxin and physical stimuli such as sheer 
stress and hypoxia.2  Chemical and physical stimuli lead to changes in the structure of 
the cell membrane cytoskeleton which ultimately results in the release of MPs (Figure 
2.1).  MP formation is reliant on a rise in cytosolic calcium concentration with 
consequent activation of calpain, protein kinases and phosphatase inhibition.15 
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Figure 2.1: MP formation16 
Cell Membrane Physiology 
Cell membranes define the boundaries of the cells and serve as a permeability 
barrier.  They regulate the movement of ions, gases and water, into and out of the cell 
and provide a surface for communication between cells and are involved in energy 
transduction.17,18 
Cell Membrane Structure 
Cell membranes are composed of a lipid bilayer with embedded globular 
proteins.  On the external surface, carbohydrate groups join with lipids to form 
glycolipids, and with proteins to form glycoproteins.   
6 
 
Phospholipids are the most abundant of the membrane lipids and are normally 
glycerol based phosphoglycerides or sphingosine based sphingolipids.  
Phosphoglycerides are derived from phosphatidic acid, a molecule of diacylglycerol 
with a phosphate group esterified to the hydroxy group on the third carbon.  The 
phosphate group esterified to carbon 3 is linked to small charged or polar compounds 
including choline (phosphatidylcholine - PC), serine (phosphatidylserine - PS), 
ethanolamine (phosphatidylethanolamine - PE) and inositol (phosphatidylinositol - PI).  
In the body, the polar head regions of the phosphoglycerides face towards the 
aqueous environment and the hydrophobic fatty acyl chains face inwards (Figure 2.2). 
In healthy humans approximately 60% of the phospholipid membrane is PC with the 
remainder PS, PE and sphingomyelin.  Also present in the cell membrane are 
glycolipids and sterols.  Cholesterol is the principle sterol found in animal cell 
membranes. 
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Figure 2.2: Lipid bilayer showing the hydrophilic polar heads and the hydrophobic fatty 
acyl chain  
Membrane proteins can be grouped into i) integral proteins, ii) peripheral 
proteins and iii) lipid-anchored proteins.  Integral proteins are transmembrane 
proteins and are involved in the transport of ions, solutes and electrons across the 
membrane.  Peripheral proteins are located on the surface of the cell membrane on 
both the intra and extra-cellular surface. (Figure 2.3)17  Peripheral proteins on the 
intracellular surface can form a fibrillar network that acts as a membrane skeleton. 
(Figure 2.4)17  Common peripheral proteins in human cell membranes include spectrin, 
actin and tropomyosin.  Lipid-anchored proteins can be found on the intra and extra-
cellular surface of the cell membrane.  
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Figure 2.3: Cell membrane showing the lipids and proteins present and demonstrating 
the lipid bilayer. 
Figure 2.4: Cell membrane of a RBC showing the peripheral proteins spectrin, actin and 
tropomyosin forming the membrane skeleton. 
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Microparticle Physiology 
The external membrane layer of eukaryotic cells involved in MP formation 
consists of PC and sphingomyelin and the internal layer consists of PS and PE.  Under 
normal conditions the distribution of the lipids in the external and internal membrane 
layers is tightly controlled by ATP-dependant enzymes. 4   
An inward directed flippase, outward-directed floppase pump and a lipid 
scramblase control the transbilayer lipid distribution.19 (Figure 2.5) The flippase, known 
as aminophospholipid translocase, is specific for PS and PE and rapidly conveys them 
from the outer to the inner leaflet maintaining lipid asymmetry.  Floppase, a member 
of the ABC transporter family, reorganizes phospholipids so that PC and sphingomyelin 
are the dominant species in the outer lipid bilayer.  Scramblase, which is ATP-
independent but calcium-dependent, facilitates bidirectional movement of 
phospholipids between the lipid bilayers. 4   
Cell-Activated Microparticle Formation 
The release of cell activation-associated MPs is time-and calcium-dependant.  
MP formation starts within minutes of an agonist binding to the cell.  Cell activation 
results in an immediate increase in cytosolic calcium concentration.2  Cell stimulation 
leading to substantial and continued increases in cytosolic calcium concentration may 
lead to the collapse of the membrane asymmetry.  Cytosolic calcium influx inhibits 
flippase activity while stimulating scramblase and floppase activities (figure 2.5).20  This 
10 
 
leads to changes in the distribution of lipids in the membrane bilayer with surface PS 
exposure and the formation of MPs. 19 
 
Figure 2.5. Flippase, floppase and scramblase activity  
A – Resting cell membrane with low cytoplasmic concentration and active flippase.  B – Cell activation 
leading to an increase in cytoplasmic calcium which inhibits flippase and activates floppase and 
scramblase.  This leads to a loss of membrane asymmetry and the formation of microparticles. 
Cytosolic calcium influx is also linked to cytoskeleton degradation associated 
with cell apoptosis.21  The intracellular cytoskeleton is formed by a network of 
structural proteins which control the membrane asymmetry and cell stability via 
covalent protein to protein and protein to lipid interactions.  Spectrin is a 
submembrane skeletal protein that connects lipids with actin cytoskeleton through 
vertical and lateral connections.  During the movement of membrane phospholipids 
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these covalent links are disrupted leading to abolishment of the spectrin anchorage 
which in turns leads to membrane budding and MP formation.4 
Cytoplasmic caspases and calpains also contribute to cytoskeleton 
reorganisation.  These calcium dependent thiol proteases facilitate vesiculation of the 
cell surface by cleavage of talin, filamin and gelsolin, proteins involved in the assembly 
and structure of actin. (Figure 2.6)20    Caspase-3 plays a major role in cytoskeleton 
reorganisation by mediating the cleavage of ROCK I phosphorylating myosin light chain 
resulting in cell membrane contraction, shrinkage and MP release.  Independent of cell 
death, another rho-kinase isoform, ROCK II is activated by caspase-2 following 
endothelial cell stimulation by thrombin and is involved in MP release. 21 
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Figure 2.6: Role of calcium in microparticle formation.  
An increase in cytoplasmic calcium results in actin cleavage and the rearrangement of the cell 
membrane resulting in the blebbing of MPs. 
Microparticle Structure 
MP membranes consist primarily of lipids and proteins.  The number and type 
of lipids and proteins depends on the cellular origin of the MPs and the process which 
triggers their formation.  Endothelial cells release phenotypically and quantitatively 
distinct endothelial microparticles (EMPs) depending on whether they are formed in 
response to cell activation or apoptosis. 22  The membranes of MPs isolated from the 
synovial fluid of patients with rheumatoid arthritis differ from the membrane of MPs 
taken from healthy individuals.23   
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MPs are surrounded by a phospholipid membrane bilayer similar to their 
parent cell.  However, unlike their parent cell, the outer membrane contains PS and PE.  
In the resting cells of healthy individuals these phospholipids are contained in the inner 
lipid membrane.   
Proteins contained in MPs originate from their cell of origin and can emanate 
from the cell surface or from intracellular bodies that are up-regulated or translocated 
by cell activation.  PMPs contain P-selectin and glycoprotein 53 that originate from 
intracellular granule membranes.  T-cell derived MPs also display glycoprotein 53 from 
endocytic origin.2  PMPs also contain glycoproteins 1b (CD42b) and platelet-
endothelium adhesion molecule-1 (PECAM-1) (CD31).  MPs from erythrocytes stain for 
glycophorine A, MPs from granulocytes stain for CD66 and EMPs stain for CD31, CD34, 
CD51, CD62E and CD146. 24   
In addition to identifying the parent cell, the phospholipid and protein content 
can also distinguish between activation derived and apoptosis derived MP formation.  
Endothelial cells have been found in vitro to release phenotypically different MPs in 
response to activation and apoptosis.  Activation of endothelial cells increases MPs 
expressing inducible markers, including CD54, CD62E and CD106.  In contrast, 
endothelial cell apoptosis results in microparticles expressing CD31 and CD105. 22  
Endothelial cell lines from renal microvasculature, brain microvasculature and 
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coronary artery microvasculature also show different responses to cell activation and 
apoptosis.  
Microparticle Measurement 
Several different methodological approaches have been used to measure MP 
including flow cytometry, electron-microscopy, enzyme-linked immunosorbent assay 
(ELISA)24 and solid-phase capture.25  There is currently no universally accepted 
standard method for the analysis of MPs although there now seems to be a concerted 
effort to seek agreement on a standard protocol. 26,27  Major differences currently exist 
in sample preparation, total MP detection and antigenic markers used. 28  The use of a 
wide variety of methodologies has made it difficult to directly compare results which 
sometimes have inconsistent or conflicting outcomes.  Table 2.1 highlights six methods 
used to measure MPs from laboratories with established research programs on the 
topic. 
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Table 2.1: Methods of MP Measurement  
     Cell-specific 
Identification 
Cell Origin 
 Principle 
Technique 
Quantitation Anti-
coagulant 
Prepare 
PPP 
Isolation 
MP 
pellet 
Generic MP 
detection 
Platelet Endothelial Leukocyte 
Biro et al. 29 
FC Counts Citrate 1550 x g 
20 min 
1800 xg, 
30 min 
Annexin V CD62P, 
CD61, CD63 
CD31, CD62E 
or CD144 
CD4, CD8 
Dignat-George 
et al. 30 
FC Counts  Citrate 1500 x g 
15 min 
13000 x g 
2 min 
    - Annexin V CD CD51, CD144 
or CD146 
CD45 
Hugal et al. 25  
SPC Prothromb-
inase 
capture 
Citrate 1500 x g 
15 min 
13000 x g 
2 min 
    - Annexin V, 
tissue 
factor 
CD62P or 
GPIba 
CD31 or 
CD62E 
CD45 
Jimenez et al. 
31 
FC Counts  Citrate 200 x g 
10min 
1500 x g 
7 min 
     -      - CD41 or 
CD42b & 
CD31 
CD31+/CD42- 
or CD62E 
CD45 
Nomura 32 
ELISA  Standard 
PMP 
EDTA 100 x g 
20min 
     -      - GP IX 
(capture) 
CD62P, 
CD40L 
          - - 
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Shet et al. 33 
FC Counts Citrate 1300 x g, 
10min 
100000 x 
g, 60min  
Annexin V CD41a CD144 CD14 
(monocyte) 
FC, flow cytometry; SPC, solid phase capture
17 
 
Sample Preparation 
There is currently large inter-laboratory variation (Table 2.1) in sample 
preparation procedures.  To avoid endothelial or platelet damage and activation it is 
recommended that venous blood samples are collected into a tube containing 
anticoagulant using a needle ≥ 21-gauge and within 1 min of placing a tourniquet.  
Citrate is the most commonly used anticoagulant.  However, EDTA and heparin have 
also been used in a number of studies.  The first 3 ml of blood should be discarded to 
avoid contamination from the application of the tourniquet.  The sample is gently 
mixed with the anticoagulant and vigorous shaking is avoided in order to avoid MP 
activation.  The cellular elements of the blood are separated from the plasma 
containing MPs using centrifugation.  The time between blood sampling and 
centrifugation has ranged from 15 min to 2 h.26,28,34  Circulating MP levels are more 
than double in blood samples that are left for 2 h before centrifugation compared to 
samples that are immediately processed.27  
There is also a large variation in the centrifugation protocol (Table 2.1).  A two-
step centrifugation is recommended but the angular velocity measured in revolutions 
per minute (RPM), or acceleration expressed as g speeds vary greatly.  Following the 
first spin the supernatant is removed, leaving the bottom 200-500 µl of undisturbed 
supernatant.  This supernatant is referred to as ‘platelet-rich plasma’ (PRP).  The same 
centrifugation procedure is repeated and the final 200-500 µl of undisturbed 
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supernatant is referred to as ‘platelet-poor plasma’ (PPP).  The PPP is immediately 
analysed or frozen.  Some investigators snap freeze the PPP in liquid nitrogen and 
store it at -80oC while others just freeze the PPP at -80oC.  Samples have been thawed 
on ice or at 37oC prior to analysis.8  Biro et al., (2004) recommend snap freezing and 
thawing on melting ice to ensure the best possible preservation of MP structure and 
function. 29  Another variation involves freezing the plasma after the first spin cycle.  
This plasma is then thawed at 37oC before analysis and centrifuged at 17000 x g 
resulting in a MP pellet.  The supernatant is removed and the MP pellet is 
reconstituted in Annexin V buffer to be analysed. 34 
Flow cytometry uses an optical-to-electronic coupling system to simultaneously 
measure multiple physical characteristics of cells, as they flow in a fluid stream through 
a beam of light (figure 2.7).  A large numbers of MPs can be analyzed in the same 
sample.  Cell origin can also be determined by detecting multiple antigens on a single 
MP.  For each event detected by flow cytometry the size, (forward angle scatter) and 
density (side scatter) are determined along with the fluorescence.   The size of the MPs 
are defined in comparison to sizing beads (1 – 1.5 µm) used to set the upper 
microparticle diameter limit and to exclude larger non-MP material from the analysis.  
Platelets have also been used as internal sizing beads with MP identified as having a 
smaller forward angle light scatter than that of the smallest platelet. 35 
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Figure 2.7: Flow cell operation 
Antibodies are used to identify the cellular origin of MPs in plasma.  The 
antibodies bind to cell-specific antigens on the surface of MPs giving information on 
the cell of origin.  Table 2.2 adapted from Simak et al., (2006)8 summarizes the major 
antigens that have been used to identify the cellular origin of MPs.   
Single antibodies and combinations of antibodies are used to identify MP 
origin.  For example EMPs can be identified by the expression of CD31+CD42b-.  
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However, the presence of an antigen does not necessarily classify the cell of origin.  In 
blood, antigens derived from one cell type may adhere to MPs derived from another 
cell type.  Also MPs may bind with the membrane of a different cell type and this cell 
may then release MPs with an adopted antigen. 8 
Table 2.2: Antigens used for MP detection 
MP origin Antigen Alternative Name 
Red Blood Cells CD235a Glycophorin A 
Leukocytes CD45 LCA, T200, B220 
Monocytes CD14 LPS-R 
Granulocytes CD66b CD67, CGM6, NCA-95 
TH lymphocytes CD4 T4, L3t4 (mouse), W3/25 (rat) 
TS lymphocytes CD8 T8, Leu-2, Lyt 2,3 
B lymphocytes CD20 B1, Bp35 
Platelets CD41 
CD41a 
CD42a 
CD42b 
CD61 
GPIIb, αIIβ integrin 
GPIIbIIIa, αIIββ3 integrin 
GPIX 
GPIbα 
GPIIIa, β3 integrin 
Endothelium CD31 
CD34 
CD62E 
CD51 
CD105 
CD144 
CD106 
PECAM-1 
gp105-120 
E selectin 
αv integrin 
Endoglin 
VE-cadherin 
VCAM-1 
The International Society on Thrombosis and Haemostasis SSC Collaborative 
workshop concluded that the standardisation of PMP counts by flow cytometry is 
feasible but is dependent on the flow cytometer and the calibration strategy used.36  
Lacroix et al., (2012) identified three major pre-analytical points that may impact on 
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MP measurement; (i) the time before the first centrifugation, (ii) agitation of the 
samples in transport and (iii) the centrifuge protocol.  37   
 
Figure 2.8: MP sample preparation overview 
PRP, platelet rich plasma; PPP, platelet poor plasma 
Coagulation 
Coagulation is the series of highly regulated steps that results in the formation 
of fibrin, a non-globular protein that provides the framework for a loose platelet plug.  
Plasma coagulation proteins, also referred to as clotting factors, circulate in the blood 
22 
 
in an inactive form.  Following activation of the coagulation system these clotting 
factors become active resulting in the formation of a blood clot composed of platelets 
and fibrin.  The formation of fibrin involves a series of sequential reactions that 
commence within 15 to 20 sec following injury such as trauma to the vessel wall and 
surrounding tissue, trauma to the blood or contact between the blood and 
procoagulatory factors in the vessel wall.  Two pathways are known to exist in the 
coagulation process, the extrinsic pathway and the intrinsic direct activation pathway.  
The two pathways interact extensively and converge to form a common pathway 
leading the formation of the enzyme thrombin, which catalyses the conversion of 
fibrinogen to fibrin. (Figure 2.8) 38 
The extrinsic pathway, also known as the tissue factor (TF) pathway is initiated 
following tissue damage.  Tissue damage can lead to exposed TF on the surfaces of 
injured endothelial cells, leukocytes and cells of the subendothelial layers, in particular 
smooth muscle and fibroblasts.  TF binds to Factor VIIa resulting in the formation of TF-
Factor VIIa complex (figure 2.9).  TF-Factor VIIa complex catalyses the conversion of 
Factor IX from its inactive to its active form, Factor IXa, which in turn activates Factor 
X, the final step of the extrinsic pathway.  Factor Xa can feedback in the pathway and 
induce further Factor VII activation. 
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Figure 2.9: Extrinsic pathway  
The intrinsic pathway, also called the direct activation pathway, begins with the 
auto activation of Factor XII to Factor XIIa.  This auto activation occurs in the presence 
of high-molecular-weight kininogen (HMWK) and prekallikrein (PK).  Factor XIIa acts 
enzymatically to convert inactive Factor XI to its activated form Factor XIa.  This in 
turns converts Factor X to its active form, Factor Xa.  Activated platelets supply the 
phospholipid membrane on which this reaction occurs and requires Factor VIIIa as a 
cofactor.  Factor VIIIa is the co-factor of FIXa and together they form the tenase 
complex which activates Factor X. 
Factor Xa, formed from either the extrinsic or the intrinsic pathway, catalyses 
the conversion of prothombin to thrombin.  The primary role of thrombin is to convert 
fibrinogen to fibrin.  In addition, it stimulates several of the coagulation factors and 
amplifies the coagulation process.  Following conversion of fibrinogen to fibrin the 
fibrin monomers automatically polymerize with each other to form a meshwork that 
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holds a newly formed clot together.  In the presence of Factor XIII the fibrin strands 
become cross-linked with covalent bonds. 38 
Figure 2.10: Coagulation Pathway.   
Extrinsic and Intrinsic pathways interacting to form a common path for the development of fibrin. 
MPs and Coagulation 
MPs are involved in many of the pathways leading to the formation of fibrin.  
When compared to a similar surface area on an activated platelet, PMPs have at least 
50- to 100-fold higher pro-coagulant properties. 39  This is due to the fact that PMPs 
have an increased density of procoagulant phospholipids and surface receptors for the 
procoagulant complexes, such as Factor X.  PMPs also contain surface receptors for 
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both Factor VIII and Factor Va and high and low affinity binding sites for Factor IXa. 40  
Phospholipids contained on the surface of MPs, particularly PS, can bind to coagulation 
factors and promote the formation and activity of tenase and prothrombinase 
complexes (figure 2.10).  2,15 
 
Figure 2.11: MPs in coagulation.15 
MPs have the capacity to harbour, deliver or induce TF activity, the prime 
cellular initiator of coagulation.40  The origins of these MPs include monocytes, tumor 
cells and endothelial cells.  MPs bearing TF circulate in low numbers in healthy 
individuals but increase in various disease states including cardiovascular disease 
(CVD), type 2 diabetes mellitus (T2DM) and with sickle cell disease.  The increase in TF 
26 
 
bearing MPs is related to increased thrombolytic events 41 suggesting that TF present 
on MPs may play a role in coagulation.   
Stimulation of cultured human umbilical vein endothelial cells with TNF-α 
increases EMPs expressing TF on their surface.  Increasing the number of these EMPs 
in a coagulation assay shortened the plasma clotting time compared with EMPs from 
unstimulated cells.  The EMPs induced coagulation in vitro via a TF/Factor VII-
dependent pathway.  Mallet et al., (2009)42 found that atherosclerotic plaques contain 
procoagulant MPs that expose TF and exhibit TF procoagulant activity.  The MPs were 
primarily of monocyte and lymphocytic origin.  These MPs accounted for almost all the 
TF activity in the plaque indicating a direct causal relation between their presence and 
TF activity.   
Most of the evidence for MP involvement in coagulation comes from in vitro 
studies.  MP membranes exposing phospholipids facilitate the binding of coagulation 
factors to the membrane enabling the formation of tenase and prothrombinase 
complexes that in conjunction with TF can initiate blood coagulation.  The negative 
charged phospholipid surface of MPs readily binds activated coagulation factors and 
exposes TF in various conditions. 2 
The presence of elevated levels of MPs in various disease conditions provides in 
vivo evidence of MP involvement in coagulation.  MPs are elevated in certain diseases 
that involve hypercoagulation and circulating levels are reduced in several bleeding 
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disorders such as Scott Syndrome, Castaman’s defect and Glanzmann’s disease.  MPs 
also expose TF in several clinical conditions that are associated with hypercoagulation 
such as the blood of patients with disseminated intravascular coagulation and the 
synovial fluid from inflamed arthritic joints.  Hypercoagulation is a characteristic of 
CVD and altered numbers and procoagulant behaviour of MPs have been reported in 
several CVDs, such as unstable angina and atherosclerosis.43  Agouni et al., (2008) 
reported an increase in procoagulant MPs in patients with the metabolic syndrome 
compared to healthy controls.44  MPs are likely to play a causal role in the 
development of hypercoagulation in CVD. 2,24 
Anticoagulant Effects of MPs 
MPs can also display anticoagulant properties.  Protein C inhibitor binds 
preferentially to the PE on platelets and PMP membranes and inhibits phospholipid 
bound activated protein C.45  MP membranes have been found to contain coagulation 
inhibiting proteins such as TF pathway inhibitor, thrombomodulin, endothelial protein 
C receptor and protein C which suggests a putative role of MPs in anticoagulation.40,46  
TF pathway inhibitor down regulates the activation of TF-factor-VIIa complex.  
Thrombomodulin binds to TF rendering it inactive.  Endothelial protein C receptor 
binds protein C, which in conjunction with its cofactor, protein S, inactivates factor Va 
and VIIIa.47 
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MPs and Inflammation 
MPs have also been found to play an important role in the inflammation 
process.  They are a source of aminophospholipids and also provide a preferential 
substrate for the enzyme phospholipase A2.  This enzyme releases lysophosphatidic 
acid from the breakdown of PC which triggers platelet aggregation and the 
inflammatory process.15  PMPs and MPs of leukocyte origin stimulate the release of 
several endothelial cytokines including IL-6, IL-1β, IL-8 and monocyte chemotactic 
protein-1 (MCP-1) and monocytic cytokines including IL-1β, TNF-α and IL-8.48  The 
release of IL-6 and IL-8 induce the expression of the adhesion molecules ICAM-1, 
VCAM-1 and E-selectin.49 
MPs may also have a positive role in the anti-inflammatory process.  The active 
anti-inflammatory protein annexin 1 is contained on MPs from leukocytes and these 
MPs inhibit the interaction between leukocytes and endothelial cells both in vitro and 
animal models.50  Andriantsitohaina et al., (2012) suggest that a delicate balance 
between the pro- and anti-inflammatory effects of MPs should be preserved to obtain 
an adequately resolved inflammatory process.16 
MPs and Endothelial Function 
A healthy endothelium has anti-inflammatory and anticoagulatory properties 
and regulates vascular tone, vascular wall permeability and cell growth ultimately 
protecting the vascular system.51  Impairment of the normal functions of the 
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endothelial is referred to as endothelial dysfunction and represents one the earliest 
events in the pathogenesis of atherosclerosis.52  EMPs exist in low concentrations in 
healthy individuals but are increased in disease states linked to endothelial 
dysfunction.2 
MPs from patients with acute MI are associated with severe endothelial 
dysfunction in healthy rat aortic rings.53  However MPs from non-ischemic patients, at 
an equivalent protein concentration, did not result in endothelial dysfunction in 
healthy rat aortic rings.53  An EMP concentration threshold may exist before 
endothelial barrier function and vasodilation become compromised.54  Esposito et al., 
(2006) found a higher level of circulating EMPs and PMPs in obese than lean women.55  
There was also a significant inverse relation between the number of circulating EMP 
and PMP and brachial artery flow mediated dilation (FMD) in the obese women.  
Endothelium-dependant relaxation is impaired in mice aorta injected with MPs from 
patients with the metabolic syndrome.  The MPs reduced the ability of acetylcholine to 
promote endothelial-dependant relaxation.44 
MPs play a role in the regulation of vascular tone by altering the production of 
nitric oxide (NO).48  MPs from patients with the metabolic syndrome reduced NO 
release in endothelial cells by ~50% compared to MPs from healthy controls.44  
Brodsky et al., (2004) reported that EMPs in rat aortic rings diminish the production 
and/or availability of NO reducing endothelium-dependant relaxation.56  In contrast, 
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Agouni et al., (2007) found that MPs containing the morphogen sonic hedgehog (Shh) 
on their surface induced NO production from endothelial cells and tissue.57  When the 
Shh pathway was silenced there was a reduction in NO production demonstrating that 
the NO production is mediated directly by the Shh pathway.  Shh is involved in adult 
and embryonic development.  Vascular endothelial growth factor (VEGF) and NO-
synthase are downstream targets of Shh signalling suggesting that Shh can be a 
modulator of VEGF regulation and NO production.48  The study also found that MPs 
decrease the production of reactive oxygen species (ROS) and these two findings 
combined might result in an increase in NO by reducing oxidative stress and the 
subsequent scavenging of NO.57 
MPs in Cardiovascular Disease 
Coagulation, inflammation and endothelial dysfunction are involved in the 
development of cardiovascular disease (CVD).  MPs from circulating blood cells or 
endothelial cells reflect the activation or damage to cells of the vasculature.  Significant 
increases in MPs have been reported for a number of coronary vascular disorders 
including stroke, aortic aneurysm disease, peripheral vascular disease and for venous 
thrombo-embolism.3  The formation and biological effects of EMPs and PMPs in CVD 
are summarized in figure 2.11 and figure 2.12.6 
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Figure 2.12: EMPs in CVD – Mechanisms for EMP production and the reported effects 
of the EMPs on CVD development. 
CRP, C-reactive protein; EC, endothelial cell; EMP, endothelial microparticle; ICAM, intracellular 
adhesion molecule; VCAM, vascular cell adhesion molecule; TF, tissue factor; ACS, acute coronary 
syndrome; CD51+, cluster of differentiation 51+ 
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Figure 2.13: PMPs in CVD – Release of PMPs and their role in inflammation and 
coagulation leading the development of CVD. 
PMP, platelet microparticles; ICAM, intracellular adhesion molecule; EC, endothelial cell; CAD, coronary 
artery disease; PAD, peripheral arterial disease; EPC, endothelial progenitor cell; ACS, acute coronary 
syndrome; PE, pulmonary embolism 
With the proposed involvement of MPs in the development of CVD the 
prevailing view may be that MPs are harmful.  However, it is well documented that 
MPs can have positive effects on coagulation, inflammation and endothelial function.  
Tushuizen et al., (2011) have proposed a model for describing the role of MPs in CVD 
highlighting both the negative and positive effects of MPs (figure 2.13).50  Under 
normal conditions MPs are released by cells to ensure homeostasis.  The MPs assist 
with the regulation of physiological processes including anticoagulation, inflammation 
and regulation of endothelial functions.  Under abnormal conditions inducing stress, 
cells release altered numbers of MPs that have different compositions and functions.  
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These stress induced MPs contribute to the development of CVD through coagulation, 
inflammation and endothelial dysfunction. 
Figure 2.14: Proposed model for describing the role of MPs in normal health and in 
CVD.   
MPs as Biomarkers for Disease 
It is clear that MPs are elevated in disease states, in particular CVD, and play 
both positive and negative roles in coagulation, inflammation and endothelial 
(dys)function, depending on their origin, composition and numbers.  However, the 
issue of whether MPs can be used as a biomarker of CVD risk or as independent 
predictors of CVD is still not resolved.  One of the major problems is a lack of a 
universal method of collection, preparation and analysis.  Nonetheless, there are a 
number of studies with large sample sizes that highlight the role of MPs as potential 
biomarkers of CVD.  Nozaki et al., (2009) found that circulating levels of CD144-EMP 
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were independent predictors of future cardiovascular events in patients at high risk for 
coronary heart disease (CHD) during a 36 month follow-up.58  Furthermore, the 
addition of multiple biomarkers, including CD144-EMP, high-sensitivity CRP and B-type 
natriuretic peptide, can identify patients vulnerable to CVD by improving the risk 
classification based on the Framingham risk model.58  Esposito et al., (2006) found that 
EMPs positively correlated with endothelial dysfunction impairment, measured by 
endothelium-dependant flow-mediated dilation, in 41 obese women.55  Preston et al., 
(2003) found an increase in PMPs and EMPs in subjects with severe hypertension.59 
MPs as Signalling Moieties 
MPs have been shown to be a vehicle for the intercellular exchange of 
biological signals with 2 principle mechanisms for intercellular signalling proposed.60  
Firstly, MPs may activate receptors on target cells via membrane associated, bioactive 
molecules.  Secondly, proteins, bioactive lipids, or RNA contained in MPs may be 
directly transferred to cells resulting in cell activation, phenotypic modification and 
reprogramming of cell function.  Laffont et al., (2013) found that platelet derived MPs 
release microRNA (miR-223) that regulates endothelial cells.61  MP’s ability to travel in 
the blood stream allows them to act as both paracrine and autocrine signalling 
molecules.  For example, CNS-derived MPs may interact with endothelial cells in the 
peripheral circulation representing a novel communication method between the 
nervous system and the cardiovascular system.62 
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MPs and Exercise 
Acute Exercise and MP 
Relatively few studies have examined the relation between exercise and MPs 
(Table 2.3).  Chaar et al., (2011) examined the effects of strenuous exercise on 
circulating cell derived microparticles.63  Seven young healthy men performed three 
  O2max tests on a cycle ergometer with a 10 min interval between the tests.  Blood for 
haematological parameters, MPs and adhesion molecules was taken before and after 
the third exercise test and at 2 h post-exercise.  Leukocytes and polymorphonuclear 
neutrophils (PMN) were significantly higher immediately after exercise and 2 h post-
exercise than before exercise.  Flow cytometry was used to enumerate MPs from RBC, 
EC, platelets and PMNs.  The total number of MPs, PMPs and PMN-derived MPs were 
significantly higher after exercise than before exercise and remained elevated at 2 h 
post-exercise.  Monocyte and endothelial derived MP were not detected in the blood 
at any of three sampling time points.  This may have been due to the antibody, anti-
CD106, used to measure EC derived MPs.  Monocyte and EC derived MPs were 
measured using antibodies anti-CD14 and anti-CD106, respectively. Compared to 
baseline values, IL-6 was significantly elevated post-exercise and remained elevated at 
2 h post-exercise.  There were no significant changes in the number of circulating 
adhesion molecules.  It was speculated that the increase in PMP and PMN derived MPs 
were in response to the pro- inflammatory response to exercise.63 
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Sossdorf et al., (2011) examined the effects of 90 min cycling at 80% of the 
individual anaerobic threshold on the concentration and procoagulant activity of MPs 
in eight trained (T) and eight untrained (UT) healthy men.64  Blood samples were taken 
before exercise, immediately post-exercise, at 45 min post-exercise and 2 h post-
exercise.  Total MP counts increased significantly above baseline levels at 45 min in the 
T group and at 2 h in the UT group with the difference between the groups significant 
at 2 h.  There was a significant increase in PMPs post-exercise and 45 min post-exercise 
in the T group with values dropping close to basal levels at 2h.  PMP levels were 
significantly higher than baseline at 45 min post-exercise in the UT group and 
remained significantly higher at 2 h post-exercise.  There were no significant changes 
in the circulating number of EMP or MMP numbers in the UT group.  In the T group 
there was a transient significant increase in EMP and MMP numbers at 45 min.  TF 
expression on MPs was also measured.  Compared to pre-exercise values there was a 
significant decrease in TF-positive PMPs in both groups at 45 min post-exercise and the 
number remained significantly lower than baseline in the UT group at 2 h post-
exercise.  The number of circulating TF-positive EMPs was significantly higher than 
baseline in the T group at 45 min post-exercise.  TF-positive MMPs were significantly 
higher at rest in the UT group than the T group and at 2 h post-exercise in the UT 
group compared to baseline.  Prothrombinase activity of MPs was significantly 
enhanced after exercise in both groups and remained elevated 2 h post-exercise.  The 
TF-initiated fibrin formation in MP-containing plasma was increased by approximately 
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15% after exercise and remained elevated compared to pre-exercise values in the T 
group.  The increase in MPs, along with the changes in the number of TF-positive MP 
and the enhanced prothrombinase activity of the MPs support the premise that MPs 
contribute to the exercise induced changes in haemostasis.  It is possible that the 
exercise induced sheer stress may play a role in the increase in circulating MPs64.  This 
view is supported by a trend towards higher MP levels in the T group.  Although both 
groups exercised at the same relative intensity the RPE scores and blood pressure were 
higher in the T group, suggesting that they were exercising at a higher relative 
intensity.   
Kirk et al., (2013) investigated whether maintaining acid-base homeostasis by 
ingesting sodium bicarbonate affected the release of MPs.65  Seven young healthy men 
performed two bouts of 10 x 15 sec sprint cycling at 120% peak power output, 
following ingestion of sodium bicarbonate supplementation or placebo.  Blood samples 
were taken pre-exercise, immediately post-exercise and at 90 min and 180 min post-
exercise and circulating EMPs were measured using both CD105 and CD106 antibodies.  
Both CD105 and CD106 EMPs peaked at 90 min post-exercise and returned to baseline 
at 180 min.  There was no significant difference in the circulating number of EMP’s 
between the sodium bicarbonate and the placebo group.  The increase in CD106 is in 
contrast to the findings of Chaar et al., (2011)63 following 3   O2max test and may be 
due to differences in pre-analytical methodology and exercise protocols. 
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The increase in EMPs may reflect the increase in sheer stress on the 
endothelium in response to supra-maximal exercise.  The fact that the EMPs returned 
to pre-exercise levels at 180 min indicates that the endothelium may have recovered 
from the exercise induced haemodynamic stress at this time.  Sossdorf et al., (2011)64 
also found that circulating MP levels returned to pre-exercise levels 2 h following 90 
min of cycling at 80% IAT.  
Parker et al., (2012) examined the effects of a marathon race on the venous 
thrombotic risk markers, D-dimer, p-selectin and MPs in 23 travellers and 18 local 
controls.  The travellers lived a minimum of a 4 h flight time from the marathon 
location while the controls lived within a 2 h drive of the marathon.66  Blood samples 
were taken at the race location the day before the marathon and immediately after 
the race and the day after the marathon in the participant’s home city following a 
flight or drive home.   
MP activity increased in both groups following the marathon and the day after 
the marathon compared to baseline levels.  There was no effect of travel, age or 
gender on the circulating number of MPs following the marathon.  Soluble p-selectin 
and d-dimer also increased significantly in both groups after the race. Since soluble p-
selectin, d-dimer and MP are associated with venous thrombosis and MPs and p-
selectin are also linked with vascular, inflammatory and coagulation diseases the 
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observed increase in these biomarkers may potentially contribute to the increased risk 
of cardiac events linked to endurance running in vulnerable subjects. 
PMP levels have been also found to increase significantly in young men and 
women (21 ± 0.3 years) immediately after reaching 85% of age predicted maximal 
heart rate following a Bruce treadmill protocol.67  PMP remained significantly elevated 
1 h following exercise.  The increase in PMPs may indicate an increase in platelet 
activation.  However, the markers of fibrinolysis and coagulation measured did not 
point to an activation of the coagulation system. 
In contrast, Mobius-Winkler et al., (2009) found no change in circulating MP 
(CD42b-/CD62E+) levels in 18 healthy men following 240 min of cycling at 70% IAT.68 
However, an increase in circulating endothelial progenitor cells (EPC), vascular 
endothelial growth factor, mature ECs and IL-6 during or after the exercise session may 
indicate some degree of endothelial damage.  The exercise intensity may not have 
been high enough to induce the production of MPs.   
Guiraud et al., (2013) compared the effect a single bout of moderate intensity 
continuous exercise and high-intensity interval exercise (HIIE) matched for caloric 
expenditure on EMPs and PMPs in 19 men with an average age of 62 ± 12 years, and 
stable CHD.69  The moderate intensity continuous bout consisted of cycling at 70% 
peak power output (PPO) for 28.7 min.  The HIIE session consisted of a 10 min warm-
up at 50% PPO followed by two 10 min bouts composed of 15 sec at 100% PPO 
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interspersed with 15 sec of passive recovery.  The bouts were separated by 4 min of 
passive recovery and the session ended with a 5 min cool-down.  Blood was taken 10 
min before exercise and 20 min, 24 h and 72 h after exercise.  MPs were enumerated 
using flow cytometry and EMPs were defined as CD31+/CD42b- and CD62E+ and smaller 
than 0.9µm.  PMPs were defined as CD42b+ and smaller than 0.9µm. 
There were no changes in MPs after exercise in either the moderate intensity 
continuous exercise or the HIIE condition.  There was an inverse relation between 
baseline EMP levels and the change in EMP levels 20 min after exercise.  Individuals 
with the highest baseline EMPs had the greatest reduction in EMPs 20 min following 
the exercise.  These results are similar to Chaar et al., (2011)63 and Mobius-Winkler et 
al., (2009)68 who also found no increase in MP numbers after exercise.  The results 
indicate that this type of HIIE does not induce harmful effects on the endothelial and 
appears safe for this population. 
Exercise Training and MPs 
To date, only two published studies have examined the effects of a training 
intervention on MP numbers70 71.  Babbitt et al., (2013) examined the effects of 24-
weeks of aerobic exercise training on EMPs and inflammation status in 42 sedentary (6 
men and 36 women) African Americans with a mean age of 52.7 ± 1.0 y.70  Participants 
completed 3 exercise sessions a week.  The exercise sessions started with 20 min at 
50%   O2max and increased to 40 min at 65%   O2max by week 8.  During week 12 
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there was an adjustment in workload to account for improvements in aerobic fitness.  
Blood for EMPs, IL-6 and IL-10 was taken after a 12 hr fast before and after the training 
program.  EMPs were identified using flow cytometry and the ability to bind CD62E+.  
Endothelial function assessed by flow mediated dilation (FMD) was measured before 
and after the exercise program.  Circulating levels of CD62E+ EMPs were 47% lower 
than baseline at the end of the 6 month training program.  There was also a significant 
decrease in IL-6 and an improvement in FMD but no significant change in IL-10.  The 
changes in CD62E+ EMPS, IL-6 and IL-10 accounted for 10% of the change in FMD%.   
Chen et al., (2013) examined the effects of hypoxic exercise training on CD61+ 
PMPs in sedentary men.71  Although hypoxia has long been used as a training aid it 
may however, have a negative effect on the haemostatic system.  Vigorous exercise in 
conjunction with hypoxia may induce a high shear stress in narrow blood vessels that 
increase the risk of prothrombotic events in patients with CAD.71   
Seventy five sedentary men in their early twenties were randomly assigned to 
one of 5 groups and were randomly assigned to one of three experimental groups.  
Group 1 received 21% O2 (normoxic) while resting; group 2 received 15% O2 (hypoxic) 
while resting; group 3 and group 4 exercised on a cycle ergometer at 50% peak power 
output at 21% O2 and 15% O2 respectively and group 5 exercised at 50% of heart rate 
reserve at 15% O2.  Each group was administered their respective intervention for 30 
min.d-1, 5 d.wk-1 for 4 weeks in a controlled chamber.  Participants performed a graded 
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exercise test (GXT) to exhaustion before and after the intervention and blood was 
taken before and immediately after each GXT.  Prior to the PMP measurement the 
blood was exposed to conditions of no stress, low-shear stress and high-shear stress 
using a rotational viscometer.  The procoagulant activity of the PMPs was measured 
and expressed as FV/Va, FVIII or TF rich PMPs. 
There was a shear stress induced increase in PMPs.  High-shear stress enhanced 
the release of FV/Va, FVIII and TF rich PMPs and this was amplified following the GXT.  
After the training period there was a reduction in the release of PMPs and 
procoagulant PMPs following high-shear stress in the normoxic exercise and the 
hypoxic relative exercise group after the GXT.  There was an increase in PMPs and 
procoagulant PMPs following the GXT in the hypoxic group exercising at 50% peak 
work rate.  There were no changes in PMPs in the other two groups.  These findings 
indicated that that it may be safer to exercise at a relative workload as there is less 
thrombotic risks as evidenced by a decrease in PMP or procoagulant PMPs. 
Exercise and MP Response to a High Fat Meal 
A number of studies have examined the prior effect of exercise on the MP 
response to a high fat meal.  Following a high-fat meal, serum triglyceride (TG) 
concentrations increase.  This increase in TG induces systemic oxidative stress and 
impairs endothelial function.72  Ferreira et al., (2004) found that postprandial 
hypertriglyceridemia increase EMPs.73   
43 
 
Harrison et al., (2009) examined the effects of a prior bout of exercise on 
CD31+/42b- EMPs following a high fat meal.74  Eight healthy, active men underwent 
two oral fat tolerance tests (OFTT) separated by 7 d.  The study participants rested on 
the evening prior to one of the OFTT.  On the evening prior to the other OFTT the 
participants cycled for 90 min at 70%   O2peak, followed by 10 x 1 min sprints 
interspersed with 1 min of recovery to maximise glycogen depletion.  Flywheel 
resistance was increased by 25% for the sprints.  On the morning of the oral fat 
tolerance test blood was taken before the meal and 30 min, 1 h, 2 h, 4 h and 6 h 
following the high-fat meal.  
Compared to baseline values, circulating EMPs increased significantly at 2 h 
following the OFTT and remained elevated at 4 h and 6 h post in both trials.  There was 
no significant difference in EMP values between the exercise and control conditions.  
Circulating IL-6 levels were significantly increased at 4 h and 6 h following the meal in 
both trials and there were no changes in sICAM-1 or sVCAM-1.  There was a significant 
increase in the number of circulating leukocytes in both groups at 6 h following the 
meal compared to baseline.  Fasted EMP counts were not related to any of the 
biomarkers in the fasted state.  The increase in EMPs, IL-6 and leukocytes may indicate 
postprandial endothelial activation.  The fact that there was an increase in EMPs with 
no changes in sICAM-1 or sVCAM-1 may suggest that EMPs are a more sensitive 
biomarker of endothelial activation than soluble adhesion molecules. 
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During the exercise trial there was a 40% reduction in postprandial lipemia and 
an 8% increase in high-density lipoprotein cholesterol (HDL-C).  However, a reduction 
of a similar magnitude was not observed for EMPs.  Considering that TG-rich 
lipoproteins are cytotoxic to endothelial cells in vitro and HDL-C has a positive effect on 
endothelial dependent dilation (EDD), a decrease in EMPs would be expected following 
the exercise trial.  Moyna et al., (2004) suggest that exercise may only improve 
endothelial function in people who have impaired endothelial function.11  The 
participants in this study were young physically active men with no CVD symptoms.  
Furthermore, postprandial free fatty acids (FFA) were higher in the exercise trial.  
Increases in lipolysis at the endothelial surface, induced by exercise may decrease TG 
but increase FFA uptake by the endothelial cells.  It is also possible that the exercise 
intensity may not have been high enough to induce an inflammatory response. 
Strohacker et al., (2012) examined the postprandial changes in circulating 
monocytes and biomarkers of endothelial function, including EMPs, in 4 men and 4 
women following a high-fat meal with or without prior exercise.75  Participants 
ingested two high-fat meal trials separated by 7 days with and without prior exercise.  
The exercise consisted of cycling at an intensity corresponding to 60 – 75%   O2peak 
for 1 h while they achieved an energy expenditure corresponding to 4 – 6 kcal.kg-1 
body mass.  The high-fat meal was taken 1 h following the exercise bout or the rest 
period.  Blood was taken before and after the exercise/rest period, before the high-fat 
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meal and at 1 h intervals for 3 h.  EMPs were enumerated using flow cytometry and 
defined as CD31+/CD42b- and < 1.5µm. 
Compared to the pre meal values circulating EMP levels at 3 h post meal were 
47% higher in the meal only trial.  In contrast, there was no significant increase in 
circulating EMP levels in the exercise condition indicating that prior exercise 
ameliorated the increase in EMPs 3 h following the high fat meal.  Monocyte CD18 and 
CD11a were lower in the exercise trial and probably reflect the lower number of EMPs. 
Jenkins et al., (2011) also examined the interaction between prior exercise and 
postprandial circulating EMPs in 10 healthy active men with a mean age of 27 yr.76  
Participants exercised at 15:00 h or rested the day before the high-fat meal.  The 
exercise involved cycling at 70%   O2max until they expended 2.5 MJ.  To ensure a fixed 
macronutrient composition the study participants received the same meal between 
19:00 h and 20:00 h on the same evening as the exercise session.  The control trial 
subjects rested the day before the high-fat meal.  The high-fat meal was taken the 
following morning at 06:00 h. Blood was taken before the meal and every hour for 4 h.  
EMPs were enumerated using flow cytometry and defined as CD31+/CD42b- 
(endothelial apoptosis) and CD62E+ (endothelial activation) and < 1.0µm. 
EMP values before and after the meal were lower with prior exercise.  During 
the exercise trial CD31+/CD42b- EMPs were 30% lower and CD62E+ 55% lower than the 
control trial.  In direct contrast to both Harrison et al., (2009)74 and Strohacker et al., 
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(2012)75 the circulating levels of EMPs did not increase following the high-fat meal.  
Also in contrast to Harrison et al., (2009)74 there was no decrease in TG in the exercise 
group.  Differences in exercise intensity, timing and, meal composition and timing, and 
methods used to quantify EMPs makes it difficult to directly compare the studies.
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Table 2.3: MPs and exercise 
 Participants Exercise  
Mode 
Exercise 
Type 
MP Time 
Points 
MPs Antigen Result Measurement 
Technique 
Charr et 
al., 
(2011)63 
7 young 
healthy 
males 
Cycle 
ergometer 
3 max test 
with 10min 
break 
Pre, post,  2 
h 
Total MP 
PMP 
EMP 
MMP  
RBC MP 
PMN MP 
Annexin V, 
CD41, 
CD106, 
CD14, 
CD235a, 
CD15 
↑ post and 2h 
↑ post and 2h 
↔ 
↔ 
↔ 
↑post and 2h 
FC 
Sossdorf 
et al., 
(2011)64 
16 young 
healthy 
males, 8 
trained (T), 
8 untrained 
(UT) 
Cycle 
ergometer 
90min at 
80% IAT 
Pre, post, 
45 min, 2 h 
Total MP 
PMP 
 
MMP 
EMP 
Annexin V 
CD42a 
 
CD14 
CD62E 
↑ in both groups 
↑ in T at post and 45 
↑ in UT at 45 and 2h 
↑ in T at post and 45 
↑in T at 45 
FC 
Kirk et al., 
(2013)65 
7 young 
healthy 
males 
Cycle 
ergometer 
2 trials 
10 x 15 sec 
sprints at 
120% PPO 
with 45 sec 
recovery 
Pre, post, 
90 min, 180 
min 
EMP CD105 
 
CD106 
↑ in both trials at 90 
min 
↑ in both trials at 90 
min 
FC 
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1 trial with 
NaHCO3 
Babbitt et 
al., 
(2013)70 
42 middle 
aged 
healthy 
African 
Americans 
6 men 
36 women 
Treadmill, stair 
stepping, 
cycling, rowing, 
arm ergometer, 
cross-trainer 
6 month 
aerobic 
exercise 
training 
Pre and 
post 
interventio
n 
EMP CD62E ↓ between pre and 
post intervention 
FC 
Mobius-
Winkler et 
al., 
(2009)68 
18 healthy 
young men 
Cycle 
ergometer 
4 h at 70% 
IAT 
16 time 
points 
during and 
after 
exercise 
Total MP 
EMP 
 
CD42b- 
CD62E+/ 
CD42b- 
↔ 
↔ 
 
 
Parker et 
al., 
Marathon 
runners, 23 
travellers, 
18 local 
Running Marathon  Pre, post 
and next 
day 
MP pro 
coagulant 
activity 
 ↑ post and the next 
day. No travel effect 
ELISA 
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(2012)66 
controls 
Maruyam
a et al., 
(2012)67 
18 healthy 
subjects 
9 men 
9 women 
Treadmill Max test 
until 85% 
of APHRM 
Pre, post 
and 1 h 
PMP  ↑ post and at 1 h ELISA 
Guiraud et 
al., 
(2013)69 
19 fit men 
with CHD 
Cycle 
ergometer 
Moderate 
intensity 
continuous 
exercise or 
HIIE 
Pre, 20 min 
post, 24 h 
and 72 h 
post 
EMP 
 
 
PMP 
CD42b-
/CD31+ 
CD62E+ 
CD42b+ 
↔ 
 
↔ 
↔ 
 
FC 
Chen et 
al., 
(2013)71 
75 
sedentary 
males 
5 groups of 
15 
Cycle 
ergometer 
Rest 
30 min, 
5xweek for 
4 weeks. 
1) 21% O2 
rest and 2) 
50% PPO 
3)15% 02 
rest and 
4)50% PPO 
Pre and 
post GXT 
before and 
after 
training 
PMP 
Procoagul
ant PMPs 
CD61+ 
FV, FVIII or 
TF rich 
↓ after training 
following the GXT in 2) 
and 5) 
↔ in group 1) or 3) 
↑ in group 4) 
FC 
50 
 
5)15% 02 
50% 
APHRR 
FC, flow cytometry; MP, microparticle, EMP, endothelial microparticle, PMP platelet microparticle, MMP, monocyte microparticle; RBC, red blood cell; PMN, 
polymorphonuclear neutrophil; T, trained; UT, untrained; IAT, individual anaerobic threshold; PPO, peak power output; HIIE, high intensity interval exercise; APHRR, 
age predicted heart rate reserve
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The Endothelium 
The vascular endothelium is a monolayer of endothelial cells that form a semi-
permeable biological interface between the vascular space and the tissues.11  
Endothelial cells are highly specialized to detect diverse physical, chemical, or 
mechanical stimuli.  In addition to their role in the regulation of vascular tone, healthy 
endothelial cells continuously adapt to local requirements and are essential for the 
maintenance of entire vascular homeostasis involving antioxidant, anti-inflammatory, 
profibrinolytic, and anticoagulant effects.  
Vascular Endothelium – Structure 
The endothelium consists of a single layer of endothelial cells (EC) providing a 
lining for the lumen of the entire vascular system.  The cells have a squamous 
morphology and are aligned in the direction of laminar blood flow.  ECs are between 
25-50 µm in length, 10-15 µm in width and up to 5 µm in depth.77  The human body 
contain up to 6 trillion ECs covering approximately 4000 to 7000 m2, representing 
about 1% of body mass.78   
Endothelial cells are separated from the underlying tissue by the basal lamina.  
The basal lamina connects to the ECs via integrins.  The surface of the ECs exposed to 
blood flow is lined by a negatively charged layer called the glycocalyx.  This layer allows 
water and small solutes to exit the blood but keeps negatively charged proteins in the 
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blood stream.38  The cytoskeleton of the EC, composed mainly of actin and myosin 
filaments, provides the structure for the cell and attaches ECs to each other and to the 
basal lamina.  Adjacent ECs are connected via junctional proteins which extend across 
the space between adjacent cells.  This space between ECs is called the intracellular 
cleft.  The junctional proteins play an important role in transport through the 
endothelial layer. 
Figure 2.15: Vascular Endothelium38 
Vascular Endothelium – Functions 
The endothelium serves as a selectively permeable barrier regulating exchange 
of nutrients and gases between the blood and tissues.  Lipid-soluble substances can 
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diffuse through the ECs while small, water-soluble substances diffuse through the 
intracellular junctions.   
ECs regulate vascular tone and basal vasomotor tone by the release of 
vasodilators and vasoconstrictors.77  Nitric oxide (NO) is the primary vasodilator 
released by EC and also plays an important role in the inhibition of thrombosis.  
Prostacyclins are also released by EC and play an important role in vasodilation and 
platelet inhibition, with PGI2 being the active prostacyclin in ECs.
78  The primary 
vasoconstrictors active in ECs include endothelins (ETs) and platelet activating factor.   
The endothelium has both anticoagulant and procoagulant properties.  In a 
healthy endothelium the balance is towards anticoagulant properties, however 
following endothelial damage procoagulant properties become apparent.77  A healthy 
endothelium has the ability to inhibit the generation and activity of thrombin which 
prevents fibrinogen being converted to fibrin.  The endothelium expresses 
procoagulant properties in response to tissue factor (TF).  Several agonists can 
stimulate TF production from the endothelium.  Shear stress, thrombin, cytokines such 
as IL-1 and TNF-α, hypoxia and oxidised lipoproteins have all been linked to 
endothelium TF production.78  
The endothelium also plays an active role in the inflammatory defence against 
pathogens.  Following injury the endothelium produces and expresses adhesion 
molecules that allow circulating leukocytes to attach and transmigrate to the intima.38  
54 
 
Depending on the type of stimuli the initial adhesion molecules produced by the 
endothelium include P-selectin, E-selectin and L-selectin.  The selectins facilitate 
“rolling” of leukocytes along the surface of the endothelium.  Rolling facilitates the 
attachment of leukocytes to the endothelium by another family of adhesion molecules 
called intracellular adhesion molecules, ICAM-1, -2, -3, and vascular cell adhesion 
molecule-1 (VCAM-1).  Platelet-endothelial cell adhesion molecule-1 (PECAM-1) 
facilitates the transmigration of leukocytes to the intima.78 
Vascular Endothelium - Dysfunction 
Endothelial dysfunction is a term used to describe a series of pathological 
changes in the function and structure of the endothelium.  These changes include 
increased permeability to plasma lipoproteins, hyperadhesiveness to leukocytes and 
imbalances in the regulation of vascular tone and haemostasis leading to a reduced 
vasodilation and an increased prothrombotic and pro-inflammatory state.38,79  
Endothelial dysfunction is an early manifestation of atherosclerosis and is predictive of 
an increased risk for cardiovascular events.79 
Vascular Endothelium – Exercise 
Exercise training promotes an acute increase in blood flow and shear stress, 
improving NO availability and increasing endothelium-dependant vasodilation.80  The 
improvement in NO availability may represent one of the most important mechanisms 
explaining the improvement in exercise-induced endothelial function.  The exercise-
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induced improvement in endothelial function is more obvious in individuals with 
impaired endothelial function.81  Studies examining the effect of exercise on 
endothelial function in healthy men and women are inconsistent, while the majority of 
studies examining individuals with impaired endothelial function have reported 
improvements with exercise. 
Rinder et al., (2000) examined endothelial function between a group of masters 
athletes and sedentary men.82  They found that endothelial-dependant dilation was 
greater in the athletes suggesting exercise may attenuate the decline in endothelial 
function associated with ageing. 
Exercise intensity is an important factor when discussing improvement in the 
vascular endothelium in response to exercise.  Moderate-intensity exercise has been 
shown to be effective in improving endothelial function in men and women with 
impaired endothelial function.83  Recent studies have found that high-intensity interval 
exercise is better stimulus than moderate-intensity exercise for improving endothelial 
function in individuals with the metabolic syndrome84 and in heart failure patients.85  
These findings may be due to increased bioavailability of NO following high shear 
stress during the high-intensity exercise. 
Lipids 
Lipids are a heterogeneous group of hydrophobic organic molecules and can be 
broadly classified as fatty acids, acylglycerols, phospholipids, eicosanoids, steroids and 
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lipoproteins.  They have a number of important functions including the formation of 
membranes, energy storage, cellular signalling protection, insulation and the 
production of steroid hormones and bile acids. 
The most commonly reported lipids in studies examining the effects of exercise 
on lipid profiles include total cholesterol, high-density lipoprotein cholesterol (HDL-C), 
low-density lipoprotein cholesterol (LDL-C) and triglycerides (TGs).86  Exercise has a 
marked effect on atherogenic dyslipidemia, a characteristic of the metabolic 
syndrome.  The metabolic syndrome is characterised by low HDL-C and high LDL-C and 
TGs.87  HDL-C transports lipids from peripheral tissue to the liver where they are 
recycled or disposed and a high concentration of HDL-C is linked to a healthy 
cardiovascular system.  In contrast, high circulating levels of LDL-C and TG are 
associated with an increased the risk of CVD.   
Exercise Training and Lipids 
Aerobic exercise, resistance training and various combinations have been 
successfully used to lower blood lipid levels.  However, the optimal type, intensity, 
frequency or duration of exercise has not been established.  The most commonly 
observed change following an exercise intervention is an increase in HDL-C, with 
decreases in LDL-C, total cholesterol and TGs less frequently observed.88 
 In a review covering 51 exercise interventions with 12 weeks or more of 
aerobic exercise Leon and Sanchez (2001) found that, on average, there was a 4.6% 
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increase in HDL-C, a 3.7% decrease in TGs and a 5% decrease in LDL.88  No change in 
total cholesterol was reported.  In a subsequent review Mann et al., (2014) found that 
moderate-intensity exercise is effective in increasing HDL-C.86   
O’Donovan et al., (2005) compared the effect of 24 week moderate-intensity 
exercise program (60%   O2max) with a calorie matched high-intensity exercise 
program (80%   O2max) on blood lipids.
89  Improvements in lipid profiles were only 
found in the high-intensity group.  There were significant decreases in total 
cholesterol, LDL-C and non-HDL-C in the high-intensity group.  Dunn et al., (1997) 
found significant reductions in total cholesterol and the total:HDL-C ratio following a 6 
month aerobic exercise program which progressed to 85% of maximum aerobic power 
for 20 – 60 min three times a week.90  LeMura et al., (2000) investigated the effects of 
16 weeks of aerobic exercise on lipid profiles in young women.91  The exercise was 
progressed from three 30 min sessions weekly at 70 – 75% HRmax for the first 8 weeks 
to four 30 min sessions at 85% HRmax for the last 8 weeks.  Significant decreases in TGs 
and increases in HDL-C were reported.  Nybo et al., (2010) compared traditional 
aerobic exercise with high intensity training on blood lipids.92  The traditional aerobic 
exercise consisted of ~150 min of exercise a week at 65%   O2max and the high 
intensity exercise sessions consisted of 40 min of intense exercise a week.  The high 
intensity session consisted of a 5 min warm-up with light jogging followed by 5 
intervals of 2 min with heart rate above 95% of heart rate max at the end of 2 min 
period.  The total:HDL-C ratio significantly improved in the traditional group.  No 
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significant changes were found in the high intensity training group.  These findings 
indicate that training volume is more important than training intensity in eliciting 
changes in lipid profiles.  A review on the impact of exercise on blood lipids and 
lipoproteins by Trejo-Gutierrez and Fletcher (2007) recommend both high-volume and 
high-intensity exercise to significantly alter blood lipid profiles.87 
Acute Exercise and Lipids 
Increases in HDL-C and reductions in TGs have been reported after a single 
exercise session.93  Reported increases in HDL-C vary from 4 to 43% and occur 18 – 24 
h after exercise.94  The duration and intensity of exercise needed to acutely increase 
HDL-C is not clearly defined but changes have been reported in moderately fit subjects 
after expending 350 – 400 kcal and in well-trained subjects following exercise 
expending 1000 kcal.94  Reductions in TGs follow the same timeline as the increases in 
HDL-C and can remain low for up to 72 h.  Reductions are greatest in individuals with 
higher pre-exercise TG levels95 and the most consistent results have been found in 
trained subjects performing prolonged endurance exercise.94 
Greene et al., (2012) investigated the effects of training on the acute effects of 
exercise on blood lipids and lipoproteins.96  Overweight and obese men and women 
performed an acute bout of exercise on a treadmill at 70%   O2max until they 
expended 400kcal before and after 12 weeks of aerobic exercise training.  The training 
consisted of land-based or aquatic-based treadmill running 3 times weekly progressing 
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to expending 500 kcal at 85%   O2max from week 6 - 12.  The acute bout of exercise 
reduced the total:HDL-C ratio in men before the training intervention, and there was 
no difference in the effect of the acute exercise following the training intervention.  
Exercise training resulted in increases in HDL-C. 
  
60 
 
 Study Rationale 
Despite declines in prevalence in recent years, CVD remains the leading cause 
of morbidity and premature mortality in men and women worldwide.132  MPs have 
been found to play a role in coagulation, inflammation and endothelial 
function/dysfunction which are all closely related to CVD.  The benefits of physical 
activity in the primary and secondary prevention of CVD are well established.  At the 
time of conception of study 1 and 2 there were no published research studies 
investigating the effects of physical activity/exercise on circulating MPs.  A series of 
studies was undertaken to investigate the effect of acute and chronic exercise on 
circulating MPs.  
Conventional exercise guidelines for reducing CVD risk factors and 
cardiovascular events have promoted continuous, moderate to vigorous intensity 
exercise training.  Exercise performed at a vigorous intensity (≥6 METs) has been 
shown to induce a greater reduction in CVD risk along with greater improvements in 
diastolic blood pressure, glucose control and aerobic capacity than exercise performed 
at a moderate intensity.10  Study 1 evaluated the dose response of moderate to high 
intensity exercise on circulating MPs in healthy physically active men.  Participants 
performed an isocaloric bout of exercise at exercise intensities corresponding to 60%, 
70% and 80%   O2max.  Study 2 examined the effects of 14 d of exercise training on 
circulating MPs in healthy sedentary men.  Improvements in aerobic capacity have 
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been linked to improvements in CVD and many of the processes leading to CVD.81,97  
Considering that an improvement of 10% in aerobic fitness has been found following 7 
– 14 d of aerobic exercise98 a 14 d training period was selected in order to provide a 
sufficient stimulus to improve   O2max.  Participants undertook 60 min of daily exercise 
at 80%   O2peak to ensure a moderate to high intensity exercise session in line with 
previous research reporting improvements in CVD risk factors.  Blood samples were 
taken before, immediately after and 13 h after the exercise on day 1, 3 7, 10 and 14 to 
investigate the possible changes in MP response to exercise during the training 
sessions. 
Participants in study 1 and 2 were young healthy men.  However, resting levels 
of EMPs are increased in individuals with established risk factors linked to endothelial 
dysfunction and CVD.44,55  Study 3 investigated the effect of exercise training on 
circulating MP and endothelial function in men and women with documented CVD.  
Recently, low volume short-duration, high-intensity interval training (LS-HIIT) involving 
repeated bouts of short-duration high-intensity exercise separated by periods of active 
or passive recovery have been shown to be a safe and effective alternative to more 
traditional continuous, moderate-to-vigorous exercise programs in improving exercise 
capacity and endothelial function in individuals with CVD.  Men and women who had 
been participating in a community based cardiac rehabilitation program for at least 6 
months were recruited and this enabled a comparison between a traditional cardiac 
rehabilitation program and a LS-HIIT program.  This is the first study to investigate the 
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relation between circulating MPs and endothelial function in response to exercise 
training in men and women with CVD  
There is strong evidence for the link between circulating lipids and CVD.97  
Exercise training has been shown to reduce total cholesterol, LDL-C, triglycerides and 
increase HDL-C.  However, there is a dearth of information regarding the relation 
between lipids and circulating MPs following acute and chronic exercise in healthy 
individuals and those with documented CVD.  Blood lipids were measured in each of 
the 3 studies in order to address these issues.  
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Chapter III 
Study I 
The Dose Response of an Acute Bout of Exercise on Circulating Microparticles 
Rationale 
 Microparticles are small membrane vesicles shed from membranes following 
cell activation or apoptosis.  EMPs and PMPs are involved in inflammatory and 
coagulation processes related to the development of CVD.6  Exercise is a commonly 
used non-pharmacological intervention in the prevention and treatment of CVD.11,99,100  
The acute effects of exercise on markers of coagulation, inflammation, and endothelial 
dysfunction have been extensively investigated.  In contrast little is currently known 
about the acute effects of exercise on circulating MPs.   
Exercise dose refers to the type, intensity, frequency and/or volume of 
exercise.  The response refers to the physiological and psychological changes that 
occur when a specific dose of exercise is performed.  Varying exercise intensities have 
been shown to elicit different responses in many of the processes linked to CVD.  
Studies that have controlled for accumulated energy expenditure (EE) found greater 
improvements in aerobic fitness at higher intensities compared to moderate 
intensities.10  To date, no studies have compared the effect of exercise at different 
intensities on circulating levels of MPs.  Since vigorous exercise elicits a greater EE than 
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moderate exercise of a similar duration it is important to control for EE when 
comparing the effect of exercise intensity on circulating levels of MPs.   
The purpose of this study was to examine the effect of isocaloric bouts of 
exercise at different intensities on circulating MPs in healthy young men. 
Specific Aims: 
1. To compare the acute effects of isocaloric bouts of exercise at 60%, 70%, and 
80%   O2max on circulating EMP levels in young healthy physically active men 
2. To compare the acute effects of isocaloric bouts of exercise at 60%, 70%, and 
80%   O2max on circulating PMP levels in young healthy physically active men 
Hypothesis: 
1. There will be no significant difference in circulating levels of EMPs following 
isocaloric bouts of exercise at 60%, 70%, and 80%   O2max in healthy young 
physically active men 
2. There will be no significant difference in circulating levels of PMPs following 
isocaloric bouts of exercise at 60%, 70%, and 80%   O2max in healthy young 
physically active men 
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Methodology 
Study Overview 
The study design is illustrated in Figure 3.1.  10 Participants visited the Human 
Performance Laboratory (HPL) in DCU on 5 separate occasions.  During the first visit 
participants underwent an initial screening consisting of a general health questionnaire 
(Appendix A), medical examination, body composition and an electrocardiograph (ECG) 
to confirm their suitability for the study.  The second visit consisted of a maximal 
exercise test to determine maximal aerobic capacity (  O2max).  During visits 3-5 
participants were randomly assigned to exercise at 60%, 70% or 80%   O2max until 
they expended 400 kcal.  Blood samples were taken before, immediately after and at 2 
h, 4 h and 6 h post-exercise.  
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Figure 3.1: Study design 
GHQ, general health questionnaire; ECG, electrocardiograph 
Participant Recruitment 
An email was sent to all undergraduate and post graduate students attending 
Dublin City University (Appendix B).  Students who expressed an interest in 
participating in the study received a plain language statement detailing the 
requirements of the study (Appendix C).  Written informed consent was obtained from 
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individuals who agreed to participate in the study (Appendix D).  The study was 
approved by the Dublin City University Research Ethics committee (Appendix E).  
Participants were excluded if they were current smokers, not involved in regular 
physical exercise or had any other medical conditions that contraindicated exercise 
participation. 
Maximal Oxygen Uptake 
Participants performed an incremental exercise test until volitional exhaustion 
on a motorised treadmill (Woodway ELG 55, Waukesha, WI).  The tests were 
conducted in a temperature controlled laboratory (19-21oC, 40-55% relative humidity).  
The test was preceded by a 5 min warm-up at 8 km.h-1.  Following the warm-up 
participants exercised for 2 min at 10.0 km.h-1 followed by a further 2 min at 12.0 
km.h-1.  The slope of the treadmill was then increased 2% a min for the first 2 min and 
then 1% every min until volitional exhaustion.  Respiratory metabolic measures were 
monitored continuously throughout the test.  Maximal oxygen uptake was determined 
by averaging the three highest consecutive 20 sec values.   
Cardiorespiratory and Metabolic Measures  
Respiratory metabolic responses were determined using standard open-circuit 
spirometry techniques (Sensormedics Vmax 29c, SensorMedics Corp., CA).  Prior to 
testing, the gas analysers were calibrated with standard gases of known concentration.  
A mass flow sensor (Sensormedics, Loma Linda, CA, USA) was used to collect breath-
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by-breath measurement of ventilation.  A 3 L volume syringe (Sensormedics, Loma 
Linda, CA, USA) was used to calibrate the mass flow sensor prior to each test.   
Mass Flow Sensor Heated Wire Anemometer-Mode of Operation  
The mass flow sensor is a low resistance tube with a tapered internal diameter 
extending from both ends of a laminar flow throat.  A cold and hot stainless steel wire 
electrically heated to -180°C and -240°C respectively, are centered in the flow stream.  
These wires are elements in a servo-controller bridge circuit that maintain the 
resistance ratio of the two wires at a constant value.  If only the temperature of the 
inspired gases changes then both wires lose heat at the same rate and no current 
change is required to keep the bridge balanced.  As air flows across the wires, the hot 
air loses heat more rapidly than the cold air and current must be added to keep the 
bridges balanced at a 3:4 ratio. The amount of current required is proportional to the 
mass flow of the gas.  This method ensures that the sensor measures only the heat loss 
from the molecular convection of the moving gas stream, and not the artefact due to 
cooling of the gas as it passes through a breathing assembly.   The mass flow meter 
responds to instantaneous flow rates between 0-16 L.sec-1 and integrated flow 
between 0-350 L min-1 with flow resistance <1.5 cmH2O L
 -1 sec-1.  The mass flow sensor 
was outputted to the analyser module of the Vmax 29c and was sampled at a rate of 
125 Hz.  
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Mass Flow Sensor Calibration  
A 3 L volume syringe (Sensormedics, Loma Linda, CA, USA) was connected to 
the mass flow sensor, and stroked four times in order to measure inspired and expired 
volumes.  The volumes were calculated by expressing 3 L as a fraction of each 
measured inspired and expired volume achieved during calibration.  An average 
correction factor was calculated for inspired and expired volumes, and used to fine-
tune the volume measurement.   
A verification procedure was performed. This involved stroking the 3 L volume 
syringe four times.  Inspired and expired volumes were measured using the newly 
calculated correction factors.  In order to pass the calibration procedure, one of the 
four strokes had to have an average flow rate < 0.5 L.sec-1, and at least one of the four 
strokes had to have an average flow > 3.0 L.sec-1.  
Gas Analysers  
The Vmax 29c utilizes a rapid response infrared measurement technique.  An 
O2 and CO2 analyser is integrated with the Vmax 29c.  A small sample of inspired air is 
drawn through a sample cell, and exposed to an infrared light through an optical that is 
passed through a band pass filter and the sample cell.  An infrared detector responds 
to the amount of infrared light that passes through the sample cell.  The amount of 
light that passes through the sample cell varies according to the concentration of CO2 
in the sample cell.  Based on measured levels of infrared light intensity, the analyser 
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computes the PCO2 in the gas sample.  The CO2 analyser is linearly scaled across the 0-
100% range with a resolution of 0.01% CO2, and a response time of < 130 ms (10-90%) 
at 500 ml min-1 flow.  The O2 analyser is based on the high paramagnetic susceptibility 
of O2.  A diamagnetic glass dumbbell suspended in a magnetic field rotates in 
proportion to the PO2.  The analyser is linearly scaled across the 0-100% range with a 
resolution of 0.01% O2 and a response time of < 130 ms (10-90%) at 500 ml min
-1 flow.  
Calibration of O2 and CO2 Gas Analysers 
The gas analysers were calibrated with standard gases of known concentration 
(BOC gases, Dublin, Ireland).  The first calibration gas contained 26.00 ± 0.02% O2 and 
the balance nitrogen (N2).  The second calibration gas contained 4.00 ± 0.02% CO2, 
16.00 ± 0.02% O2, and the balance N2.  A small bore drying tube connected to the CO2 
and O2 analysers sampled the calibration gases.  The absorption and evaporative 
properties of the drying tube ensured that the relative humidity of the calibration gas 
was equilibrated to ambient conditions prior to sampling by the O2 and CO2 analysers.  
The calibration gas was sampled at a rate of 125 Hz. The response time was similar 
between O2 and CO2 analyser. 
Calculation of Exercise Intensities  
Oxygen uptake at 60%, 70% and 80%   O2max was estimated for each 
participant using the individual linear regression equation between   O2 and treadmill 
velocity obtained during the initial three stages of the   O2max test based on the linear 
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relation between oxygen uptake (y-axis) and treadmill velocity (x-axis).  For a given 
percentage of the   O2max, the corresponding treadmill velocity was estimated by 
solving for x using the linear function y=mx + c, where y is   O2, x is speed, m is the 
slope of the relationship between   O2 and speed and c is the intercept point on the y 
axis.   
Submaximal Exercise Session 
On three separate occasions the participants reported to the Human 
Performance Laboratory in DCU the morning following an overnight fast.  The first 
submaximal exercise session was performed one week after the completion of the 
  O2max test.  A cannula was placed in a prominent forearm in order to take serial 
blood samples.  A resting blood sample was taken following 5 min of rest in a seated 
position.  Participants then exercised at a treadmill velocity corresponding to 60%, 70% 
or 80%   O2max until they expended 400 kcal.  Sessions were randomised and 
performed at least 4 d apart. Blood samples were taken immediately after exercise 
while the participant was standing on the treadmill and in a seated position at 2 h, 4 h 
and 6 h.   
The treadmill velocity was adjusted during the first 10 min of each exercise 
session in order to ensure that participants were exercising at the required intensity.  
Expired air was collected continuously throughout the exercise session and used to 
calculate caloric expenditure.101 Participants were weighed to the nearest 0.1 kg in 
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minimal clothing immediately before and after exercise in order to monitor fluid loss 
during the submaximal exercise sessions.  They were given a volume of plain water 
equivalent to 150% of weight loss to drink after the training session to ensure proper 
hydration levels.   
Dietary Control 
Participants were required to record their daily intake of food and fluids for 3 d 
prior to the first submaximal exercise session.  They were asked to repeat this dietary 
pattern before the remaining two submaximal exercise sessions to avoid any possible 
changes from variation in day to day dietary intake.  Participants consumed a 400 kcal 
drink immediately following the 4 h blood sample.  The drink consisted of 13.9 g of 
protein, 55.9 g of carbohydrate and 13.4 g of fat. 
Assessment of Body Composition  
Body density was calculated using the sum of seven skinfolds (triceps, 
subscapular, pectoral, mid-axillary, suprailiac, abdomen and thigh) by the method of 
Jackson and Pollock (1978).102  Skinfolds were measured using Harpenden skinfold 
callipers.  Percentage body fat was calculated using the Siri equations.103 
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Calculations of Energy Expenditure 
Values for   O2,   CO2, RER, VE (STPD), and FEO2 values were averaged from 
expired air every 60 s and used to calculate the rate of energy expenditure using the 
Weir equation.101  
Blood Sampling and Storage 
Serum vacutainers for lipid analysis were allowed to stand for 30 min at room 
temperature before being centrifuged at 3000 rpm (1600g) for 15 min at 4OC.  Blood 
for microparticles analysis was collected, prepared and stored according to methods 
described by Bernal-Mizrachi et al., (2004).104  Blood was collected in pre-chilled 
sodium citrate vacutainers before being centrifuged twice.  The first spin, 160 g for 9 
min, produced platelet rich plasma (PRP).  The top layer of this plasma was harvested 
and spun for a further 9 min at 1000g to PPP.  The PPP was aliquoted and stored at -
80C.  Blood for a complete blood count (CBC) was collected in EDTA vacutainers and 
allowed stand at room temperature before analysis. 
Microparticle Analysis 
Flow cytometry, using CellQuest software (FACScan, Becton Dickinson), was 
used to quantify microparticle numbers.  Microparticles were identified in PPP based 
on size and fluorescence, using 1.0 µm sizing beads and anti-CD 31 FITC and anti-
CD42b PE monoclonal antibodies.  EMPs were defined as CD31+/42b- and PMP were 
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defined as CD42b+.  An 85 µl volume of PPP was incubated for 20 min with 10 µl of 
anti-CD31 and 5 µl of anti-CD42b.  Samples were then diluted with 400 µl of PBS and 
analysed for 60 sec at medium speed.  The flow rate was calibrated before each run 
using 15 µl of flow count beads diluted in 485 µl of PBS.  Fluorescence thresholds were 
set using PPP incubated with isotype-matched control antibodies.  Samples were 
analysed in duplicate and all samples for each participant were analysed in the same 
run. 
Lipid Analysis 
Triglycerides, total cholesterol, HDL-C and LDL-C were analysed using an 
automated clinical chemistry analyser (Randox Daytona, Randox, NI).  A standard curve 
was generated from supplied calibrators of zero and a known concentration and 
control samples were subsequently analysed to check for accuracy.  Samples were run 
in duplicate and each participant’s samples were analysed in the same run. 
Leukocytes and Platelets 
Leukocytes and platelet numbers were measured using a Coulter AcTdiff2 
analyser (Beckman Coulter, Indianapolis, IN).  Each EDTA vacutainer was mixed gently 
by inversion before sampling and each sample was run in duplicate. 
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Statistical Analysis 
Prior to statistical analysis the data was checked for normality using the 
Shapiro-Wilk test.  EMP and PMP data was log transformed to conform to normality. 
An exercise intensity (60%, 70% and 80%   O2max) by time (pre, post, 2 h, 4 h and 6 h 
post-exercise) repeated measure ANOVA was used to compare the differences in 
EMPs, PMP, lipids and blood counts across the 3 different exercise intensities.  A one-
way ANOVA was used to compare the physiological responses, speed and time across 
the 3 exercise intensities.  Significant main effects and interactions were probed using 
a Bonferroni post hoc test, in the presence of significant interactions there was no 
analysis of main effects.  SPSS for Windows statistical software (ver. 19.0) was used to 
perform the statistical analysis. Statistical significance was accepted at the p<0.05 level 
of confidence. 
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Results 
Participant Characteristics 
A total of 10 healthy, physically active young men participated in the study 
(age, 21.6 ± 1.0 yr; BMI, 23.2 ± 0.4 kg.m-2; % body fat, 7.7 ± 1.0;   O2max, 58.8 ± 2.1 
ml.kg-1.min-1).   
Exercise Trials 
Total exercise time, %  O2max and total caloric expenditure during the 
submaximal exercise sessions are summarised in table 3.2.  There was no significant 
difference in caloric expenditure between the 3 exercise trials.  The time required to 
expend 400 Kcal was significantly longer during the exercise trial at 60%   O2max than 
70%   O2max and 80%   O2max and during the exercise trial at 70%   O2max than 80% 
  O2max.  There was no significant difference between predicted   O2 and actual   O2 
(Figure 3.2) or predicted treadmill velocity and actual treadmill velocity at any of the 
three exercise intensities. (Figure 3.3)  
Table 3.1: Percent   O2, total caloric expenditure and total exercise time 
    O2max 
 60% 70% 80% 
%   O2 60.93 ± 0.42 70.36 ± 0.44* 79.73 ± 0.45*† 
Total Kcal 405.05 ± 4.45 403.90 ± 2.04 398.01 ± 2.94 
Time (min) 30.88 ± 1.10 26.63 ± 0.81* 23.15 ± 0.68*† 
Values are mean ± SE; *p < 0.001 vs. 60%   O2max; †p < 0.001 vs. 70%   O2max 
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Figure 3.2: Predicted and measured   O2 (L
.min-1)  
Figure 3.3: Predicted and measured treadmill velocity (km.h-1)    
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Endothelial Microparticles 
The mean number of circulating EMPs 4 h following exercise at 70%   O2max 
and 6h following isocaloric bouts of exercise at 60%, 70% and 80%   O2max were 
significantly higher than pre-exercise.  Compared to post-exercise there was a 
significant decrease in the mean number of circulating EMPs 2 h following exercise at 
70%   O2max and a significant increase at 4 h following isocaloric bouts of exercise at 
60% and 80%   O2max.  There was a significant increase in the mean number of 
circulating EMPs at 4 h and 6 h following isocaloric bouts of exercise at 60%, 70% and 
80%   O2max than 2 h post-exercise.  There are no significant differences in circulating 
levels of EMPs between the three exercise intensities pre-exercise, post-exercise, 2 h, 
4 h and 6 h post-exercise. 
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Table 3.2: Circulating levels of EMPs (counts.µl-1) before and after isocaloric bouts of 
exercise at 60%, 70% and 80%   O2max 
    O2max 
 60% 70% 80% 
Pre-exercise 2029 ± 333 1451 ± 116 1647 ± 201 
Post-exercise 1749 ± 198 2170 ± 374 1695 ± 163 
2 h post-exercise 1969 ± 230 1275 ± 225† 1448 ± 199 
4 h post-exercise 2949 ± 487†‡ 2740 ± 450*‡ 2076 ± 165†‡ 
6 h post-exercise 2945 ± 328*‡ 2403 ± 198*‡ 2529 ± 284*‡ 
Values are mean ± SE. *p < 0.01 vs. pre-exercise; †p < 0.01 vs. post-exercise; ‡p < 0.05 
vs. 2 h post-exercise 
Platelet Microparticles 
The circulating levels of PMPs before and after isocaloric bouts of exercise at 
60%, 70% and 80%   O2max are summarised in table 3.4.  There was no significant 
difference in circulating PMP levels between the three different exercise intensities at 
pre-exercise, post-exercise, 2 h, 4 h and 6 h post-exercise.   
 
Table 3.3: Circulating levels of PMPs (counts.µl-1) before and after isocaloric bouts of 
exercise at 60%, 70% and 80%   O2max 
    O2max 
 60% 70% 80% 
Pre-exercise 10403 ± 1402 14206 ± 2857 19651 ± 3834 
Post-exercise 11595 ± 2334 17065 ± 2870 19916 ± 3790 
2 h post-exercise 20218 ± 7170 29347 ± 12846 15914 ± 3095 
4 h post-exercise 18664 ± 3123 17357 ± 4235 20929 ± 3803 
6 h post-exercise 15891 ± 2661 27468 ± 7099 17975 ± 4371 
Values are mean ± SE 
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Total Cholesterol 
Total serum cholesterol is summarized in table 3.5.  Total cholesterol was 
significantly higher (p<0.05) 2 h following exercise at 60% than 70%   O2max (p<0.05).  
There were no other significant differences in serum cholesterol levels between any of 
the three different exercise intensities at pre-exercise, post-exercise, 2 h, 4 h and 6 h 
post-exercise.  Within a given exercise intensity there was no significant difference in 
total serum cholesterol at any time point. 
Table 3.4: Total cholesterol (mmol.L-1) before and after isocaloric bouts of exercise at 
60%, 70% and 80%   O2max 
    O2max 
 60% 70% 80% 
Pre-exercise 4.20 ± 0.22 4.04 ± 0.16 4.15 ± 0.19 
Post-exercise 4.51 ± 0.24 4.17 ± 0.14  4.43 ± 0.20 
2 h post-exercise 4.77 ± 0.28* 3.98 ± 0.13 4.28 ± 0.16 
4 h post-exercise 4.34 ± 0.21 3.95 ± 0.14 4.23 ± 0.18 
6 h post-exercise 4.33 ± 0.19 4.16 ± 0.14 4.31 ± 0.20 
Values are mean ± SE; *p<0.05 vs. 70%   O2max 
Triglycerides 
Serum triglyceride concentrations at rest and at four time points following an 
isocaloric bout of exercise at 60%, 70% and 80%   O2max are summarised in table 3.6.  
Compared to pre-exercise there was a significant increase (p<0.01) in the mean serum 
triglyceride concentrations immediately following exercise at 80%   O2max.  Mean 
serum triglyceride concentrations were significantly lower than baseline 2 h following 
isocaloric bouts of exercise at 60%, 70% and 80%   O2max (p<0.01).  Compared to 2 h 
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post-exercise there was a significant increase in the mean serum triglyceride 
concentrations 6 h following isocaloric bouts of exercise at 60% and 70%   O2max 
(p<0.01).  There was no significant difference in triglyceride concentrations between 
any of the three different exercise intensities at pre-exercise, post-exercise, 2 h, 4 h 
and 6 h post-exercise. 
Table 3.5: Triglycerides (mmol.L-1) before and after isocaloric bouts of exercise at 60%, 
70% and 80%   O2max 
    O2max 
60% 70% 80% 
Pre-exercise 0.94 ± 0.08 0.95 ± 0.06 0.90 ± 0.08 
Post-exercise 1.01 ± 0.10 1.06 ± 0.05 1.03 ± 0.08¥ 
2 h post-exercise 0.86 ± 0.10† 0.84 ± 0.07† 0.90 ± 0.08† 
4 h post-exercise 0.97 ± 0.15 0.90 ± 0.09 0.98 ± 0.12 
6 h post-exercise 1.17 ± 0.15* 1.10 ± 0.10* 1.04 ± 0.10 
Values are mean ± SE. †p < 0.01 vs post-exercise; ‡p < 0.01 vs 2h; *p < 0.01 vs 2 h; ¥p < 
0.01 vs pre-exercise 
HDL-C 
Circulating levels of HDL-C at rest and at 4 time points following isocaloric bouts 
of exercise at 60%, 70% and 80%   O2max are summarized in table 3.7.  Compared to 
pre-exercise Serum HDL-C levels were significantly higher (p<0.01) immediately 
following exercise at 80%   O2max than pre-exercise and significantly lower (p<0.01) 
following exercise at 70%   O2max than immediately post-exercise.  There was no 
significant difference in serum HDL-C concentrations between the three exercise 
intensities at pre-exercise, post-exercise, 2 h, 4 h and 6 h post-exercise. 
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Table 3.6: HDL-C (mmol.L-1) before and after isocaloric bouts of exercise at 60%, 70% 
and 80%   O2max 
    O2max 
 60% 70% 80% 
Pre-exercise 1.29 ± 0.09 1.24 ± 0.05 1.29 ± 0.08 
Post-exercise 1.31 ± 0.09 1.29 ± 0.07 1.38 ± 0.09† 
2 h post-exercise 1.32 ± 0.09 1.21 ± 0.06* 1.33 ± 0.09 
4 h post-exercise 1.29 ± 0.08 1.24 ± 0.07 1.32 ± 0.10 
6 h post-exercise 1.30 ± 0.09 1.27 ± 0.07 1.32 ± 0.08 
Values are mean ± SE. *p < 0.01 vs. post-exercise; †p < 0.01 vs. pre-exercise 
LDL-C 
Serum LDL-C concentrations at rest and following isocaloric bouts of exercise at 
60%, 70% and 80%   O2max are summarized in table 3.8.  There were no significant 
difference in the serum [LDL-C] at any time within a given exercise intensity or 
between the three exercise intensity levels at pre-exercise, post-exercise, 2 h , 4 h and 
6 h post-exercise. 
 
Table 3.7: LDL-C (mmol.L-1) before and after isocaloric bouts of exercise at 60%, 70% 
and 80%   O2max 
    O2max 
 60% 70% 80% 
Pre-exercise 2.49 ± 0.16 2.37 ± 0.13 2.45 ± 0.13 
Post-exercise 2.75 ± 0.23 2.40 ± 0.10  2.58 ± 0.13 
2 h post-exercise 3.05 ± 0.30 2.39 ± 0.11 2.54 ± 0.11 
4 h post-exercise 2.61 ± 0.16 2.31 ± 0.11 2.46 ± 0.12 
6 h post-exercise 2.50 ± 0.15 2.39 ± 0.12 2.52 ± 0.15 
Values are mean ± SE 
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Leukocytes 
The number of circulating leukocytes at rest and following isocaloric bouts of 
exercise at 60%, 70% and 80%   O2max are summarized in table 3.9.  At each of the 
three exercise intensities the number of circulating leukocytes was significantly higher 
immediately post-exercise and at 4 h post-exercise than pre-exercise.  Compared to 
pre-exercise, there was a significant increase in the mean number of circulating 
leukocytes 6 h following an isocaloric bout of exercise at 60% and 80%   O2max and at 
2 h following exercise at 80%   O2max.  There was no significant difference the number 
of circulating leukocyte between the three different exercise intensities at pre-
exercise, post-exercise, 2 h, 4 h and 6 h post-exercise. 
Table 3.8: Leukocytes (x103.µl-1) before and after isocaloric bouts of exercise at 60%, 
70% and 80%   O2max 
    O2max 
 60% 70% 80% 
Pre-exercise 6.21 ± 0.29 6.58 ± 0.54 6.39 ± 0.61 
Post-exercise 7.49 ± 0.50† 8.55 ± 0.61† 9.48 ± 0.81† 
2 h post-exercise 7.11 ± 0.59 7.55 ± 0.79 8.02 ± 0.68† 
4 h post-exercise 7.46 ± 0.41‡ 7.99 ± 0.61‡ 8.41 ± 0.69† 
6 h post-exercise 7.69 ± 0.41† 7.47 ± 0.63 8.07 ± 0.64† 
Values are mean ± SE. †p < 0.01 vs. pre-exercise; ‡p < 0.05 vs. pre-exercise. 
 
Platelets 
Platelet numbers at rest and following isocaloric bouts of exercise at 60%, 70% 
and 80%   O2max are summarised in table 3.10.  Compared to pre-exercise there was a 
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significant increase in the number of circulating platelets immediately following 
isocaloric bouts of exercise at 70% and 80%   O2max.  Circulating levels of platelets 
were significantly higher immediately post-exercise than 2 h and 4 h post-exercise 
following isocaloric bouts of exercise at 60%, 70% and 80%   O2max and at 6 h 
following exercise at 80%   O2max.  There was no significant difference in platelet 
numbers between the three different exercise intensities at pre-exercise, post-
exercise, 2 h, 4 h and 6 h post-exercise. 
 
Table 3.9: Platelets (x103.µl-1) before and after 3 isocaloric bouts of exercise at 60%, 
70% and 80%   O2max 
    O2max 
 60% 70% 80% 
Pre-exercise 276.00 ± 22.24 260.50 ± 16.93 267.40 ± 20.52 
Post-exercise 311.60 ± 22.06† 326.10 ± 23.65*† 343.30 ± 30.12*†‡ 
2 h post-exercise 277.30 ± 20.18 263.80 ± 17.19 269.00 ± 20.72 
4 h post-exercise 279.70 ± 20.74 275.30 ± 20.07 281.40 ± 21.61 
6 h post-exercise 290.80 ± 15.24 291.60 ± 23.47 284.50 ± 2.93 
Values are mean ± SE. *p < 0.01 vs pre-exercise; †p < 0.05 vs. 2 h post-exercise and 4 h 
post-exercise; ‡p < 0.01 vs 6 h post-exercise 
 
Summary 
Isocaloric bouts of exercise at 60%, 70% and 80%   O2max resulted in 
significantly higher circulating levels of EMPs at 6 h post-exercise than pre-exercise.  
Compared to pre-exercise values there was no significant change in circulating levels of 
PMPs at any time up to 6 h following isocaloric bouts of exercise at 60%, 70% and 80% 
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  O2max.  An exercise induced leucocytosis was evident immediately post-exercise and 
4 h post-exercise following isocaloric bouts of exercise at 60%, 70% and 80%   O2max 
and at 6 h following isocaloric bouts of exercise at 60% and 70%   O2max.  Platelet 
levels immediately post-exercise were significantly higher than baseline following 
exercise at the two highest intensities. 
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Discussion 
The first study examined the acute effects of an isocaloric bout of exercise (400 
kcal) at 60%, 70% and 80%   O2max on circulating EMP and PMP numbers.  Circulating 
EMP numbers were significantly higher than pre-exercise values at 6 h following 
exercise at 60%, 70% and 80%   O2max.  The findings indicate that the exercise induced 
alterations in circulating EMPs are possibly related to caloric expenditure and 
independent of exercise intensity.  The minimum caloric expenditure required to 
increase circulating EMPs is currently unknown and should be addressed in future 
studies. 
The time course of the acute exercise-induced changes in EMP numbers in the 
present study is in contrast to previously findings.  Kirk et al., (2013) found an increase 
in EMPs (CD105 and CD106) 90 min following a bout of repeated supra-maximal sprint 
cycling.  The values returned to baseline at 180 min post-exercise.65  Sossdorf et al., 
(2011) found an increase in EMPs (CD62E) in trained individuals 45 min following 1.5 h 
of cycling at 80% IAT and values returned to basal levels 2 h post-exercise.64  In the 
present study there was an increase in EMPs immediately following the exercise bout 
at 70%   O2max with values returning to baseline at 2 h post-exercise.  Mobius-Winkler 
et al., (2009) 68 found an increase in markers of endothelial damage but no change in 
EMPs (CD42b-/CD62E+) following 240 min of cycling at 70% IAT.  Methodological 
differences across studies make it difficult to compare results.  Participant fitness 
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levels, relative workload, blood sampling time points, exercise duration and modality 
may affect the release of MPs and should be controlled in future studies.  MP origin 
also makes it difficult to compare studies.  CD62E EMPs are associated with cell 
activation, while the EMPs in the present study are associated with cell apoptosis. 
Similar to previous studies circulating PMPs numbers were significantly higher 
than EMP numbers at all time points in the three exercise trials.  Compared to baseline 
values, there was no change in circulating PMP numbers following an isocaloric bout of 
exercise at 60%, 70% or  0%   O2max.  In contrast, Sossdorf et al., (2011) reported an 
increase in PMP numbers following 90 min of cycling at 80% IAT.64  The fact that the 
bout of exercise was considerably longer than the present study may help to explain 
the different findings.  However, Maruyama et al., (2012) using ELISA, found an 
increase in PMPs following an incremental exercise test to only 85% of age predicted 
heart rate maximum.67  It is possible that the ELISA may be a more sensitive method of 
measuring of PMP numbers or that it could be less sensitive and misclassified the 
number of circulating PMPs. 
The number of circulating leukocytes increased significantly immediately 
following exercise at 60%, 70% and  0%   O2max and remained elevated at all time 
points up to 6 h following exercise at  0%   O2max.    Platelet numbers follow a similar 
trend with circulating numbers significantly higher immediately post-exercise and 
remaining slightly elevated for up to 6 h of recovery.   
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Exercise induced leucocytosis is a common response to acute exercise and is 
due primarily to an increase in circulating numbers of leukocytes and lymphocytes.105  
The degree of leucocytosis is dependent on the intensity, duration and type of 
exercise.  A major source of leukocytes appears to be the marginated pool.  Leukocytes 
adhere to areas of the vascular endothelium outside the main axial flow where blood 
flow in much slower.  An increase in shear stress appears to be responsible for the 
majority of leukocyte demargination in response to exercise.  Other factors that may 
influence demargination include opening of capillaries and the direct effect of 
catecholamine’s on 1 adrenergic receptors on cell surface adhesion molecules, in 
multiple vascular beds.106  
The increase in platelet numbers was not related to an increase in PMPs.  PMPs 
have been linked to increases in inflammation in previous studies.15,107  It is possible 
that the inflammatory response to the acute exercise bouts may not have reached a 
threshold for the release of PMP.  The longest trial, (60%   O2max) was 31 min in 
duration and this may not be long enough to activate PMPs.  The large inter-individual 
variation in PMP numbers makes it difficult to detect significant changes.  Differences 
in blood processing and antibodies used in PMP analyses may also help to explain the 
different findings. 
At all exercise intensities circulating triglyceride levels were significantly lower 2 
h post-exercise than immediately post-exercise and in the 60% and 70%   O2max trials 
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values are significantly higher 6 h post-exercise than 2 h post-exercise.  Acute exercise 
transiently reduces serum triglycerides with the effect not always immediately 
apparent.93,108  Decreased levels of post-exercise triglycerides have been linked to 
increased levels of muscle lipoprotein lipase activity.  Lipoprotein lipase (LPL), located 
on the capillary endothelium of extrahepatic tissues, catalyzes the rate limiting step in 
the hydrolysis of triglycerides from circulating chylomicrons following a meal and 
endogenously produced very low density lipoprotein (VLDL).  Quantitatively, the 
majority of LPL is found in muscle and adipose tissue, where the liberated free fatty 
acids are taken up and either stored or oxidized, respectively.109  The significant 
increase in triglycerides immediately following exercise at  0%   O2max was an 
unexpected finding and may have been due to plasma fluid shifts. 96 
This study aimed to compare the acute effects of isocaloric bouts of exercise at 
moderate to vigorous intensities on circulating EMP and PMP levels in young healthy 
physically active men.  EMP levels increase following acute exercise at all intensities.  
There are no changes in PMP levels. 
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Chapter IV 
Study II 
The Effect of Exercise Training on Microparticle Formation in Men 
Rationale 
 Isolated exercise sessions elicit acute responses that when repeated produce 
more permanent adaptations, referred to as the exercise training response.  Exercise 
training has been reported to have numerous beneficial effects on cardiovascular and 
metabolic health.  MPs have been linked to a number of the processes linked to these 
beneficial effects.  To date the effect of exercise training on MP formation is not 
currently known.  The purpose of this study was to examine the effects of exercise 
training on circulating levels of EMPs and PMPS in young healthy men.   
Specific Aims: 
1. To examine the time-course changes in circulating EMP numbers pre-exercise, 
immediately following 1 h of exercise at 80%   O2peak and 13 h following 
exercise on days 1, 3, 7, 10 and 14 of a 14 day training program 
2. To examine the time-course changes in circulating PMP numbers pre-exercise, 
immediately following 1 h of exercise at 80%   O2peak and 13 h following 
exercise on days 1, 3, 7, 10 and 14 of a 14 day training program 
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3. To examine the changes in total cholesterol, LDL-C, HDL-C and triglycerides 
following 14 consecutive days of training at 80%   O2peak  
 
Hypothesis: 
1. There will be no significant difference in circulating EMP numbers pre-exercise, 
immediately following 1 h of exercise at 80%   O2peak and 13 h following 
exercise on days 1, 3, 7, 10 and 14 of a 14 day training program 
2. There will be no difference in circulating PMP numbers pre-exercise, 
immediately following 1 h of exercise at 80%   O2peak and 13 h following 
exercise on days 1, 3, 7, 10 and 14 of a 14 day training program 
3. There will be no significant difference in total cholesterol, LDL-C, HDL-C and 
triglycerides following 14 consecutive days of training at 80%   O2peak  
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Methodology 
Study Overview 
An overview of the study design is illustrated in figure 4.1.  Eight healthy, 
sedentary men performed 60 min of submaximal exercise training once a day for 14 
consecutive days.  Prior to commencing the training, participants visited the Human 
Performance Laboratory (HPL) in DCU on two separate occasions.  During the first visit 
they underwent a brief medical screen consisting of a general health questionnaire 
(Appendix A), medical examination, body composition assessment, ECG and an 
exercise test on a cycle ergometer to measure peak oxygen uptake (  O2peak).  
Participants returned to the HPL within a week and performed a test to verify the work 
rate corresponding to 80%   O2peak.  Exercise commenced 7 d after the verification 
trial.  Peak oxygen uptake was re-assessed 48 to 72 h following the final exercise 
session.  
 
 
Figure 4.1: Study overview 
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Participants 
Eight healthy, sedentary men volunteered to participate in the study.  
Participants were excluded if they were current smokers, involved in regular physical 
exercise or had any other medical conditions that contraindicated exercise 
participation. 
Participant Recruitment 
An email was sent to all registered undergraduate students, graduate students 
and staff in Dublin City University (Appendix F).  Individuals expressing interest 
received a plain language statement detailing the requirements of the study (Appendix 
G).  Written informed consent was obtained from individuals who met the inclusion 
and exclusion criteria and agreed to take part in the study. (Appendix H).  The study 
was approved by the Dublin City University Research Ethics committee. (Appendix I)   
Training program 
Training consisted of 14 x 1 h supervised exercise training sessions on 14 
consecutive days. (Figure 4.2)  Each training session was 60 min in duration and 
performed at an intensity corresponding to 80% of pre-training   O2peak.  To avoid any 
influence from changes in circadian variation on exercise performance participants 
performed their session at the same time ± 1 h each day.  Participants trained between 
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17:00 and 20:00.  Plain water was allowed to be consumed ad libitum throughout the 
training sessions.   
 
Figure 4.2: Exercise overview 
Exercise intensity was monitored by measuring oxygen uptake between 15-20 
min, 35-40 min and 55-60 min of each exercise session and workload was adjusted 
when appropriate.  Heart rate and RPE were recorded at 5 min intervals throughout 
each training session.  To ensure that exercise intensity matched the expected increase 
in   O2peak during the training session, target   O2 was increased by 10% after day 7 of 
training.  Using similar training protocols, Gulve and Spina (1995)98 and Spina et al., 
(1996)110 have shown a 9-10% increase in   O2peak after 7-10 days of cycle ergometer 
training. 
A total of 16 blood samples were taken during the period of exercise training.  
On the morning of day 1, participants reported to the HPL after an overnight fast and 
the first blood sample was taken (#1).  Participants returned later on day one for their 
first training session. Blood was taken before (#2 pre-exercise) and after the training 
session (#3 post-exercise). Participants were asked not to eat or consume caffeine for 
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2 h before the start of the training session.  The following morning, day 2, participants 
returned to the HPL after an overnight fast and a blood sample was taken (#4).  Blood 
was taken before and after the third training session (#5, #6) and again the following 
morning, day 4, after an overnight fast (#7).  This procedure was repeated for training 
session 7 (#8, #9, #10), session 10 (#11, #12, #13) and session 14 (#14, #15, #16).   
Workload Determination 
The   O2 relating to a given power output was calculated based on the linear 
relation between oxygen uptake (y-axis) and power output (x-axis).  For a given 
percentage of   O2peak, the corresponding power output was estimated by solving for 
x using the linear function y=mx + c, where y is   O2, x is power output, m is the slope 
of the relation between   O2 and power and c is the intercept point on the y axis.   
Verification of Exercise Intensity 
Each participant performed three 10 min verification trials involving exercising 
at 15 W below the predicted power output, 15 W above the predicted power output 
and at the predicted power output.  They were encouraged to keep the pedal cadence 
between 75 and 80 rpm for all exercise sessions.   
Peak Oxygen Uptake 
Participants performed an incremental exercise test to volitional exhaustion on 
an electronically braked cycle ergometer (Ergoline 900, SensorMedics, Yorba Linda, CA) 
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to determine   O2peak.  Following a 5 min warm-up at 80 W, the workload was 
increased by 40 W every 2 min until volitional exhaustion.  Respiratory metabolic 
measures were monitored continuously throughout the test.  Peak oxygen uptake was 
determined by averaging the three highest consecutive 20 sec values.   
Assessment of Body Composition  
Body density was calculated using the sum of seven skinfolds (triceps, 
subscapular, pectoral, mid-axillary, suprailiac, abdomen and thigh) by the method of 
Jackson and Pollock (1978).102  Skinfolds were measured using Harpenden skinfold 
callipers.  Percentage body fat was calculated using the Siri equation.103 
Calculations of Energy Expenditure 
Values for   O2,   CO2, RER,   E (STPD), and FEO2 were recorded from expired air 
using 60 s averages and used to calculate the rate of energy expenditure using 
equations from Kuo et al., (2005).111  
Cardiorespiratory and Metabolic Measures  
As described in the methods section of Chapter 3 
Mass Flow Sensor Heated Wire Anemometer-Mode of Operation  
As described in the methods section of Chapter 3. 
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Mass Flow Sensor Calibration  
As described in the methods section of Chapter 3. 
Gas Analysers 
As described in the methods section of Chapter 3. 
Calibration of O2 and CO2 Gas Analysers 
As described in the methods section of Chapter 3. 
Blood Sampling and Storage 
Morning blood samples were taken from a prominent forearm vein using 
standard venipuncture. Prior to the blood draw participants rested in a seated position 
for 5 min with legs uncrossed to avoid plasma fluid shift changes.  Pre and post-
exercise samples were taken using a cannula placed in a prominent forearm vein.  Pre-
exercise samples were collected following 5 min rest in a seated position. Post-exercise 
samples were taken at the end of the training session with the participant sitting on 
the cycle ergometer.   
Serum vacutainers were allowed stand for 30 min at room temperature before 
being centrifuged at 3000 rpm (1600 g) for 15 min at 4OC.  Blood for microparticles 
analysis was collected, prepared and stored according to methods described by Bernal-
Mizrachi et al., (2004).104  Blood was collected in pre-chilled sodium citrate vacutainers 
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before being centrifuged twice.  The first spin, 160 g for 9 min, produced platelet rich 
(PRP) plasma.  The top layer of this plasma was harvested and spun for a further 9 min 
at 1000 g to produce platelet poor plasma (PPP).  The PPP was aliquoted and stored at 
-80OC. 
Microparticle Analysis 
As described in the methods section of Chapter 3. 
Lipid analysis 
As described in the methods section of Chapter 3. 
Dietary Control 
Participants were required to record their daily intake of food and fluids for 3 d 
before the start of the training sessions.  They repeated this dietary pattern 
throughout the training phase to avoid any possible changes from variation in day to 
day dietary intake.  Participants were weighed to the nearest 0.1 kg in minimal clothing 
immediately before and after each training session in order to monitor fluid loss during 
the training sessions.  To ensure proper hydration levels they were given a volume of 
plain water equivalent to 150% of weight loss to drink after the training session.  After 
each training session, participants were given two cereal bars (Nutrigrain, Kellog’s, UK) 
to consume with the water.  The cereal bars contained 50 g of carbohydrates, 3 g of 
protein and 7 g of fat. 
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Statistical analysis 
Prior to statistical analysis the data was checked for normality using the 
Shapiro-Wilk test.  EMP and PMP data were log transformed to conform to normality.  
An independent t-test was used to compare anthropometric data,   O2peak, lipids, MPs 
and estimated EE before and after the 14 days training and to compare O2 
consumption between week 1 and week 2 of training.  A repeated measure ANOVA 
was used to compare MP formation during the 14 d of training.  A one way ANOVA was 
used to compare circulating MP levels within training days.  A one way ANOVA was 
used to compare morning samples, pre-exercise samples and post-exercise samples.  
Significant main effects were probed using a Bonferroni post hoc test.  The relation 
between changes in MP numbers and changes in aerobic fitness after the intervention 
was established using Pearson’s product moment correlation.  SPSS for Windows 
statistical software (ver. 19.0) was used to perform the statistical analysis. Statistical 
significance was accepted at the p < 0.05 level of confidence.   
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Results 
Participant Characteristics 
After completion of the experiment one of the participants was diagnosed with 
a chronic inflammatory disease.  As this condition may affect MP formation his data 
was excluded and data from the remaining 7 participants was analysed.  They were 
(mean ± SE) 20.7 ± 0.9 yr, had a body mass of 75.2 ± 3.4 kg and had an estimated % 
body fat of 12.2 ± 2.2.  Physical characteristics and aerobic endurance before and after 
the 14 d training program are summarised in Table 4.1.  There were no significant 
changes in body mass or BMI following the 14 d training period.  There was an 18.3% 
(p<0.01) and 17.9% (p<0.01) increase in relative and absolute   O2peak respectively, 
following the 14 d of training.   
Table 4.1: Anthropometrics 
 Time 
 Pre Training Post Training 
BMI (kg.m-2)  23.3 ± 1.0 23.2 ± 1.0 
  O2max (L
.min-1) 2.88 ± 0.43 3.36 ± 0.25* 
  O2max (ml
.kg-1.min-1) 39.4 ± 3.9 45.8 ± 3.1* 
Values are mean ± SE; *p < 0.01 vs. pre training  
Oxygen consumption 
The absolute O2 consumption and percentage of   O2peak averaged across the 
entire 14 d training period are summarised in table 4.2.  The average absolute   O2 was 
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significantly higher in week 2 than week 1.  During the 14 d training period participants 
exercised at 80.7   2.0% and 6 .9   2.5% of the pre training   O2peak of the post 
training   O2peak, respectively.   
Table 4.2: Average metabolic data 
 Metabolic Data 
   O2 (L min
-1) %   O2peak Pre %   O2peak Post 
Day 1 to 7 2.24 ± 0.10 78.0 ± 2.0 66.6 ± 2.2 
Day 8 to 14 2.39 ± 0.11* 83.4 ± 2.1* 71.2 ± 2.7* 
Day 1 to 14 2.32 ± 0.11 80.7 ± 2.0 68.9 ± 2.5 
Values are mean ± SE.  *p < 0.01 vs. day 1 - 7 
Energy Expenditure 
Average EE for the first 7 days, the second 7 days and the 14 d training period 
(mean ± SE) are summarised in figure 4.3.  The average training EE over the 14 day 
period was 695 ± 30 kcal.  The average training EE was significantly higher in week 2 
than week 1 (672 ± 30 vs. 718 ± 34 kcal). 
Relative and absolute O2 uptake, EE and % contribution of CHO and fats during 
exercise on day 1, 7 and 14 are summarised in table 4.3.  Oxygen consumption was 
8.6% higher on day 14 than day 1, although the difference did not reach statistical 
significance (p = 0.07).  Relative   O2 was significantly higher on day 14 than day 1.  
There was a non-significant (p = 0.07) increase in EE over the 14 days.  The percentage 
contribution from CHOs was significantly higher at day 7 compared to day 1.  The % 
contribution from fat was significantly lower at day 7 compared to day 1. 
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Figure 4.3: Estimated EE during the training period; *p<0.05 vs day 1 - 7  
 
Table 4.3: Oxygen uptake, energy expenditure and substrate utilisation during exercise 
on day 1, 7 and 14 
Metabolic Data 
  O2 
(L/min) 
%   O2peak 
Pre 
%   O2peak 
Post 
Estimated 
EE (kcal) 
% CHO 
oxidation 
% Fat 
oxidation 
Day 1 2.22 ± 0.1 77.5 ± 2.1 65.9 ± 1.5 665 ± 22 86.0 ± 2.0 14.0 ± 2.0 
Day 7 2.26 ± 0.1 78.7 ± 1.4 67.2 ± 1.9 680 ± 27 89.6 ± 2.1* 10.4 ± 2.1* 
Day 14 2.41 ± 0.1 83.8 ± 2.2* 71.5 ± 2.5 724 ± 39 89.5 ± 1.0 10.5 ± 1.0 
Values are mean ± SE.  *p < 0.05 vs. day 1 
 
Endothelial Microparticles 
Circulating levels of EMPs before training and 13 h following the last training 
session are illustrated in figure 4.4.  There was a significant decrease in EMPs 13 h 
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following the last exercise bout than baseline.  Circulating levels of EMPs at pre-
exercise, immediately post-exercise and 13 h  post-exercise following 5 of the exercise 
bouts (day 1, 3, 7, 10, 14) are illustrated in figure 4.5.  There were no differences 
between morning EMP numbers on day 2, 4, 8, 11, or 15.  There was no significant 
difference between the pre-exercise circulating EMP numbers on day 1, 3, 7, 10 and 
14.  There was no difference between the post-exercise EMP numbers on day 1, 3, 7, 
10 and 14.  On training days 3, 7, 10 and 14 EMP values increased (non-significantly) 
immediately after exercise compared to pre-exercise values.  With the exception of the 
day 10 exercise bout, circulating EMPs were significantly lower than immediately post-
exercise 13 h following each of the exercise bouts.  On training days 1, 7 and 14 EMP 
values were significantly lower 13 h post-exercise than the pre-exercise values (figure 
4.5).   
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Figure 4.4: EMP values before training and 13 h after the last bout. *p < 0.05 vs. pre 
training  
Figure 4.5: EMP values around training bouts 1, 3, 7, 10 and 14; *p < 0.05 vs. post-
exercise, †p < 0.05 vs. pre-exercise  
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Platelet Microparticles 
PMP values during the 14 d training period are illustrated in figure 4.6.  There 
were no significant differences in the number of circulating PMP at any time point 
during the 14 d of training.  The only pattern apparent during the training sessions is a 
decrease immediately post-exercise compared to pre-exercise on training days 1, 3, 7, 
10 and 14.  However none of the values reached statistical significance. 
 
Figure 4.6: PMP values around training bouts 1, 3, 7, 10 and 14 
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Endothelial Microparticles and Aerobic Fitness 
There was no relation between changes in circulating EMP values between pre 
training and values on day 15 and changes in aerobic fitness following exercise training 
in young healthy men (r=0.453, p=0.307). 
Lipids 
Serum triglycerides, total cholesterol, LDL-C and HDL-C were measured before 
training, at day 8 and 13 h after the last training bout and the results are illustrated in 
figure 4.7.  Serum cholesterol and LDL-C concentrations were significantly lower on day 
8 than baseline.  Post training serum cholesterol and LDL-C concentrations remained 
low compared to baseline. However, the difference did not reach significance (p = 
0.057).  There were no significant changes in triglyceride or HDL-C concentrations 
during or following the 14 d training protocol. 
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Figure 4.7: Lipid values at baseline, day 8, post 14 d training.  *p < 0.05 vs. pre training 
Summary 
Following 14 consecutive days of exercise training there was a significant 
increase in aerobic fitness.  There was a significant decrease in circulating EMPs 13 h 
following the last exercise bout compared to baseline.  Circulating EMPs did not 
change significantly immediately following any if the five exercise bouts. In contrast 
circulating EMPs 13 h following exercise were significantly lower than pre-exercise on 
days 1, 7 and 14 and significantly lower than post-exercise on days 1, 3, 7 and 14.   
There was no relation between changes in circulating EMP numbers and changes in 
aerobic fitness.  Total serum cholesterol and LDL-C were significantly lower than pre 
training values after 7 days of training.  They remained lower than baseline after 14 
days but were not significantly lower.   
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Discussion 
Study two examined the effect of 14 consecutive days of exercise on MP 
numbers in sedentary men.  Participants cycled at 80%   O2peak for 1 h each day and 
blood was taken before exercise, immediately after exercise and 13-14 h following 
exercise on 5 separate days during the 2 weeks of training.  The high volume and 
intensity training protocol was employed in an attempt to elicit a significant change in 
aerobic fitness in a short time period.  The 14 d training was a sufficient stimulus to 
improve aerobic fitness as indicated by a significant increase in both absolute and 
relative   O2peak.   
EMP numbers followed a similar trend throughout the duration of the study.   
Compared to pre-exercise values there was on average a small non-significant 10% 
increase in EMPs immediately post-exercise.  Circulating EMP levels were on average 
50% below pre-exercise values and 45% below immediately post-exercise the following 
morning (+13 h).  The morning EMP values were significantly lower than pre-exercise 
on day 1, 7 and 14 and significantly lower than post-exercise values on day 1, 3, 7 and 
14.  Increased EMP numbers have been associated with CVD risk factors so it is 
possible the lower EMP numbers point to cardio protective benefits of the exercise.  
The circulating levels of PMPs did not change at any time during the 15 days.   
It is difficult to draw any definite conclusion from the fact that circulating EMP 
numbers were significantly lower than pre training values 13 h following the 14 d 
109 
 
training period.  This is due to the fact that no exercise was performed the day prior to 
the pre training blood sample whereas participants exercise for 1 h at 80%   O2peak 13 
h prior to the blood draw.  In hindsight, a blood sample for MP quantification post 
training should have been taken 2 – 3 days following the cessation of the final exercise 
session to avoid possible interference from the exercise. 
It is evident from the pre-exercise EMP numbers that time of day and possibly 
daily activities have an effect on EMP numbers.  Pre-exercise circulating EMP numbers, 
taken in the evening between 17:00 and 19:00 h following a 2 h fast, were consistently 
higher than morning samples, taken 13 h after the training session and following an 
overnight fast.  Although blood samples were not taken on the morning of the training 
sessions it is unlikely, based on the measurements taken on 5 of the 14 days, that 
there would be a significant difference in circulating EMPs from the values measured 
on the morning after each training session.  Future studies need to more rigorously 
assess diurnal variation in circulation EMP levels.  Future research will also need to 
take time of day into account when designing their research. 
This is the first short term training study to assess the changes in EMP numbers 
in young healthy men.  Babbitt et al., (2013) found a decrease in EMPs and IL-6 and an 
improvement in FMD following 6 months of aerobic exercise training in middle aged, 
healthy African American men and women.70  Participant and methodological 
differences makes it difficult to compare the results between the two training studies. 
110 
 
During the 14 days of training there was no change in MP numbers pre-
exercise, immediately post-exercise or 13 h post-exercise across the 5 training days in 
which MPs were measured.  Average caloric expenditure equated to 695 kcal per day, 
or approximately 10000 kcal over the 14 day period.  There was a significant increase 
in both relative and absolute   O2peak and a decrease in total cholesterol and LDL-C 
but no change in MP numbers.  This consistent response at each time point may 
indicate that MPs in young healthy men are resistant to change despite the high 
workload during the training protocol.   
An increase in HDL-C is the most commonly reported change in lipid profiles 
following exercise training with decreases in LDL-C, total cholesterol and TGs less 
frequently reported.112  In study 2 there were no changes in HDL-C or TGs.  Total 
cholesterol and LDL-C and were significantly lower on morning 8 compared to baseline 
values.  Although the LDL-C values remained lower on morning 15 the decrease did not 
reach significance (p = 0.057).  Changes in LDL-C and total cholesterol are associated 
with exercise training programs in which participants expend more than 1200 kcal.wk-
1. 113  Changes are also more likely to be found in previously sedentary individuals.  
Participants in study 2 had an average   O2peak of 39.4 ± 3.9 ml
.kg.min-1 at pre training, 
which places them in the bottom 25% of aerobic fitness for their age.114  The average 
estimated EE for each session over the 14 days was 695 ± 32 kcal which is considerably 
higher than the 1200 kcal/wk reported to be associated with decreases in LDL-C and 
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total cholesterol.  The training protocol may however, not have been of sufficient 
length to elicit changes in HDL-C. 
There was no relation between changes in aerobic fitness and changes in MP 
numbers.  The large individual variations between the changes in MP numbers and the 
small sample size make correlations difficult to examine.  
The aim of study 2 was to compare circulating EMP and PMP numbers pre-
exercise, immediately following 1 h of exercise at 80%   O2peak and 13 h following 
exercise on days 1, 3, 7, 10 and 14 of a 14 day training program.  EMP numbers were 
significantly lower 13 h after exercise possibly due to a cardio protective role of the 
exercise.  There were no significant changes in PMP numbers.  Triglycerides and LDL-C 
improved during the course of the training and could also be linked to improvements 
in CVD risk factors. 
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Chapter V 
Study III 
Microparticles and Endothelial Function Response to Exercise Training in Individuals 
with Cardiovascular Disease 
Rationale 
The vascular endothelium is a complex dynamic barrier that plays a central role 
in maintaining vascular integrity.  Established CVD risk factors promote the 
development of atherosclerosis through their deleterious effects on endothelial 
structure and function.  Impairment of the normal function of the endothelium, a 
process known as endothelial dysfunction (ED), represents one of the earliest events in 
the pathogenesis of atherosclerosis and is evident prior to angiographic detection of 
the disease.   
Circulating levels of EMPs are increased in individuals with established 
cardiovascular disease risk factors linked to endothelial dysfunction.44,55  Furthermore, 
MPs from patients following a myocardial infarction cause severe endothelial 
dysfunction in healthy rat aortic rings.115  Impairment in endothelial function may be 
related to a reduced production and/or availability of NO.  To date, no in vivo studies 
have examined the relation between circulating MPs and endothelial function in men 
and women with CVD.   
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An increase in cardiorespiratory fitness in response to traditional continuous, 
moderate-to-vigorous exercise training programs can reverse endothelial dysfunction 
in individuals with atherosclerotic CVD.  Relatively few studies have examined the 
effects of exercise training on MP formation in this clinical population.  More recently, 
low volume short duration, high-intensity interval training (LS-HIIT) involving repeated 
bouts of short-duration high intensity exercise separated by periods of active or 
passive recovery have been shown to be a safe and effective alternative to more 
traditional continuous, moderate-to-vigorous exercise programs in improving exercise 
capacity and endothelial function in individuals with CVD.  Studies in healthy 
individuals have found physiological and metabolic improvements following 4 - 8 
sessions of LS-HIIT involving 30 sec exercise bouts.   
The purpose of this study is to compare the effects of 4 weeks of LS-HIIT and 
cardiac rehabilitation (CR) on endothelial function and circulating microparticles in 
individuals with CVD.   
Specific Aims: 
1. To compare the number of circulating EMPs before and after 4 weeks of LS-HIIT 
or CR in men and women with cardiovascular disease 
2. To compare the number of circulating PMPs before and after 4 weeks of LS-HIIT 
or CR in men and women with cardiovascular disease 
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3. To compare endothelial function before and after 4 weeks of LS-HIIT or CR in 
men and women with cardiovascular disease 
4. To examine the relation between circulating MPs and endothelial function in 
men and women with CVD before and after exercise training.   
Hypothesis: 
1. Circulating levels of EMPs will not significantly change following 4 weeks of LS-
HIIT or CR in individuals with cardiovascular disease 
2. Circulating levels of PMPs will not significantly change following 4 weeks of LS-
HIIT or CR in individuals with cardiovascular disease 
3. Endothelial function will significantly improve following 4 weeks of LS-HIIT or 
CR in individuals with cardiovascular disease 
4. Improvements in endothelial function will not correlated with MPs in 
individuals with cardiovascular disease 
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Methodology 
Participants 
Twenty-two men and four women with documented CVD, who had been 
participating in a community-based phase IV cardiac rehabilitation programme for a 
minimum of 6 months and received medical clearance were recruited for the study.  
Exclusion criteria were smoking, unstable angina, uncontrolled hypertension (systolic 
blood pressure (BP) >180 mmHg, diastolic BP >100 mmHg), resting tachycardia or 
unstable/acute heart failure, or any other medical condition that contraindicated 
exercise participation.  Participants were randomly assigned to LS-HIIT (n=15, 66.6 ± 
1.73 yr; mean ± SE) or to continued participation in CR (n=11, 68.6 ± 1.71 yr; mean ± 
SE). 
Study Overview 
An overview of the study design is illustrated in figure 5.1.  Following an initial 
screening visit the participants visited the Health and Human Performance 
Laboratories on two occasions before and after the 4 weeks of LS-HIIT or CR.   
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Figure 5.1: Overview of the study design 
Screening visit: The nature and risks of the study were explained and written 
informed consent was obtained from each participant.  The experimental procedures 
were approved by the Research Ethics Committee at Dublin City University, Ireland. 
(Appendix J)  Participants completed a general health questionnaire (Appendix A) and 
physical activity readiness questionnaire (PAR-Q). (Appendix K)   
Visit 1: Participants abstained from strenuous physical activity for 24 h, and 
abstained from food, alcohol and caffeine for at least 4 h before the visit.  During this 
visit, height, weight, and blood pressure were measured and maximal aerobic capacity 
(  O2max) was assessed.   
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Visit 2: Participants abstained from strenuous physical activity for 24 h and 
arrived at the Vascular Research Unit at DCU following an overnight fast.  Resting 
blood pressure was obtained, blood sample was drawn and endothelial function was 
assessed. 
Training Protocols 
High Intensity Interval Training 
 Participants assigned to LS-HIIT, undertook two supervised high intensity 
interval sessions per week for 4 weeks, and did not attend the phase IV cardiac 
rehabilitation for the duration of the study.  Following a 10 min warm-up, participants 
performed three blocks of 8 x 45 sec intervals of high-intensity exercise at 85 – 90 
%HRmax on a treadmill (Figure 5.2).  Each interval was interspersed with a 15 sec 
period of passive recovery and a 2 min interval separated each block.  The session 
concluded with a 5 min cool-down.  Angina score was obtained after each 45 sec 
exercise bout.  The electrical activity of the heart and O2 saturation were continuously 
monitored with a 12 lead ECG and pulse oximetry, respectively.  Blood pressure was 
measured and RPE was obtained at the end of each exercise block. 
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Figure 5.2:  Overview of a LS-HIIT session 
Cardiac Rehabilitation  
 Participants in the CR group continued to attend a community-based CR 
program, two days per week.  The cardiac rehabilitation program was multi-faceted 
but predominantly focused on exercise.  Exercise classes were 60 min in duration and 
involved aerobic exercise and some form of resistance training.  Sessions commenced 
with a 10 min warm up at a low exercise intensity and were followed by 40 min at 
moderate-intensity.  The participants exercised in small groups and rotated between 
the various exercise stations during each class.  The class concluded with a 10 min 
cool-down. 
Anthropometrics 
 Height and body mass were measured using a wall stadiometer and electronic 
balance (Seca 797, USA) respectively.  Footwear was removed prior to the 
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measurement.  Height was measured to the nearest cm, and weight was measured to 
the nearest 0.1 kg. 
Determination of Maximal Oxygen Uptake 
Maximal aerobic capacity (  O2max) was assessed on a treadmill (Woodway ELG 
55, Waukesha, WI) using a Balke protocol that was modified to allow participants 
reach volitional fatigue in 8 – 12 min. (Appendix L)  A 2 min warm up preceded each 
test and the gradient was increased 2.5% every 2 min until the participant reached 
volitional fatigue or presented with contraindications to exercise.  Participants were 
verbally encouraged to give their best effort.  Respiratory metabolic measures and ECG 
were continuously monitored throughout the test.  RPE was recorded every 2 min. 
Maximal oxygen uptake was determined by averaging the three highest consecutive 
20 second values.   
Cardiorespiratory and Metabolic Measures  
As described in the methods section of Chapter 3 
Mass Flow Sensor Heated Wire Anemometer-Mode of Operation  
As described in the methods section of Chapter 3 
Mass Flow Sensor Calibration  
As described in the methods section of Chapter 3 
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Gas Analysers 
As described in the methods section of Chapter 3 
Calibration of O2 and CO2 Gas Analysers 
As described in the methods section of Chapter 3 
Ratings of Perceived Exertion  
RPE was obtained using the 16-point Borg category RPE scale.116  Prior to the 
maximal exercise test participants read a standard set of perceptual scaling 
instructions.  These instructions followed an established format used in previous 
investigations.117  Low and high “perceptual anchors” were established during the 
maximal exercise test.  This involved asking participants to assign a rating of 6 (low 
anchor) to the lowest exercise intensity, and 20 (high anchor) to the highest exercise 
intensity.  During the HIIT sessions the participants were instructed to make their 
subjective assessments of perceived exertion relative to these minimum and maximum 
standards (perceptual anchors). 
Electrocardiographic Monitoring (ECG) 
The electrical activity of the heart was monitored using a 12-lead ECG monitor 
(GE Case 8000 12 Lead ECG).  The signal to noise ratio at the skin electrode interface 
was reduced by cleansing the area with an alcohol saturated gauze pad.  The 
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superficial layer of skin was then removed using light abrasion with fine grain emery 
paper.  The electrodes were placed on 10 standard anatomical landmarks.  
Endothelial Function Assessment 
Endothelial function was assessed by measuring brachial artery dilatory 
response to reactive hyperemia and glyceryl-trinitrate.118  Participants arrived to the 
Vascular Research Unit, DCU at 07:00 following an overnight fast.  They were not 
allowed to exercise, ingest substances, such as caffeine or vitamin C, which may affect 
flow mediated dilation (FMD), for at least 6 h before the study.  Water consumption 
was permitted and where possible, vasoactive medications were withheld for at least 4 
half-lives.  Since the 4 women participants were post-menopausal menstrual cycle 
phase was not controlled. 
Endothelial function was assessed with the participants in a supine position in a 
quiet, temperature-controlled room.  The right arm rested on an examination table 
perpendicular to the bed, and was extended and externally rotated to permit imaging 
of the right brachial artery.  An automated pneumatic cuff was placed on the forearm, 
distal to the brachial artery and electrodes for a 3-lead ECG were placed on their chest.  
The ECG tracing was activated and settings adjusted to ensure clear identification of 
the R wave, which corresponds to the end of diastole in the cardiac cycle.   
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Endothelial-Dependent Dilation 
Figure 5.3 illustrates the FMD protocol.  Following a 10 min rest period the 
pneumatic cuff was inflated to 250 mmHg for 5 min.  The cuff was rapidly deflated and 
peak systolic velocity was measured using Doppler within 15 sec of cuff release.  M-
mode images were named and recorded every 30 sec post-deflation for 5 min.  FMD 
was normalised for the shear stimulus.  Shear rate was calculated using the formula, 4 
x peak velocity/peak diameter.119 
 
Figure 5.3: Overview of endothelial-dependent dilation 
Endothelial-Independent Dilation 
Following a 15 min rest period, a baseline brachial artery image was again 
recorded.  Gylceryl-trinitrate (GTN; 400 g) was then administered sublingually.  To 
assess brachial artery diameter, M-mode images were named and recorded every 30 
sec post GTN administration for 5 min (Figure 5.4).  Brachial artery diameter was 
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analyzed off-line, using a semi-automated custom designed edge-detection software 
program. 
 
 
Figure 5.4: Overview of endothelial-independent dilation 
All images were selected for analysis using a standard dialog box (Figure 5.5).  
For each image, the artery was located and the area between the anterior and 
posterior arterial walls was manually selected.  The software used this point to 
segment the arterial boundary using a constrained region-growing algorithm, and the 
result was depicted visually in that the segmented arterial lumen was highlighted using 
grey shading.  The segmentation of the artery was updated in real-time.  Gated 
measurements of the brachial artery diameter were recorded using a minimum of 2 
and maximum of 3 consecutive R waves on an ECG.  The mean of the 2-3 
measurements was taken as the brachial artery diameter.   
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Figure 5.5:  Standard dialog box 
Blood sampling and storage 
Blood samples were taken from a prominent forearm vein using standard 
venipuncture.  Serum vacutainers were allowed stand for 30 min at room temperature 
before being centrifuged at 3000 rpm (1600 g) for 15 min at 4oC.  Blood for 
microparticles analysis was collected, prepared and stored according to methods 
described by Lacroix et al., (2012).37  Whole blood was gently mixed with the coagulant 
by inversion.  Centrifugation was completed within 15 min at 3730 rpm at 20oC to 
pellet the cells.  The plasma containing the MPs was carefully aspirated, leaving a 1 cm 
layer undisturbed above the buffy layer.  The cell-free plasma was aliquotted (250 µL 
portions) into eppendorf tubes.  The platelet rich plasma (PRP) was then centrifuged 
for a second time at 5160 rpm for 15 min at 20oC.  The platelet poor plasma (PPP) was 
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aliquotted (250 µL portions) into fresh eppendorf tubes, snap-frozen in liquid nitrogen, 
and stored at 80oC until analysis.  
Microparticle Analysis 
Flow cytometry, using GUAVA easyCYTE8 HT Flow Cytometry System (Millipore 
Corporation, Billerica, MA) was used to quantify microparticle numbers.  
Microparticles were identified in PPP based on size and fluorescence, using 1.0 µm 
sizing beads and anti-CD 31 FITC, anti-CD 41a PE and anti-CD 62E monoclonal 
antibodies.  EMPs were defined as CD31+/CD41a- and CD62E+ and PMPs were defined 
as CD41a+ and CD31+/CD41a+. 
Prior to use, antibodies were diluted and centrifuged to remove aggregates.  
Antibodies CD31 and CD41a were diluted 1:2 in filtered (0.2 µm) PBS.  Antibody CD62E 
was diluted 1:50 in filtered PBS.  The diluted antibodies were then centrifuged at 
19000 g for 5 min at 4oC in order to remove aggregates and the supernatant pipetted 
into fresh Eppendorf tubes. 
Samples were removed from the freezer and allowed to thaw slowly on ice.  
Samples were doubled stained with CD31/CD41a and single stained with CD62E.  For 
the doubled stained samples 15 µl of both CD31 and CD41a were added to 30 µl of 
PPP.  For the single stained sample 15 µl of CD62E was added to 30 µl of PPP.  Samples 
were then incubated in the dark for 20 min at room temperature.  Following 
incubation 500 µl of PBS was added to each sample and mixed well.  A 200 µl volume 
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of each sample was loaded into one well on the plate and analysed.  Fluorescence 
thresholds were set using PPP incubated with isotype-matched control antibodies.  All 
samples were analysed in duplicate and samples for each participant were analysed in 
the same run.  Samples were counted for 5000 counts at a low flow rate. 
Lipid analysis 
As described in the methods section of Chapter 3. 
Statistical analysis 
Prior to statistical analysis the data was checked for normality using the 
Shapiro-Wilk test.  A group (HIIT and CR) x time (pre training and post training) 
repeated measures ANOVA was used to compare the mean differences within and 
between groups.  A one way repeated measure ANOVA was used to compare 
physiological responses averaged across the 3 sets during the HIIT training sessions.  
Significant main effects were probed using a Bonferroni post hoc test.  The relation 
between MP numbers and FMD before and after the intervention was established 
using Pearson’s product moment correlation.  SPSS for Windows statistical software 
(ver 19.0) was used to perform the statistical analysis.  Statistical significance was 
accepted at the p<0.05 level of confidence.   
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Results 
Participant Characteristics 
Physical characteristics and blood lipid levels before and after LS-HIIT and CR 
are presented in table 5.1.  There was no significant difference in height, body mass, 
BMI or blood lipids between the two experimental groups at baseline or after 4 weeks 
of training.  Compared to pre training serum triglycerides were significantly higher 
(p=0.02) in the LV-HIIT and HDL-C significantly lower (p=0.02) post training in CR.  
Participant medications are summarised in table 5.2 
Maximal Exercise Tests 
The responses at maximal exercise are summarised in table 5.3.  Treadmill time 
to exhaustion was significantly greater in the LS-HIIT at post training than pre training.  
There was no significant difference in treadmill velocity, treadmill grade,   O2max, 
heart rate, ventilation and RER between the two experimental groups before and after 
4 weeks of training.  There was no significant difference in treadmill velocity, treadmill 
grade,   O2max, heart rate, ventilation and RER in LS-HIIT or CR between pre training 
and post training.   
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High Intensity Interval Training 
ST-segment changes ranged from 1 – 3 mm, and returned to normal during the 
15 sec passive recovery.  None of the participants reported angina symptoms during or 
following the 4 weeks of LS-HIIT. 
The average physiological and perceptual responses for each LS-HIIT exercise 
block are summarized in table 5.4.  Treadmill velocity was significantly greater during 
block 2 and 3 than block 1.  Heart rate, %HRmax and RPE were significantly higher 
during block 2 than block 1 and during block 3 than block 1 and 2.  SPO2 was 
significantly lower during block 3 than block 1.  There are no differences in treadmill 
grade or blood pressure between the 3 training blocks.   
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Table 5.1:  Physical characteristics and blood lipids of the participants before and after training 
Values are means   SE; *p < 0.05 vs. pre-training 
  
 Group 
 LS-HIIT (n=15) CR (n=11) 
 Pre-Training Post-Training Pre-Training Post-Training 
Height (cm) 170.63 ± 1.77 170.64 ± 1.78 167.61 ± 2.49 167.64 ± 2.51 
Body mass (kg) 80.80 ± 2.65 80.41 ± 2.58 77.83 ± 3.62 79.28 ± 4.06 
BMI (kg.m-2) 27.70 ± 0.67 27.31 ± 0.72 27.75 ± 1.31 28.17 ± 1.70 
Total cholesterol (mmol.L-1) 3.40 ± 0.21 4.48 ± 0.55 3.63 ± 0.30 3.40 ± 0.17 
HDL-cholesterol (mmol.L-1 1.21 ± 0.05 1.26 ± 0.08 1.26 ± 0.10 1.03 ± 0.10* 
LDL-cholesterol (mmol.L-1) 1.42  ± 0.09 1.80 ± 0.19 1.79 ± 0.38 1.51 ± 0.14  
Triglycerides (mmol.L-1) 0.96 ± 0.10 1.28 ± 0.12* 1.08 ± 0.18 1.12 ± 0.07 
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Table 5.2: Participant medications 
Main Drug Class LS-HIIT CR 
Statins 9 5 
ACE Inhibitor 6 3 
Beta Blocker 2 2 
Anti-platelet 9 6 
Diuretic 1  
Proton Pump 3 2 
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Table 5.3:  Responses at maximal exercise before and after training  
 Group 
 LS-HIIT (n=15)  CR (n=11) 
 Pre-Training Post-Training  Pre-Training Post-Training 
Treadmill velocity (km.h1) 5.50 ± 0.30  5.38 ± 0.36  5.30 ± 0.26 5.91 ± 0.77 
Treadmill grade (%) 12.00 ± 0.82 12.31 ± 0.72  9.50 ± 0.92 10.54 ± 1.26 
Time to exhaustion (s) 524.54 ± 30.77 591.77 ± 27.13*  584.86 ± 64.82 550.00 ± 57.47 
  O2max (ml
.kg1.min1) 30.48 ± 2.05 32.23 ± 2.15  28.52 ± 1.85 29.20 ± 2.38 
  O2max (L
.min1) 2.37 ± 0.21 2.40 ± 0.16  2.03 ± 0.16 2.10 ± 0.23 
Heart rate (bpm) 138.20 ± 3.63 135.87 ± 3.55  126.90 ± 4.57 129.38 ± 7.96 
Ventilation (L.min1) 63.95 ± 5.43 66.20 ± 4.37  56.02 ± 4.87 59.63 ± 6.57 
RER 1.13 ± 0.02 1.14 ± 0.02  1.09 ± 0.03 1.15 ± 0.03 
Values are means   SE; *p < 0.05 vs. week 1 
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Table 5.4:  Average responses during each exercise block of LS-HIIT 
 Exercise Blocks 
 1 2 3 Mean 
Treadmill velocity (km.h1) 6.83 ± 0.39 7.06 ± 0.46* 7.17 ± 0.50* 7.02 ± 0.46 
Grade (%) 4.13 ± 0.43 4.15 ± 0.43 4.10 ± 0.44 4.13 ± 0.48 
Heart rate (bpm) 108.51 ± 4.02  114.53 ± 4.67† 122.03 ± 5.10†‡ 115.00 ± 4.64 
%HRmax 77.50 ± 3.58 82.25 ± 4.17† 86.02 ± 4.4†‡ 81.60 ± 4.19 
Systolic blood pressure (mmHg) 163.22 ± 5.89 160.55 ± 6.17 156.23 ± 6.65 160.03 ± 7.50 
Diastolic blood pressure (mmHg) 74.09 ± 1.16 73.43 ± 1.42 71.36 ± 1.43 73.10 ± 2.12 
RPE 12.92 ± 0.49 13.83 ± 0.45¥ 14.63 ± 0.40¥‡ 13.88 ± 0.56 
SPO2 95.47 ± 0.57 95.10 ± 0.56 95.06 ± 0.54* 95.10 ± 0.65 
 Values are means   SE, *p < 0.05 vs. block 1; †p < 0.01 vs. block 1; ‡p < 0.01 vs. block 2; ¥p < 0.001 vs. block 1 
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Endothelial Microparticles 
Circulating levels of CD31+ and CD62E+ EMPs are summarised in table 5.5.  
Before training, the number of circulating CD31+ and CD62E+ EMPs was similar in LS-
HIIT and CR. Compared to pre training, there was no change in the number of 
circulating CD31+ EMPs (Figure 5.6) or CD62E+ EMPs (Figure 5.7) in either LS-HIIT or CR 
after 4 weeks of training. 
Figure 5.6: Circulating CD31+ EMPs pre and post training 
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Figure 5.7: Circulating CD62E+ EMPs before and after training 
 
Platelet Microparticles 
Circulating levels of CD41a+ and CD41a+/CD31+ PMPs are summarised in table 
5.5.  Before training, the number of circulating CD41a+ and CD41a+/CD31+ PMPs was 
similar in LS-HIIT and CR. Compared to pre-training, there was no change in the 
number of circulating CD41a+ PMPs (Figure 5.8) or CD41a+/CD31+ PMPs (Figure 5.9) in 
either LS-HIIT or CR after 4 weeks of training. 
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Figure 5.8: CD41a+ PMPs before and after 4 weeks 
 
Figure 5.9: CD41a+/CD31+ PMP before and after 4 weeks
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Table 5.5:  Circulating microparticles pre training and post training 
 Group 
 LS-HIIT (n=15)  CPCR (n=11) 
 Pre-Training Post-Training  Pre-Training Post-Training 
CD31+ EMP (counts.µl-1) 38258 ± 857  38337 ± 673  39003 ± 847 39128 ± 1168 
CD62E+ EMP (counts.µl-1) 75488 ± 2806 76951 ± 2518  77825 ± 4670 80947 ± 4275 
CD41a+ PMP (counts.µl-1) 22355 ± 573 22544 ± 412  22253 ± 639 22461 ± 814 
CD31+/CD41a+ PMP  (counts.µl-1) 40062 ± 1328 38927 ± 1091  39690 ± 1759 38453 ± 2162 
Values are means   SE 
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Endothelial Function 
Pre-training flow mediated endothelial dependent dilation was similar in LS-
HIIT and CR.  Post training flow mediated endothelial dependent dilation was 
significantly higher than pre training in LS-HIIT. Brachial artery FMD was also 
significantly higher LS-HIIT than CR group training (Figure 5.10).   
There was no significant difference in endothelial-independent dilation 
between the two experimental groups before and after training.  Compared to pre 
training there was no significant difference in endothelial-independent dilation in the 
LS-HIIT or CR after 4 weeks of training. (Figure 5.11)  Compared to pre-training, there 
was no change in shear rate in LS-HIIT (951.2 ± 294.1 s-1 vs. 1020.5 ± 245.1 s-1) or CR 
(1009.5 ± 179.9 s-1 vs. 932.5 ± 146.2 s-1) post training.  There was no relation between 
changes in endothelial function and changes in aerobic fitness (r=0.351, p=0.108) 
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Figure 5.10: Percent change in FMD in LS-HIIT and CR group pre training and post 
training. *p < 0.05 vs pre training; †p < 0.05 vs CR 
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Figure 5.11: Percent change in brachial artery diameter (%) following GTN 
administration pre training and post training 
 
Microparticles and Endothelial Function Correlations 
Pre training there was a significant relation between circulating CD31+ EMP 
numbers and absolute and percentage change in FMD. (Figure 5.11)  Post training 
CD41+ PMP numbers in the CR group were significantly related to the post training 
absolute and percentage change in FMD (Figure 5.12).  After the 4 weeks of training 
there was a significant inverse relation between CD31+/41a+ PMP numbers and the 
absolute and relative change in FMD in the LS-HIIT group. (Figure 5.13) There was a 
0.0
3.0
6.0
9.0
12.0
15.0
18.0
Pre training Post training
P
e
rc
e
n
t 
LS-HIIT
CR
140 
 
significant relation between CD31+/41a+ PMP numbers and the absolute and relative 
change in FMD in the CR group. (Figure 5.14) 
 
 Figure 5.12: Relation between CD31+ EMP numbers and absolute (A) and percentage 
change (B) in FMD pre training 
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Figure 5.13: Relation between absolute change in FMD and CD41a+ PMP (A) and % 
change in FMD and CD41a+ PMP (B) following the intervention in the CR group. 
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Figure 5.14: Relation between CD31+/41+ PMP numbers and the absolute (A) and 
percentage (B) change in FMD following the intervention in the LS-HIIT group. 
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Figure 5.15: Relation between CD31+/41+ PMP numbers and the absolute (A) and 
percentage (B) change in FMD following the intervention in the CR group. 
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 Summary 
There was no increase in aerobic fitness following 4 weeks of LS-HIIT or CR.  
There was however, a statistically significant improvement in treadmill time to 
exhaustion in the LS-HIIT group only.  There were no changes in circulating MP 
numbers between or within groups before or after the exercise intervention.  There 
was no difference in FMD between groups at baseline.  There was an improvement in 
FMD in the LS-HIIT group only following the exercise intervention and at post training 
the FMD was significantly higher in the LS-HIIT group.  There was a positive relation 
between CD31+ EMP numbers and absolute and percentage change in FMD pre 
training. 
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Discussion 
Study 3 evaluated the effect of 4 weeks of LS-HIIT and CR on circulating MPs, 
aerobic fitness and endothelial function in men and women with CVD and evaluated 
the relation between MPs and endothelial function.  Conventional exercise guidelines 
for reducing CVD risk factors and cardiovascular events have promoted continuous, 
moderate to vigorous intensity exercise training.  Exercise performed at a vigorous 
intensity (≥6 METs) has been shown to induce a greater reduction in C D risk along 
with greater improvements in diastolic blood pressure, glucose control and aerobic 
capacity than exercise performed at a moderate intensity.10  In recent years LS-HIIT has 
been proposed as a safe and effective method for improving both CVD risk factors and 
aerobic fitness in patients with CVD.120  A number of studies have found an increase in 
aerobic fitness and endothelial function in patients with CVD following a HIIT exercise 
program.85,121,122  In the present study there was a significant improvement in 
endothelial function following 4 weeks of HIIT but no change in   O2max.  There was 
however, an increase in the time to exhaustion during the incremental treadmill 
exercise test.   
The improvement in endothelial function may be due in part to the positive 
effect of exercise on the regulation of endothelial NO bioavailability.  Exercise induced 
increases in shear-stress augments the expression of nitric oxide synthase in 
endothelial cells and the repeated sheer stress during HIIT may partly explain the 
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improvements in flow mediated dilation.  Shear stress can also increase the 
endothelium’s antioxidative defence mechanisms by increasing the activity of 
superoxide dismutase.123  
Differences in exercise prescription and study duration may help to explain the 
relatively small improvement in   O2max.  Previous studies that have found a 
significant improvement in aerobic fitness following short-term HIIT have primarily 
involved healthy young college age students.124,125  Although the exercise prescription 
in the present study involved LS-HIIT it is unlikely that the older patients with CVD will 
be able to exercise at the same intensity as healthy college age students.  Previous HIIT 
studies involving college age students involved 2 sessions.wk-1 for 2 – 4 weeks whereas 
HIIT studies involving individuals with CVD have been greater than 8 weeks in duration.  
It is possible that 2 session of HIIT per week for 4 weeks may not have been of 
sufficient duration to increase aerobic fitness.  
 Recent epidemiological research found that a 1 MET increase in aerobic fitness 
is associated with a 13% decrease in all-cause mortality and a 15% decrease in 
CHD/CVD.126  Although not statistically significant,   O2max increased 5.7% and by 0.5 
METS in the LS-HIIT group.  It is feasible that this increase in aerobic fitness has 
important positive influences on the cardiovascular health in men and women with 
CVD.   
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There were no changes in EMP or PMP numbers following the LS-HIIT or the CR.  
A recent study that used similar laboratory protocols and antibodies to the present 
study found no change in circulating EMP or PMP numbers up to 72 h following an 
acute bout of HIIT in men with CHD.69  The fact that there was no change in serum 
troponin would indicate that HIIT does not induce myocardial injury in the short-term 
and is safe in this population.  There is some evidence to indicate that circulating EMPs 
may also be used to indicate myocardial injury.23  Troponin was not measured in the 
present study but the fact that circulating CD62E+ or CD31+ did not change in response 
to LS-HIIT may indicate that the training regime employed in the present study is safe 
and does not induce myocardial injury or endothelial activation.  Clinical trials will need 
to be undertaken to further investigate the efficacy of EMP’s as a putative biomarker 
for myocardial injury. The fact that there was no significant change in circulating MPs 
despite an improvement in endothelial function indicates that MPs may not be a 
suitable marker of endothelial function.    
CD31+ EMPS are associated with endothelial cell apoptosis and are elevated in 
disease states associated with vascular dysfunction such as the metabolic syndrome 
and acute coronary syndromes (ACS).104,127  In contrast, CD62E+ EMPs are associated 
with an increase in activation of endothelial cells.  Circulating levels of CD31+ MPs are 
significantly higher in individuals with the metabolic syndrome and ACS than healthy 
controls.  In contrast, circulating levels of CD62E+ EMPs were similar in both groups 
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suggesting that there may be increased levels of endothelial cell apoptosis in patients 
with the metabolic syndrome and ACS.  
Feng et al., (2010) also found significantly higher circulating CD31+ EMPs in 
diabetic patients than healthy controls.128  There was no difference in CD62E+ EMPs 
between the LS-HIIT and the CR groups.  The absence of a healthy control group in the 
present study makes it difficult to determine if circulating EMP numbers are elevated.  
There was however, no significant change in CD31+ or CD62E+ following the exercise 
intervention suggesting that the LS-HIIT does not induce greater endothelial cell 
apoptosis or activation than CR. 
The fact that there was a significant positive relation between circulating 
CD31+ and changes in endothelial-dependent FMD before training indicates that 
increased circulating CD31+ EMP numbers may be associated with improved vascular 
health in the present study.  This is in contrast to a previous study showing a significant 
inverse relation between CD31+ EMP numbers and changes in FMD in diabetic patients 
but not in healthy controls.128  The participants in the current study were participating 
in a structured CR program for at least 6 months.  Previous exercise may have had an 
effect on EMP phenotype.  It is also possible that CD31+ EMPs are related to 
alterations due to the diabetic condition as Tramontano et al., (2010) also found a 
significant increase in CD31+ EMPs in diabetic patients compared to non-diabetic 
controls. 
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The significant positive relation between the absolute and percentage change 
in FMD and the absolute and percentage change in circulating CD41+ in the CR group is 
a unique finding and suggests that this MP may have cardio protective properties.  
Although the increase in the circulating number of CD41+ PMPs was related to an 
increase in endothelial function the relatively small sample size and two obvious 
outliers (figure 5.12) makes it difficult to draw any definite conclusions on the clinical 
relevance of this finding. 
Following the training study there was a significant inverse relation between 
circulating CD31+/41+ PMP numbers and changes in FMD in the LS-HIIT group 
indicating that lower numbers of CD31+/41+ PMPs are associated with improved 
endothelial function.  It is possible that PMPs positive for both CD31+ and CD41+ have 
a more deleterious effect on the endothelium than CD41+ alone.  In contrast, 
circulating CD31+/41+ PMP numbers were positively related to changes in FMD in the 
CR group.  The correlation coefficient may however have been significantly influenced 
by two outliers.  The relation between CD31+/41+ PMP numbers and FMD was no 
longer significant when the outliers were removed from the statistical analysis.  Future 
studies involving men and women with CVD should further investigate the acute and 
chronic effects of exercise on MPs and investigate if there is a minimum threshold of 
exercise needed to induce changes in MPs.   
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The aim of study 3 was to i) compare the number of circulating EMPs and PMPs 
before and after 4 weeks of LS-HIIT or CR in men and women with CVD and ii) to 
examine the relation between MP numbers and FMD, a measure of endothelial 
function associated with CVD.  There were no changes in MP numbers in either group 
despite an improvement in FMD in the LS-HIIT group. 
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Chapter VI 
Synthesis of Findings 
MPs are small membrane vesicles shed from cells following activation or 
apoptosis.  Small numbers of MPs are constantly released from a variety of cells under 
normal physiological conditions.  The effect of exercise on circulating MP numbers is 
relatively unknown.  To date no studies have quantified the dose-response of exercise 
intensity on MP production.  With the exception of one study that evaluated the 
effects of a 6 month exercise training program on MP production in overweight and 
obese African Americans there is currently no information on the effects of short or 
long-term training on MP production in healthy or disease populations.  Although 
there is evidence that circulating MP numbers increase in men and women with CVD, 
no published studies have examined the relation between exercise training, MPs and 
endothelial function in this population.  A series of studies were undertaken to assess 
the effects of acute and chronic exercise on the number and composition of MPs and 
to examine the relation between MPs and endothelial function before and after 
exercise training.   
Study one examined the effects of isocaloric bouts of exercise at 60%, 70% and 
80%   O2max on circulating EMP and PMP numbers.  For the most part, circulating 
EMPs did not change significantly immediately after exercise and at 2 h post exercise.  
However, circulating EMPs were elevated at 4 h and 6 h post exercise compared to 2 h 
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post exercise at all 3 exercise intensities.  It may be that following the exercise bouts 
there is increased gene expression resulting in cell activation and MP production.  
There may be a cellular response to the over production of proteins leading to MPs 
containing these proteins being released from cells.  Unpublished work by Fitzpatrick 
and Murphy (DCU) has described an increase in the protein Lasp-1 in sheer induced 
MPs.  Lasp-1 is an adhesion protein essential for cell migration and survival in reply to 
growth factors and extra cellular matrix proteins.129 
Study two examined the effect of 14 consecutive days of exercise on circulating 
MP numbers in sedentary men.  Changes in aerobic fitness have been linked to 
improvements in the processes associated with the development of CVD and the 
present study succeeded in significantly improving both absolute and relative aerobic 
fitness.  Despite the fact that circulating MPs have been associated with CVD, the study 
did not find a relation between changes in aerobic fitness and changes in circulating 
MPs.  There was a significant decrease in EMP numbers compared to pre-training 
levels.  However, it is possible that EMP numbers may have been influenced by the 
acute bout of exercise the previous evening. 
Although not statistically significant, circulating EMP values were lower at all 
time points on training day 14 compared to day 1, 3, 7 and 10.  PMP values on day 10 
and day 14 were different to values on days 1, 3 and 7 with less variation within 
samples and very similar responses.  It is possible that there is an adaptive response 
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affecting both the release of EMPs and PMPs following 10 to 14 days of exercise 
training.  The lower PMP values may be a result of improvements in platelet function.  
It is possible that lower numbers of MPs are released from platelets after the first 
week of training due to alteration in megakaryocytopoiesis. 
Study 3 evaluated the effects of exercise training on circulating MPs in men and 
women with documented CVD.  Endothelial dysfunction is one of the earliest events in 
the development of atherosclerosis and is predictive of an increased risk for 
cardiovascular events.79  Brachial artery flow mediated dilation was assessed to 
provide a measure of endothelial function and to assess the relation between 
endothelial function and circulating MPs before and after 4 weeks of exercise training.  
In contrast to the first two studies, there was no change in EMPs in men and 
women with CVD despite an improvement in the FMD in the LS-HIIT group.  This may 
be due to the fact that the i) laboratory procedures used to measure MPs were 
different in study 3 compared to the first two studies, ii) circulating EMPs are not 
sensitive to changes in endothelial function and iii) a higher training volume may be 
required to increase EMPs in men and women with CVD.   
The participants in study 3 had been participating in a community based CR 
program for at least 6 months prior to the start of the study.  It is unclear if this 
exercise period affected circulating MP numbers.  The lack of an age matched, non-
exercising control group makes it difficult to evaluate the independent effect of 
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exercise training on circulating MPs.  Different analytical methods make it difficult to 
compare the results of study 3 to study 1 and 2.  Efforts are currently being made to 
standardise MP analysis. 
In conclusion, independent of exercise intensity circulating levels MPs increase 
in healthy physically active young men at 6 h following an acute bout of exercise 
involving a caloric expenditure of 400 kcal.  Circulating EMPs decrease significantly in 
healthy sedentary young men 13 h following a vigorous exercise session lasting 1 h 
with a possible training effect following 10 – 14 days.  In men and women with CVD 
eight sessions of LS-HIIT significantly improves brachial artery and does not 
significantly change circulating MP numbers.  Future studies should i) establish the 
putative role of MPs as markers of CVD, ii) describe the in vivo mechanisms involved in 
MP release and iii) establish disease specific MP biomarkers.  
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Study Limitations 
 At the present time there are many limitations associated with the 
measurement of microparticles.  These include blood sampling techniques, anti-
coagulants, the time prior to blood processing, number and speed of centrifugations, 
freezing and storage time, and antibodies used for detection.  Enumeration of MPs in 
study 3 involved different preparation protocols and a different flow cytometer than 
used for study 1 and study 2.  The change in the preparation protocol reflected a 
change in the guidelines over the time period of the study. 
A major limitation to the work is that post exercise data points were not 
subject to correction for a possible exercise induced haemoconcentration or 
haemodilution. Bouts of acute exercise can produce a transient haemoconcentration 
immediately after exercise, while exercise training can cause long term expansion of 
the plasma volume.130  Both of which may affect lipid and MP results. 
The sample size in study 2 was small and there was no control group.  In 
addition, participants in study 2 were asked to consume a similar diet for the duration 
of the exercise training intervention.  This was monitored verbally but changes in daily 
dietary intake may have influenced MP numbers.  The final post training blood sample 
was taken 13 h following the last training session.  In order to make a valid comparison 
with baseline, a 48 h time period should be allowed between the final training session 
and the blood draw.  
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More than 50% of the participants in study 3 were taking HMG CoA reductase 
inhibitors.  This class of drug has been shown to effect circulating MPs.131  
Future Direction 
This series of experiments aimed to assess the acute and chronic effects of 
exercise on MP production in young healthy men and the effects of chronic LS-HIIT and 
CR on circulating MPs in men and women with CVD.  Future research should determine 
the appropriate volume of exercise needed to induce changes in MP numbers in 
different populations and examine the relation between exercise induced changes in 
MPs and established markers of cardiovascular health.  If flow cytometry is to be used 
as the gold standard method of MP analyses more work needs to be done on 
establishing standard protocols for sample collection, preparation and analysis. 
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Appendix A 
Dublin City University 
 
 
General Health Questionnaire 
 
Name:……………………………….. Occupation:…………………………… 
 
Address:………………………………………………………………………………. 
 
Telephone: (Home)………………….. (Work):……………………………….. 
_____________________________________________________________________ 
 
Do you have, or have you ever suffered from: -Diabetes?   Yes / No 
 
      -Asthma?   Yes / No 
 
      -Epilepsy?   Yes / No 
 
Have you ever had pains in your chest or heart?     Yes / No 
 
Do you ever feel faint or have spells of dizziness?    Yes / No 
 
Do you have or have you ever had high blood pressure?    Yes / No 
 
Do you have a muscle, back or joint problem that could be aggravated by physical                                                                                                             
activity or made worse with exercise?      Yes / No 
 
Do you have any current injuries?      Yes / No 
 
In the past week, have you  suffered from any illness which required you to be in bed 
or off work for one day or more?       Yes / No 
 
Do you smoke?   If yes, how many per day?   Yes / No 
 
Do you drink?  If yes, how many units per week?   Yes / No 
 
Is there a good physical reason not mentioned here why you should not carry out 
laboratory testing?        Yes / No 
 
Please provide any further information concerning any condition/complaints which you suffer 
from and any medication which you may be taking by prescription or otherwise: 
 
…………………………………………………………………………………………………………… 
 
…………………………………………………………………………………………………………… 
 
…………………………………………………………………………………………………………… 
 
Date:     Signature: 
 
 
Authorising Signature: 
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Appendix B 
 
 
E-mail to be sent to staff and students 
 
The School of Health and Human Performance are conducting research looking at how different 
exercise intensity effect levels of microparticles in the blood. Microparticles are tiny fragments of 
cells that may be linked with disease such as heart disease. 
 
The study would involve having your fitness assessed on a treadmill and on three other days 
jogging at different intensities on the treadmill until 400 kcal are burned. To look at the 
microparticles we need to take some blood samples. 
 
We are looking for men and women between 18-30 years, who have no history of 
cardiovascular disease, and do not smoke. 
 
Following the research you would get information on your fitness levels and receive fitness and 
nutritional advice if required. 
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Appendix C 
Plain Language Statement 
 
Title: Effect of an acute bout of exercise on circulating microparticles. 
Principal Investigators 
Prof. Niall Moyna niall.moyna@dcu.ie  (Phone No. 7008802) 
Paul O’Connor  paul.l.oconnor@dcu.ie  (Phone No. 7008474) 
Dr. Noel McCaffrey noel.mccaffery@dcu.ie  (Phone No. 7008187) 
School of Health and Human Performance, Dublin City University 
What is the study about? 
Microparticles are tiny fragments of cells that can be found in the blood.  During some diseases, 
the level of microparticles circulating in the blood rises.  There is now evidence that elevated 
levels of these microparticles can lead to cardiovascular disease.  Regular physical activity has 
been shown to reduce the risk for cardiovascular disease.  The purpose of this study is to 
determine the effects of exercise intensity on the number of microparticles in healthy 
asymptomatic individuals.  
You will be asked to make 5 visits to the School of Health and Human Performance in DCU.  
Each visit will last approximately 1 hour.  You will arrive for each visit after an overnight fast.  
During the first visit you will have a blood sample taken and undergo a brief examination by a 
medical doctor to make sure you are suitable for the study.  About 10 days after this visit you 
will be contacted by phone or email to let you know if you are eligible to participate in the study.  
During the second visit you will exercise on a treadmill for approximately 15-mins to determine 
your fitness level.  The exercise will get progressively harder, but you should try to keep going 
as long as you can.  During  visits 3-5, you will exercise at an intensity equal to 60, 70 and 80%, 
of your maximal capacity until you burn 400 calories.  The exercise intensity of each visit will be 
determined randomly.  A blood sample will be taken immediately before and after exercise, and 
again at 2 hours, 4 hours and 6 hours after the exercise.  You will be asked to drink a nutritious 
shake 2 hours after the exercise.    
Exercise does carry a risk of injury, such as a pulled muscle, muscle soreness or in extreme 
cases abnormal heart rhythm, heart attack or death.  The benefits of being involved in this study 
include a detailed assessment of your fitness, your response to exercise and your cholesterol 
levels.  All information we gather will be stored in a secure filing cabinet.  The results of the 
study will be used for a postgraduate thesis and may be published in academic journals.  You 
will not be identified, as your information will be presented as part of a group.  Confidentiality of 
information provided can only be protected within the limitations of the law.  It is possible for 
data to be subject to subpoena, freedom of information claim or mandated reporting by some 
professions.  All data will be destroyed after 5 years.  Your participation in this research project 
is voluntary and you may withdraw your consent at any time. 
If participants have concerns about this study and wish to contact an independent 
person, Please contact: 
The Secretary, Dublin City University Research Ethics Committee, c/o Office of 
the Vice-President for Research, Dublin City University, Dublin 9.  Tel 01-7008000 
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Appendix D 
Informed Consent 
INFORMED CONSENT FORM 
Title:  Dose-response of circulating microparticles to acute bouts of exercise 
Principal Investigators: Prof. Niall Moyna, Dr. Noel McCaffrey and Kevin O’Brien 
Purpose 
To determine the effects of a different intensities of exercise on the number of endothelial and 
platelet derived microparticles in healthy asymptomatic individuals.. 
This is what will happen during the research study 
1. I will have the purpose of the study, each of the steps involved and the risks of participating 
in the study explained to me.  I will have the opportunity to ask any questions and if I am 
happy with the answers I will:  
i). Provide written informed consent for participation in the research project.  
ii). I will have a small blood sample taken from a vein in my arm, undergo a brief physical 
examination by a medical doctor, and complete a medical history form, which will ask 
questions about my general health, personal and family health history, smoking, 
exercise, and dietary habits.   
iii). I will be contacted by phone or email to let me know if I am eligible to participate in the 
study.  
iv) I am eligible to participate in the study I will visit the laboratory in the School of Health 
and Human on 2 occasions separated by at least one week.   Each visit will involve 
exercising on a treadmill. 
2. Visit 1: Screening 
 I will have a small blood sample taken from a vein in my arm, undergo a brief physical 
examination by a medical doctor, and complete a medical history form, which will ask 
questions about my general health, personal and family health history, smoking, 
exercise, and dietary habits.  I will have a number of measurements of my body size 
and shape.  My percentage body fat will be measured by the thickness of skin and fat 
on 7 sites around the body including the chest, leg, arm, back and side of the body.  I 
will practice walking and running on a treadmill while wearing a special mouthpiece like 
a snorkel in my mouth to measure the amount of air I breathe in and out. 
 I understand that any of these procedures or tests may be waived at the discretion of 
the doctor for the following reasons: (i) I have completed the same or similar step in the 
past 6 months as part of another research protocol at the School of Health and Human 
Performance; (ii) It has been determined that I am not eligible to participate in this 
research project; and thus completion of the entire screening process will not be 
necessary. 
Visit 2: Fitness Evaluation 
 I will undergo an exercise test designed to measure my fitness.  I understand that I will 
walk or run on a treadmill, with the slope gradually increasing until fatigue, 
breathlessness, chest pain and/or symptoms that indicate to the doctor or myself that I 
should stop exercise.  I will wear a mouthpiece to measure the amount of air I breathe in 
and out.  My heart will be monitored by an electrocardiogram (ECG) throughout the test.   
 Visits 3-5: Experimental Trials 
 I will walk or run on a treadmill at 60, 70 and 80% of my maximal capacity until I use 400 
calories.   During this time I will also wear the mouthpiece, to determine oxygen use.  I 
will have a plastic tube called a cannula, inserted into a vein in my arm to allow blood 
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samples to be taken.  This plastic tubing is introduced into my vein with a needle, which 
is then withdrawn.  The plastic cannula will remain in my arm, and will be used to take 
blood samples before and during exercise.  A 10.0 ml blood sample will be taken at the 
beginning and end of each experimental trial, and at 6 h and 24 h  after exercise.  The 
24 h  blood sample will be taken using standard venipuncture.  About two and half 
tablespoons of blood will be taken all together.  After exercise I will eat a balanced 
breakfast and 2 other meals throughout the day.  This is to control my caloric intake, as 
high-fat meals can increase microparticle levels.  
Sometimes there are side effects from performing exercise tests. These side effects are 
often called risks, and for this project, the risks are: 
1. Exercise testing carries with it a very small risk of exercise induced asthma, abnormal 
heart rhythms, heart attack, or death in less than one in 30,000 patients.  The risk of 
sudden death during exercise for healthy men is 1:15000-18000.  Because I will be 
asked to give a maximum effort, I may experience some muscle soreness in my arms 
and legs or nausea following the maximal exercise test.  It should be noted that if the 
experimental protocol is adhered to, the likelihood of these risks occurring is minimal. 
2. I understand that the insertion and placement of a cannula (to take blood samples) 
should be minimally painful but a slight ache may be felt and a small bruise may appear 
on my arm.  There is also a small risk of infection, but by using the appropriate 
techniques this risk is minimal. 
There may be benefits from my participation in this study.  These are: 
1. I will receive a copy of my personal results, body fat and fitness measurements and 
cholesterol levels 
2. I understand that no other benefits have been promised me. 
Expenses incurred during the study 
I understand that I will not be reimbursed for my participation in this study  
Participant – please complete the following (Circle Yes or No for each question) 
I have read the Plain Language Statement    Yes  No  
I understand the information provided     Yes  No  
I have had an opportunity to ask questions and discuss this study  Yes  No  
I have received satisfactory answers to all my questions    Yes  No  
My confidentiality will be guarded: 
Dublin City University will protect all the information about me, and my part in this study, within 
the limitations of the law.  My identity or personal information will not be revealed or published.  
All records associated with my participation in the study will be subject to the usual 
confidentiality standards applicable to medical records.  In addition, the study findings may be 
presented at scientific meetings and published in a scientific journal and/or as part of a 
postgraduate thesis, but my identity will not be divulged and only presented as part of a group.   
If I have questions about the research project, I am free to call Niall M. Moyna at 01-
7008060.   
Taking part in this study is my decision.   
I understand that my participation in this study is voluntary and that I may withdraw my consent 
at any time by notifying any of the investigators.  I may also request that my data and samples 
be removed from the database or storage and destroyed.  My withdrawal from this study, or my 
refusal to participate, will in no way affect my relationship with Dublin City University or my 
entitlements as a student or staff member.  I understand that my participation in this research 
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may be terminated by the investigator without regard to my consent if I am unable or unwilling to 
comply with the guidelines and procedures explained to me.  
Signature: 
I have read and understood the information in this form.  My questions and concerns have been 
answered by the researchers, and I have a copy of this consent form.  Therefore, I consent to 
take part in this research project 
Participants Signature:  _____________________________________________ 
Name in Block Capitals:  _____________________________________________ 
Witness:   _____________________________________________ 
Date:     _____________________________________________ 
This Informed Consent form was officially approved by the DCU Research Ethics Committee on:  
____/____/____ 
Official DCU Stamp: 
If you have concerns about this study and wish to contact someone independent, you may 
contact: 
The Chairperson of the Dublin City University Research Ethics Committee 
c/o Office of the Vice-President for Research, Dublin City University, Dublin 9.  Tel 01-
7008000 
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Appendix E 
 
 
 
 
 
Dublin City University 
RESEARCH ETHICS COMMITTEE 
 
APPLICATION FOR APPROVAL OF A PROJECT 
INVOLVING HUMAN PARTICIPANTS 
 
Application No. (office use only)  DCUREC/2006/ 
  
 
Period of Approval (office use only) ....../....../...... to ....../....../.... 
 
This application form is to be used by researchers seeking ethics approval for individual projects and studies. 
 
The signed original and an electronic copy of your completed application must be submitted to the DCU Research 
Ethics Committee.  Applications must be completed on the form; answers in the form of attachments will not be 
accepted, except where indicated.  No handwritten applications will be accepted.  Research must not commence 
until written approval has been received from the  
Research Ethics Committee. 
PROJECT TITLE Dose response of circulating microparticles to acute bouts of exercise 
 
PRINCIPAL 
INVESTIGATOR (S) 
Prof. Niall M. Moyna, Dr. Noel McCaffrey, Paul O’Connor 
 
 
 
 
1. ADMINISTRATIVE DETAILS 
 
 
THIS PROJECT IS:  Research Project  Funded Consultancy 
(tick as many as 
apply) 
 Practical Class  Clinical Trial 
  Student Research Project  
(please give details) 
 Other  - Please Describe:  
  Masters  Undergraduate 
  PhD   
 
Project Start 
Date: 
Oct 2006 Project End 
date: 
Oct 2008 
1.1 INVESTIGATOR CONTACT DETAILS  
Supervisors and co-supervisors of student projects are Principal Investigators. PhD and 
Doctoral students can be listed as Investigators 
PRINCIPAL INVESTIGATORS:  
TITLE SURNAME FIRST NAME PHONE FAX EMAIL 
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Prof Moyna Niall 7008802 7008888 niall.moyna
@dcu.e 
Dr  Mc Caffrey Noel 7008187 7008888 noel.mccaff
ery@dcu.ie 
Mr  O’Connor Paul 7008474 7008888 paul.l.ocon
nor@dcu.ie 
OTHER INVESTIGATORS: 
TITLE SURNAME FIRST NAME PHONE FAX EMAIL 
      
 
FACULTY/DEPARTMENT/SCHOOL/ 
CENTRE: 
 
School of Health and Human 
Performance 
 
 
1.2 WILL THE RESEARCH BE UNDERTAKEN ON-SITE AT DUBLIN CITY 
UNIVERSITY? 
 YES  NO (If NO, give details of off-campus location.) 
1.3 IS THIS PROTOCOL BEING SUBMITTED TO ANOTHER ETHICS COMMITTEE, OR 
HAS IT BEEN PREVIOUSLY SUBMITTED TO AN ETHICS COMMITTEE?) 
 YES  NO (If YES, please provide details and copies of 
approval(s) received etc.)   
 
 
DECLARATION BY INVESTIGATORS 
The information contained herein is, to the best of my knowledge and belief, accurate.  I have read the 
University’s current research ethics guidelines, and accept responsibility for the conduct of the procedures 
set out in the attached application in accordance with the guidelines, the University’s policy on Conflict of 
Interest and any other condition laid down by the Dublin City University Research Ethics Committee or its 
Sub-Committees.  I have attempted to identify all risks related to the research that may arise in conducting 
this research and acknowledge my obligations and the rights of the participants. 
If there any affiliation or financial interest for researcher(s) in this research or its outcomes or any other 
circumstances which might represent a perceived, potential or actual conflict of interest this should be 
declared in accordance with Dublin City University policy on Conflicts of Interest.  
I and my co-investigators or supporting staff have the appropriate qualifications, experience and facilities 
to conduct the research set out in the attached application and to deal with any emergencies and 
contingencies related to the research that may arise. 
Signature(s): 
Principal investigator(s):  _________________  _________________ 
 ________________ 
Print name(s)   Niall M. Moyna   Noel McCaffrey   Paul 
O’Connor 
Date:    22 August 2006   22 August 2006   22 
August 2006 
 
 
 
 
 
186 
 
 
 
 
 
7 PROJECT OUTLINE  
2.1 LAY DESCRIPTION  
Microparticles are tiny fragments of cells that can be found in the blood.  Under normal 
physiological conditions, low levels of microparticles are continually being shed into the 
blood from cells that line the inside of blood vessels, and appear to cause no problems.  
However, during some diseases, the level of endothelium-derived microparticles 
circulating in the blood rises.  There is now evidence that elevated levels of these 
microparticles can lead to cardiovascular disease.  Regular physical activity has been 
shown to reduce the risk for cardiovascular disease.  The purpose of this study is to 
determine the effects of different bouts of exercise intensity on circulating microparticles 
in healthy asymptomatic people.  The study will involve 5 separate exercise trials of 
approximately 1 hour in duration.  During the first visit subjects will read and sign an 
informed consent, undergo a medical examination questionnaire, have a blood sample 
taken, and familiarise themselves with walking on a treadmill.  The second visit will be 
used to assess their cardiovascular fitness level.  During the experimental trials (visits 
3-5), they will exercise at an intensity equal to 60, 70 and 80% of their maximal capacity 
until they burn 400 calories.  The exercise intensity of each visit will be randomly 
determined. A blood sample will be taken immediately before and after exercise, and 
again at 6 and 24 hours after the exercise.   
2.2 AIMS OF AND JUSTIFICATION FOR THE RESEARCH  
Aims of the Research 
1. To determine the effects of a different intensities of exercise on the number of 
endothelial and platelet derived microparticles in healthy asymptomatic 
individuals  
2. To use an in-vivo cell culture to examine the cellular/molecular mechanism(s) 
responsible for the effect of fitness on EMP.   
Microparticles (MP) are cell fragments shed from formed elements such as circulating 
platelets, leukocytes, and vascular endothelial cells.  During their formation, EMP are 
packaged and exocytosed in a portion of the original plasma membrane.  Depending on 
the dynamic morphological state of the parent cell, phenotypically varied EMP may be 
secreted.  Specific phenotypic subsets carry identifiable surface markers that allow 
them to be detected.  Microparticles of different origin have been shown to play an 
important role in atherosclerotic and inflammatory vascular disease.  For example, high 
levels of endothelial microparticles (EMP) are associated with endothelial dysfunction by 
altering the production and/or bioavailability of nitric oxide (NO).  EMP’s also inhibit 
mitral valve growth.  Significant differences exist between microparticle fractions found 
in the circulation of healthy subjects and those found in patients with atherosclerotic 
cardiovascular disease, diabetes, hypertension and end-stage renal failure. 
 
.3 PROPOSED METHOD  
Study Overview: Subjects will visit the Cardiovascular Research Unit in the School of 
Health and Human Performance on 5 separate occasions.  Each visit will last 
approximately 1 h.  During the first visit the nature and risks of the study will be 
explained, and written informed consent will be obtained.  Subjects will undergo a 
medical examination, have a 10 ml blood sample taken, and familiarize themselves with 
exercising on a treadmill.  Subjects who meet the entry criteria will return to the 
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laboratory for a second visit to assess their maximal aerobic capacity (VO2max).  
During the final visit subjects will exercise on a treadmill at 60, 70 and 80% of their 
maximal capacity until they use 400 kcal.  Blood sample will be taken immediately 
before and after exercise, and again at 6 and 24 hours after the exercise.  
Maximal Exercise Test: VO2max will be assessed using a ramped treadmill protocol.  
The test will begin with an initial speed between 5.0 - 7.0 mph and 0% gradient, and will 
increase in 0.5% incline every 2 min, until volitional exhaustion.  A 12 lead ECG, blood 
pressure, rating of perceived exertion, and expired gases will be monitored throughout 
the test. 
Experimental Trials (Visits 3-5): Subjects will arrive at 9.00 am following an overnight 
fast.  An indwelling catheter will be inserted in a prominent forearm vein in order to take 
blood samples.  Subjects will exercise on a treadmill at 60, 70 and 80% VO2max until 
they burn 400 kcal.  The exercise intensity of each visit will be determined randomly.  
Metabolic measurements and heart rate will be recorded continuously throughout each 
trial.  A 10 ml blood sample will be taken at the beginning and end of each experimental 
trial, and at 6 h and24 h after exercise.  The 24 h  blood sample will be taken using 
standard venipuncture.  The experimental trials (visits 3-5) will be undertaken within 5 d 
of the beginning of menses in menstruating women to reduce the confounding effects of 
menstrual cycle mediated alterations in estrogen and progesterone.  During the 18 h 
following exercise, subjects will be required to eat 3 balanced meals provided by the 
researcher.  Research has shown that high-fat meals can elevate EMP levels. There is 
a need to standardise the food intake throughout the 24 h of the experimental trial.     
Respiratory Metabolic Measures: Breath-by-breath expired O2, CO2 and ventilatory 
volume will be determined using open circuit spirometry (Vmax 29, Sensormedics 
Corp., Yorba Linda CA).  
Blood Sample Analysis: Blood samples will be processed and stored at -80°C until 
analysis. 
2.4 PARTICIPANT PROFILE 
Ten apparently healthy men and ten apparently healthy women (18-30 yr) will be 
recruited.  
Exclusion criteria:  Smoking, anaemia, metabolic syndrome, history of heart disease 
or uncontrolled thyroid dysfunction, liver or kidney dysfunction, pancreatitis, pregnancy 
and other major signs or symptoms suggestive of cardiovascular and pulmonary 
disease (angina, dizziness or syncope, orthopnea or paroxysmal dyspnea, ankle 
oedema, palpitations or tachycardia, intermittent claudication known heart murmur or 
unusual fatigued or shortness of breath with usual exercise). 
 
2.5 MEANS BY WHICH PARTICIPANTS ARE TO BE RECRUITED 
A recruitment advertisement will be emailed to DCU staff and students.  In addition, a 
recruitment advertisement will be posted on the DCU campus.  Permission will be 
sought from the relevant authorities prior to posting the advertisement.  Contact details 
for the research team will be included on the advertisement.  Potential subjects will 
undergo a brief telephone interview to assess their suitability for inclusion in the study.  
Suitable candidates will be asked to attend a screening session in the School of Health 
and Human Performance.  They will be told by agreeing to attend the screening session 
they are not obligated to participate in the study.  A brief 10 min presentation will be 
given to each potential subject to explain the nature, benefits, risks and discomforts of 
the study.  The informed consent will be explained.  Any individual with doubts about 
participating in the study will be encouraged to take time before making a final decision.   
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E-mail to be sent to staff and students 
 
The School of Health and Human Performance are conducting research looking at how 
different exercise intensity effect levels of microparticles in the blood. Microparticles are 
tiny fragments of cells that may be linked with disease such as heart disease. 
 
The study would involve having your fitness assessed on a treadmill and on three other 
days jogging at different intensities on the treadmill until 400 kcal are burned. To look at 
the microparticles we need to take some blood samples. 
 
We are looking for men and women between 18-30 years, who have no history of 
cardiovascular disease, and do not smoke. 
 
Following the research you would get information on your fitness levels and receive 
fitness and nutritional advice if required. 
 
. 
If you would like to hear more about this study or would consider participating, please 
contact Paul O’Connor (Tel: 7008474; e-mail: paul.l.oconnor@dcu.ie) 
2.6 PLEASE EXPLAIN WHEN, HOW, WHERE, AND TO WHOM RESULTS WILL BE 
DISSEMINATED, INCLUDING WHETHER PARTICIPANTS WILL BE PROVIDED WITH ANY 
INFORMATION AS TO THE FINDINGS OR OUTCOMES OF THE PROJECT? 
The study findings may be presented at scientific meetings and published in scientific 
journals. Participants will receive a written report outlining the principle findings of the 
study.  Study participants will receive a one-page report summarizing the results from 
the tests that were undertaken during the screening visit.  The identity of individual 
subjects will not be divulged, and will only be presented as part of a group. 
2.7 OTHER APPROVALS REQUIRED Has permission to gain access to another location, 
organisation etc. been obtained?  Copies of letters of approval to be provided when 
available. 
 YES  NO  NOT APPLICABLE 
(If YES, please specify from whom and attach a copy.  If NO, please explain when this will be 
obtained.) 
2.8 HAS A SIMILAR PROPOSAL BEEN PREVIOUSLY APPROVED BY THE REC? 
 
 YES  NO 
 
3.0 RISK AND RISK MANAGEMENT 
 
3.1 ARE THE RISKS TO SUBJECTS AND/OR RESEARCHERS ASSOCIATED WITH 
YOUR PROJECT GREATER THAN THOSE ENCOUNTERED IN EVERYDAY LIFE? 
 
 YES  NO If YES, this proposal will be subject to full REC review 
If NO, this proposal may be processed by expedited 
administrative review 
 
3.2 DOES THE RESEARCH INVOLVE: 
 
 YES NO 
 Use of a questionnaire? (Attach copy)?   
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 Interviews (attach interview questions)?   
 Observation of participants without their knowledge?   
 Participant observation (provide details in section 2)?   
 Audio- or video-taping interviewees or events?   
 Access to personal and/or confidential data (including student, patient or client 
data) without the participant’s specific consent? 
  
 Administration of any stimuli, tasks, investigations or procedures which may be 
experienced by participants as physically or mentally painful, stressful or 
unpleasant during or after the research process? 
  
 Performance of any acts which might diminish the self-esteem of participants or 
cause them to experience embarrassment, regret or depression? 
  
 Investigation of participants involved in illegal activities?   
 Procedures that involve deception of participants?   
 Administration of any substance or agent?   
 Use of non-treatment of placebo control conditions?   
 Collection of body tissues or fluid samples?   
 Collection and/or testing of DNA samples?   
 Participation in a clinical trial?   
 Administration of ionising radiation to participants?   
3.3 POTENTIAL RISKS TO PARTICIPANTS AND RISK MANAGEMENT PROCEDURES  
The nature and risks involved in the study will be explained prior to starting the study 
and a contact number will be provided.  
Exercise.  There is a risk of delayed muscle soreness following an exercise session in 
sedentary individuals.  Exercise testing carries with it a very small risk of abnormal heart 
rhythms, heart attack or death in less than one in 30,000 patients.   
Blood draws.  There may be discomfort during the insertion of a cannula in a vein and 
the development of a small bruise at the site of puncture.  An individual trained in 
phlebotomy will insert the IV catheter.  The total amount of blood taken during the entire 
study will be approximately 50 ml.  This is much less than the 570 ml of blood that is 
usually donated at blood banks.  Individuals who are anaemic will be excluded form 
participation in this study. 
The laboratory is equipped with an emergency crash cart and defibrillator.  A medical 
doctor will supervise the maximal exercise test.  Standard sterile techniques will be 
used for blood sampling.  
Alternatives to the risks 
All of the methods employed for the study are standard procedures for exercise testing 
and blood collection.  These procedures are currently the best methods available for the 
questions being addressed.  The investigators are very experienced in the 
implementation of these techniques from previously published studies. 
Confidentiality is an important issue during data collection. Participants’ identity or other 
personal information will not be revealed, published or used in further studies.  Subjects 
will be assigned an ID number under which all personal information will be stored in a 
secure file and saved in a password protected file in a computer in DCU.  The principle 
investigator, graduate students and medical director will have access to the data.  The 
study results may be used as part of a series of studies being conducted by the 
Cardiovascular Research Unit.  
3.4 ARE THERE LIKELY TO BE ANY BENEFITS (DIRECT OR INDIRECT) TO 
PARTICIPANTS FROM THIS RESEARCH? 
 YES  NO Subjects will receive a summary of the 
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results of the screening visit. This will 
include their fitness levels (VO2max) 
ECG, body composition, complete blood 
count and cholesterol levels.   
3.5 ARE THERE ANY SPECIFIC RISKS TO RESEARCHERS? (e.g. risk of infection or where 
research is undertaken at an off-campus location) 
 YES  NO The exposure to blood and muscle tissue and needles are 
minimal but the School of Health and Human Performance 
has standard operating procedures for the handling of 
biological products. 
3.6 ADVERSE/UNEXPECTED OUTCOMES 
The School of Health and Human Performance has the facilities to deal with all aspects 
of this study and an emergency plan for adverse events.  The laboratory is equipped 
with an emergency crash cart and defibrillator. An individual trained in Advanced 
Cardiac Life Support (ACLS) will be present during each test.  In the unlikely event of an 
adverse outcome, an ambulance will be called and the subject will immediately be sent 
to Beaumont Hospital. 
3.7 MONITORING  
 The principal investigator will be involved in all aspects of the research, including 
subject recruitment and data collection.  The research team have weekly meeting to 
update on all aspects of the study. The School of Health and Human Performance has 
a detailed list of Standard Operating Procedures for each of the protocols in this study.  
All researchers, including students, must be familiar with the procedures and the Safety 
Statement before beginning data collection. 
3.8 SUPPORT FOR PARTICIPANTS  
This project does not require additional support for participants. 
3.9 DO YOU PROPOSE TO OFFER PAYMENTS OR INCENTIVES TO PARTICIPANTS? 
 
 YES  NO (If YES, please provide further details.)      
 
4.0 INVESTIGATORS’ QUALIFICATIONS, EXPERIENCE AND SKILLS  
Niall Moyna is an exercise physiologist. He is a professor and head of the School of 
Health and Human Performance in the Faculty of Health and Human Performance at 
DCU.  He was Director of the Applied Physiology Laboratory in the Division of 
Cardiology in the University of Pittsburgh Medical Centre and a Senior Research 
Scientist and Director of the Clinical Research Laboratory in the Division of Cardiology 
at Hartford Hospital, Connecticut, USA.  Prof. Moyna is currently the associate Director 
of the Vascular Health Research Centre at DCU.  He is certified in Advanced Cardiac 
Life Support.  
Dr. Noel Mc Caffrey will act as the study physician.  He is a sports medicine physician 
with an adjunct position in the Faculty of Science and Health. 
Paul O’Connor is a laboratory technician in the School of Health and Human 
Performance. Kevin graduated from the Sport Science and Health programme at DCU 
with 1
st
 class honours in 2003.  He has extensive knowledge of all the equipment and 
procedures in the School of Health and Human Performance. Paul is certified in 
Occupational First Aid and Advanced Cardiac Life Support. 
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5.0 CONFIDENTIALITY/ANONYMITY 
5.1 WILL THE IDENTITY OF THE PARTICIPANTS BE PROTECTED? 
 YES  NO (If NO, please explain) 
IF YOU ANSWERED YES TO 5.1, PLEASE ANSWER THE FOLLOWING 
QUESTIONS: 
5.2 HOW WILL THE ANONYMITY OF THE PARTICIPANTS BE ENSURED? 
Confidentiality is an important issue during data collection. Participant’s identity, or 
other personal information, will not be revealed or published.  Subjects will be assigned 
an ID number under which all personal information will be stored in a secure file and 
saved in password protected file in a computer at DCU.  The investigators alone will 
have access to the data. 
5.3 LEGAL LIMITATIONS TO DATA CONFIDENTIALITY: 
 YES  NO  
 
6.0 DATA/SAMPLE STORAGE, SECURITY AND DISPOSAL  
For the purpose of this section, “Data” includes that in a raw or processed state (e.g. 
interview audiotape, transcript or analysis).  “Samples” include body fluids or tissue 
samples. 
6.1 WILL THE DATA/SAMPLES BE STORED?  
 (The REC recommends that all data be stored on campus) 
Stored at DCU       
Stored at another site      
6.2 WHO WILL HAVE ACCESS TO DATA/SAMPLES? 
Access by named researchers only     
Access by people other than named researcher(s)  
Other:        
6.3 IF DATA/SAMPLES ARE TO BE DISPOSED OF, PLEASE EXPLAIN HOW, WHEN 
AND BY WHOM THIS WILL BE DONE? 
The data will be shredded after five years. Prof. Niall Moyna will carry this out. 
7.0 FUNDING 
7.4 HOW IS THIS WORK BEING FUNDED?  
The study is being funding from resources within the School of Health and Human 
Performance 
7.2 PROJECT GRANT NUMBER (If relevant and/or known) 
7.3 DOES THE PROJECT REQUIRE APPROVAL BEFORE CONSIDERATION FOR 
FUNDING BY A GRANTING BODY?  
 YES  NO  
7.4 HOW WILL PARTICIPANTS BE INFORMED OF THE SOURCE OF THE FUNDING? 
8.0 PLAIN LANGUAGE STATEMENT 
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Title: Effect of an acute bout of exercise on circulating microparticles. 
Principal Investigators 
Prof. Niall Moyna niall.moyna@dcu.ie  (Phone No. 7008802) 
Kevin O’ Brien  kevin.obrien7@mail.dcu.ie (Phone No. 7008470) 
Dr. Noel McCaffrey noel.mccaffery@dcu.ie  (Phone No. 7008187) 
School of Health and Human Performance, Dublin City University 
What is the study about? 
Microparticles are tiny fragments of cells that can be found in the blood.  During some diseases, 
the level of microparticles circulating in the blood rises.  There is now evidence that elevated 
levels of these microparticles can lead to cardiovascular disease.  Regular physical activity has 
been shown to reduce the risk for cardiovascular disease.  The purpose of this study is to 
determine the effects of exercise intensity on the number of microparticles in healthy 
asymptomatic individuals.  
You will be asked to make 5 visits to the School of Health and Human Performance in DCU.  
Each visit will last approximately 1 hour.  You will arrive for each visit after an overnight fast.  
During the first visit you will have a blood sample taken and undergo a brief examination by a 
medical doctor to make sure you are suitable for the study.  About 10 days after this visit you 
will be contacted by phone or email to let you know if you are eligible to participate in the study.  
During the second visit you will exercise on a treadmill for approximately 15-mins to determine 
your fitness level.  The exercise will get progressively harder, but you should try to keep going 
as long as you can.  During  visits 3-5, you will exercise at an intensity equal to 60, 70 and 80%, 
of your maximal capacity until you burn 400 calories.  The exercise intensity of each visit will be 
determined randomly.  A blood sample will be taken immediately before and after exercise, and 
again at 6 hours and 24 hours after the exercise.  You will be asked to eat 3 balanced meals 
throughout the 24 h of the experimental trials.    
Exercise does carry a risk of injury, such as a pulled muscle, muscle soreness or in extreme 
cases abnormal heart rhythm, heart attack or death.  The benefits of being involved in this study 
include a detailed assessment of your fitness, your response to exercise and your cholesterol 
levels.  All information we gather will be stored in a secure filing cabinet.  The results of the 
study will be used for a postgraduate thesis and may be published in academic journals.  You 
will not be identified, as your information will be presented as part of a group.  Confidentiality of 
information provided can only be protected within the limitations of the law.  It is possible for 
data to be subject to subpoena, freedom of information claim or mandated reporting by some 
professions.  All data will be destroyed after 5 years.  Your participation in this research project 
is voluntary and you may withdraw your consent at any time. 
If participants have concerns about this study and wish to contact an independent 
person, Please contact: 
The Secretary, Dublin City University Research Ethics Committee, c/o Office of 
the Vice-President for Research, Dublin City University, Dublin 9.  Tel 01-7008000 
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Appendix F 
 
E-mail to be sent to staff and students 
The School of Health and Human Performance at DCU are conducting a research study 
to investigate the influence of the intensity of exercise training on changes in skeletal 
muscle that occur with training.  The purpose of this project is to look at the impact of 
training at two different exercise intensities for 14 days on muscle function. One group 
will exercise at a low intensity for 60 minutes each day and another group will exercise 
at a high intensity for 30 minutes each day.  
 
We are looking for healthy males between 18-35 years, who have not been involved in 
regular exercise for the last 6 months and do not smoke.  The study would involve a 
fitness test on a bicycle followed by two weeks of exercise training.  To determine the 
impact of exercise on the muscle cells, we would take muscle biopsies from the leg at 
different points during the training programme. 
 
If you would like to hear more about this study or would consider participating, please 
contact Brendan Egan (Tel: 7008472; e-mail: brendan.egan6@mail.dcu.ie) 
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Appendix G 
Plain Language statement 
Title:  The influence of training intensity on adaptations to exercise training in human skeletal muscle 
 
Principal investigators: 
Dr. Donal O’Gorman  - donal.ogorman@dcu.ie  01-7008060 
Mr. Brendan Egan  - brendan.egan6@mail.dcu.ie 01-7008472 
Metabolic Physiology Research Unit, School of Health and Human Performance, Dublin City University 
 
It is well known that exercise training has many health benefits, including weight loss and the 
prevention of diabetes and cardiovascular disease.  Despite the known benefits, we don’t fully 
understanding what changes occur in the body, especially skeletal muscle. Learning more about 
these changes would have important implications for (i) future treatments of these diseases and (ii) 
more specific exercise recommendations. 
 
The purpose of this project is to look at how the intensity/effort of exercise influences the adaptations 
to training. You will be asked to make several visits to the lab.   
 On the first visit you will have a medical examination from the doctor, to make sure you are 
suitable for the study.  You will then exercise on a bicycle for approximately 15 minutes to 
determine your fitness level. 
 On the second visit to the lab you will cycle at either 40% or 80% of your maximal ability to 
verify the intensity that you will train at.  This will take approximately 30 minutes.   
 After a week, you will begin an exercise training program lasting 14 days. You will be required 
to train every day at either 40% of your maximal ability for approximately 60-mins or 80% for 
approximately 30-mins. Your training will be supervised at all times.   
 A muscle biopsy will be taken from your leg before you start the training programme and 
following 1-, 3-, 7-, 10- and 14-days of training. A blood sample will also be taken at this time, 
and at the exercise session the previous evening. 
 For three days prior to the commencement of training you will be asked to record your daily 
food intake. You will be advised to continue this pattern of intake for the duration of the 
program. 
 
Exercise does carry a risk of injury, such as a pulled muscle, muscle soreness or in extreme cases 
abnormal heart rhythm, heart attack or death.  The benefits of being involved in this study include a 
detailed assessment of your fitness, your response to exercise and your energy use.  All information 
we gather will be stored in a secure filing cabinet.  The results of the study will be used for a 
postgraduate thesis and may be published in academic journals.  You will not be identified, as your 
information will be presented as part of a group.  Confidentiality of information provided can only be 
protected within the limitations of the law.  It is possible for data to be participant to subpoena, freedom 
of information claim or mandated reporting by some professions.  All data will be destroyed after 5 
years. Your participation in this research project is voluntary and you may withdraw your consent at 
any time.  There will not be any penalty nor will your rights as a student or staff member of DCU be 
affected in any way.   
 
This research project is being funded from a grant awarded within DCU and the funding of a 
postgraduate student by the Irish Research Council for Science, Engineering and Technology 
(IRSCET). 
 
If participants have concerns about this study and wish to contact an independent person, 
please contact: 
The Secretary, Dublin City University Research Ethics Committee, c/o Office of the Vice-
President for Research, Dublin City University, Dublin 9.  Tel 01-7008000 
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Appendix H 
Informed Consent 
Title: The influence of training intensity on adaptations to exercise training in human skeletal muscle 
 
Principal investigators: Dr. Donal O’Gorman, and Mr. Brendan Egan: School of Health and Human 
Performance 
 
Other investigators: Brian Carson, David Ashley, Dr. Gavin McHugh, Dr. Ray Walls, Prof. Niall Moyna, 
Paul O’Connor 
 
Purpose 
The purpose of this project is to look at the impact of changing the intensity of exercise training on 
changes that occur in muscle proteins in response to 14 days of exercise training. 
 
This is what will happen during the research study 
1. I will have the purpose of the study, each of the steps involved and the risks of participating in the 
study explained to me. I will have the opportunity to ask any questions and if I am happy with the 
answers I will:  
a. Provide written informed consent for participation in the research project.  
b. I will then complete a medical history form, which will ask questions about my general 
health, personal and family health history, smoking, exercise, and dietary habits.   
c. I will talk with a medical doctor about the information I have provided and I understand, 
based on the information provided, the medical doctor may exclude me from 
participating in the research project. 
d. I will be provided with dietary advice, which I will follow for three days prior to each visit 
to the laboratory.  I will not consume caffeine or alcohol during this period. 
2. Pre-test evaluation 
a. I will have a number of measurements of my body size and shape.  Firstly, my blood 
pressure will be measured.  I will have an electrocardiogram (ECG) done to evaluate my 
heart.  This is a painless, 5 minute procedure that involves lying down and having adhesive 
pads attached to my arms, legs and chest.  My height and weight will be measured in light 
clothing, and without shoes.  My percentage body fat will be measured by the thickness of 
skin and fat on 7 sites around the body including the chest, leg, arm, back and side of the 
body. I will provide a blood sample to check some health indicators. 
b. I understand that any of these procedures or tests may be waived at the discretion of the 
doctor for the following reasons: (i) I have completed the same or similar step in the past 6 
months as part of another research protocol at the School of Health and Human 
Performance; (ii) It has been determined that I am not eligible to participate in this research 
project; and thus completion of the entire screening process will not be necessary. 
3. Exercise capacity and determination of exercise intensity 
a. I will undergo an exercise test designed to measure my fitness, and to evaluate my current 
physical condition.  I understand that I will pedal on a stationary bicycle, with the pedal 
resistance getting more difficult every 2 minutes until, fatigue, breathlessness, chest pain 
and/or symptoms that indicate to the doctor or myself that I should stop exercise.  To assess 
my fitness I will have a mouthpiece similar to a snorkel in my mouth to measure the amount 
of air I breathe in and out. 
b. At least 4 days later, I will cycle on a stationary bike for 30 minutes to determine the 
resistance that corresponds to either 40% or 80% of my exercise capacity (depending on the 
training group that I will be assigned to).  During this time I will also wear the mouthpiece to 
determine oxygen use 
4. Impact of training on muscle cell function 
a. Approximately one week later I will begin the exercise training phase of the study. I will 
exercise on consecutive days for 14 days. 
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b. I will be assigned to one of two training groups and as such will train at an intensity 
corresponding to either 40% of my maximum ability for approximately 60 minutes or at an 
intensity corresponding to 80% of my maximum ability for approximately 30 minutes 
depending on my group. I understand that I will be breathing more often, and will sweat, but 
that I will be able to maintain a conversation. 
c. I understand that all my exercise training sessions will take place in the MPRU on a 
stationary bicycle under supervision by one of the study’s investigators and that training 
sessions will take place in the late afternoon to early evening. 
d. On the morning of the first day of training, I will come to the MPRU between 0800h and 
0900h after an overnight fast, with only water taken for the previous 10 hours. After resting 
for 15 minutes, I will have a blood sample taken from my arm and a muscle biopsy taken 
from my thigh. For the biopsy I will have the area anaesthetised with local anaesthetic, then 
a small 0.5 cm incision will be made in the skin and a needle inserted briefly into the muscle.  
A small piece of muscle, less that 0.15 of a gram, will be taken from my leg.  The incision is 
pulled close with sterile strips and my leg will be wrapped snugly with an elastic bandage to 
maintain pressure. Before I leave I will be given contact information and supplies to change 
the dressing around the biopsy sites. 
e. I will then leave the lab before returning that afternoon to complete the first exercise training 
session. On the morning following the 1
st
, 3
rd
, 7
th
, 10
th
, and 14
th
 training sessions, I will report 
to the MPRU under the same fasting conditions for subsequent blood and muscle sample 
collection. I will have additional blood samples taken immediately prior to and immediately 
after the 1
st
, 3
rd
, 7
th
, 10
th
, and 14
th
 training sessions. This will complete my participation in 
the study. 
f. In preparation for the training phase I will be required to record my daily food intake in the 
three days leading up to the commencement of training. I will maintain a similar level of 
dietary intake throughout the two week training period. 
g. I will be weighed immediately prior to and immediately after each training session to 
determine the volume of fluid loss through sweating that has occurred. I will be advised to 
replace this loss with the appropriate amount of fluid based on established 
recommendations. However, I understand that water will be available ad libitum throughout 
the training sessions. 
 
Sometimes there are side effects from performing exercise tests. These side effects are often 
called risks, and for this project, the risks are: 
1. Exercise testing carries with it a very small risk of exercise induced asthma, abnormal heart 
rhythms, heart attack, or death in less than one in 30,000 patients.  The risk of sudden death 
during exercise for healthy men is 1:15000-18000.  Because I will be asked to give a maximum 
effort, I may experience some muscle soreness in my arms and legs or nausea following the 
maximal exercise test. It should be noted that if the experimental protocol is adhered to that the 
likelihood of these risks occurring is minimal. 
2. I understand that the insertion of a needle into a superficial arm vein (to take blood samples) 
should be minimally painful but a slight ache may be felt and a small bruise may appear on my 
arm.  There is also a small risk of infection, but by using the appropriate techniques this risk is 
minimal. 
3. I understand that there may be discomfort during the muscle biopsy with some pain and delayed 
soreness afterward.  There is a risk of bleeding, bruising, infection and scaring of the skin.  After 
the biopsy, my leg may feel stiff and sore.  Temporary numbness of the skin near the biopsy may 
also occur. 
 
There may be benefits from my participation in this study.  These are: 
1. I will receive a copy of my personal results, body fat and fitness measurements and energy use 
during exercise when the study is finished. 
2. I will be given guidelines to maintain or increase my physical activity/training program if I feel I 
would like to continue to exercise after the study. 
3. I understand that no other benefits have been promised me. 
 
Costs associated with the study 
I understand that there will not be any payment for participation in this study but legitimate expenses to a 
maximum value of €150 will be recompensed. 
 
Participant – please complete the following (Circle Yes or No for each question) 
I have read the Plain Language Statement     Yes/No 
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I understand the information provided     Yes/No 
I have had an opportunity to ask questions and discuss this study   Yes/No 
I have received satisfactory answers to all my questions    Yes/No 
 
My confidentiality will be guarded: 
Dublin City University will protect all the information about me, and my part in this study, within the 
limitations of the law.  My identity or personal information will not be revealed or published. All records 
associated with my participation in the study will be participant to the usual confidentiality standards 
applicable to medical records.  In addition, the study findings may be presented at scientific meetings and 
published in a scientific journal and/or as part of a postgraduate thesis, but my identity will not be divulged 
and only presented as part of a group.   
 
If I have questions about the research project, I am free to call Donal O’Gorman at 01-7008060.   
 
Taking part in this study is my decision.   
I understand that my participation in this study is voluntary and that I may withdraw my consent at any time 
by notifying any of the investigators.  I may also ask that the information gathered about me be removed 
from the database, or storage, and destroyed.  My withdrawal from this study, or my refusal to participate, 
will in no way affect my relationship with Dublin City University or my entitlements as a student or staff 
member.  I understand that my participation in this research may be terminated by the investigator without 
regard to my consent if I am unable or unwilling to comply with the guidelines and procedures explained to 
me.  
 
Project Funding 
This research project is being funded from an award to Dr. Donal O’Gorman from the Faculty of Science 
and Health at Dublin City University and funding for a postgraduate student from the Irish Research 
Council on Science, Engineering and Technology. 
 
Signature: 
I have read and understood the information in this form.  My questions and concerns have been answered 
by the researchers, and I have a copy of this consent form.  Therefore, I consent to take part in this 
research project 
 
Participants Signature:         
 
Name in Block Capitals:         
 
Witness:             
 
Date:                 
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Appendix I 
 
 
 
 
Dublin City University 
RESEARCH ETHICS COMMITTEE 
 
APPLICATION FOR APPROVAL OF A PROJECT 
INVOLVING HUMAN PARTICIPANTS 
 
Application No. (office use only)  DCUREC/2007/ 
  
 
Period of Approval (office use only) ....../....../...... to ....../....../.... 
 
This application form is to be used by researchers seeking ethics approval for individual projects and studies. 
 
The signed original and an electronic copy of your completed application must be submitted to the DCU Research 
Ethics Committee.  Applications must be completed on the form; answers in the form of attachments will not be 
accepted, except where indicated.  No handwritten applications will be accepted.  Research must not commence 
until written approval has been received from the Research Ethics Committee. 
 
 
PROJECT TITLE Adaptations in human skeletal muscle following  
short term exercise training at two different intensities 
 
PRINCIPAL 
INVESTIGATOR(S) 
Donal O’Gorman, PhD 
Brendan Egan 
 
 
 
Guidelines to Applicants 
 
1.1 PRINCIPAL INVESTIGATOR(S):  Supervisors and co-supervisors of student projects are Principal Investigators.  
PhD and Doctoral students can be listed as Investigators. 
 
2.0 PROJECT OUTLINE:  Provide a brief outline of the project, aims, methods, duration, funding, profile of participants 
and proposed interaction with them. This description must be in everyday language that is free from jargon.  Please 
explain any technical terms or discipline-specific phrases.  
 
2.1 LAY DESCRIPTION:  Provide a brief outline of the project, including what participants will be required to do.  This 
description must be in everyday language which is free from jargon.  Please explain any technical terms or discipline-
specific phrases. (No more than 300 words). 
 
2.2 AIMS OF AND JUSTIFICATION FOR THE RESEARCH:  State the aims and significance of the project (approx. 
400 words). Where relevant, state the specific hypothesis to be tested. Also please provide a brief description of current 
research, a justification as to why this research should proceed and an explanation of any expected benefits to the 
community. NB – all references cited should be listed in an attached bibiliography. 
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2.3 PROPOSED METHOD:  Provide an outline of the proposed method, including details of data collection techniques, 
tasks participants will be asked to do, the estimated time commitment involved, and how data will be analysed. If the 
project includes any procedure which is beyond already established and accepted techniques please include a 
description of it.  (No more than 400 words.) 
 
2.4 PARTICIPANT PROFILE:  Provide number, age range and source of participants.  Please provide a justification of 
your proposed sample size.  Please provide a justification for selecting a specific gender. 
 
2.5 MEANS BY WHICH PARTICIPANTS ARE TO BE RECRUITED:  Please provide specific details as to how you will 
be recruiting participants. How will people be told you are doing this research?  How will they be approached and asked 
if they are willing to participate?  If you are mailing to or phoning people, please explain how you have obtained their 
names and contact details. This information will need to be included in the plain language statement.  If a recruitment 
advertisement is to be used, please ensure you attach a copy to this application. 
 
3.3 POTENTIAL RISKS TO PARTICIPANTS AND RISK MANAGEMENT PROCEDURES:  Identify, as far as possible, 
all potential risks to participants (physical, psychological, social, legal or economic etc.), associated with the proposed 
research. Please explain what risk management procedures will be put in place. 
 
3.6 ADVERSE/UNEXPECTED OUTCOMES:  Please describe what measures you have in place in the event that there 
are any unexpected outcomes or adverse effects to participants arising from involvement in the project. 
 
3.7 MONITORING:  Please explain how you propose to monitor the conduct of the project (especially where several 
people are involved in recruiting or interviewing, administering procedures) to ensure that it conforms with the 
procedures set out in this application.  In the case of student projects please give details of how the supervisor(s) will 
monitor the conduct of the project. 
 
3.8 SUPPORT FOR PARTICIPANTS:  Depending on risks to participants you may need to consider having additional 
support for participants during/after the study.  Consider whether your project would require additional support, e.g., 
external counseling available to participants.  Please advise what support will be available. 
 
4.0 INVESTIGATORS’ QUALIFICATIONS, EXPERIENCE AND SKILLS:  List the academic qualifications and outline 
the experience and skills relevant to this project that the researchers and any supporting staff have in carrying out the 
research and in dealing with any emergencies, unexpected outcomes, or contingencies that may arise. 
 
5.2 HOW WILL THE ANONYMITY OF THE PARTICIPANTS BE RESPECTED?  Please bear in mind that where the 
sample size is very small, it may be impossible to guarantee anonymity/confidentiality of participant identity.  
Participants involved in such projects need to be advised of this limitation. 
 
5.3 LEGAL LIMITATIONS TO DATA CONFIDENTIALITY:  Participants need to be aware that confidentiality of 
information provided can only be protected within the limitations of the law - i.e., it is possible for data to be participant 
to subpoena, freedom of information claim or mandated reporting by some professions. Depending on the research 
proposal you may need to specifically state these limitations.   
 
6.0 DATA/SAMPLE STORAGE, SECURITY AND DISPOSAL: For the purpose of this section, “Data” includes that in a 
raw or processed state (e.g. interview audiotape, transcript or analysis).  “Samples” include body fluids or tissue 
samples. 
 
8.0 PLAIN LANGUAGE STATEMENT:  Written information in plain language that you will be providing to participants, 
outlining the phases and nature of their involvement in the project and inviting their participation.  Please note that the 
language used must reflect the participant age group and corresponding comprehension level. 
 
9.0 INFORMED CONSENT FORM:  This is a very important document that should be addressed by participants to 
researchers, requiring participants to indicate their consent to specific statements, and give their signature. 
 
FOR FURTHER INFORMATION AND NOTES ON THE DEVELOPMENT OF PLAIN LANGUAGE STATEMENTS 
AND INFORMED CONSENT FORMS, PLEASE CONSULT THE DCU REC WEBSITE: 
WWW.DC.IE/RESEARCH/ETHICS 
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1. ADMINISTRATIVE DETAILS 
 
 
THIS PROJECT IS:  Research Project  Funded Consultancy 
(tick as many as apply)  Practical Class  Clinical Trial 
  Student Research Project  
(please give details) 
 Other  - Please Describe:       
  Masters  Undergraduate 
  PhD   
 
Project Start Date: May 2007 Project End date: April 2008 
 
 
1.1 INVESTIGATOR CONTACT DETAILS (see Guidelines) 
 
PRINCIPAL INVESTIGATOR(S):  
 
TITLE SURNAME FIRST NAME PHONE FAX EMAIL 
Dr. O’Gorman Donal 7008060 7008888 donal.ogorman@dcu.ie 
      Egan Brendan 7008472  brendan.egan6@mail.dcu.ie 
 
OTHER INVESTIGATORS: 
 
TITLE SURNAME FIRST NAME PHONE FAX EMAIL 
 O’Connor Paul 7008474  paul.l.oconnor@.dcu.ie 
Prof. Moyna Niall 7008802 7008888 niall.moyna@dcu.ie 
 Carson Brian 7008472  brian.carson2@mail.dcu.ie 
 Ashley David 7008472  david.ashley2@mail.dcu.ie 
Dr. McCaffrey Noel 7008187  mccaffs@eircom.net 
Dr. McHugh Gavin 7008472  mchughgavin@yahoo.co.uk 
Dr. Walls Ray 7008472  raywalls1@hotmail.com 
 
FACULTY/DEPARTMENT/SCHOOL/ CENTRE: 
 
Metabolic Research Unit, School of Health and 
Human Performance 
 
1.2 WILL THE RESEARCH BE UNDERTAKEN ON-SITE AT DUBLIN CITY UNIVERSITY? 
 
 YES  NO (If NO, give details of off-campus location.) 
      
 
1.3 IS THIS PROTOCOL BEING SUBMITTED TO ANOTHER ETHICS COMMITTEE, OR HAS IT 
BEEN PREVIOUSLY SUBMITTED TO AN ETHICS COMMITTEE?) 
 
 YES  NO (If YES, please provide details and copies of 
approval(s) received etc.)   
 
 
DECLARATION BY INVESTIGATORS 
The information contained herein is, to the best of my knowledge and belief, accurate.  I have read the University’s 
current research ethics guidelines, and accept responsibility for the conduct of the procedures set out in the attached 
application in accordance with the guidelines, the University’s policy on Conflict of Interest and any other condition laid 
down by the Dublin City University Research Ethics Committee or its Sub-Committees.  I have attempted to identify all 
risks related to the research that may arise in conducting this research and acknowledge my obligations and the rights 
of the participants. 
 
If there any affiliation or financial interest for researcher(s) in this research or its outcomes or any other circumstances 
which might represent a perceived, potential or actual conflict of interest this should be declared in accordance with 
Dublin City University policy on Conflicts of Interest.  
 
I and my co-investigators or supporting staff have the appropriate qualifications, experience and facilities to conduct the 
research set out in the attached application and to deal with any emergencies and contingencies related to the research 
that may arise. 
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Signature(s): 
 
Principal investigator(s):  ____________________________ 
 ____________________________ 
 
 
Print name(s) in block letters:  ____________________________
 __________________________
__ 
 
Date:       ____________________________           ____________________________ 
 
 
 
 
 
2. PROJECT OUTLINE  
 
2.1 LAY DESCRIPTION (see Guidelines) 
 
Exercise training has many important health-related benefits.  In addition to helping with weight 
loss, it can decrease the risk of developing many chronic diseases.  Despite the many positive 
outcomes, we know relatively little about how exercise contributes to these changes.  It is known 
that exercise training improves the function of muscle cells. Recent research has shown that 
many of the changes that occur in response to one exercise session have been shown to depend 
on the intensity/effort of the exercise. How this occurs is poorly understood at present. The 
purpose of this study is to determine the impact of exercise training at two different intensities on 
the changes in muscle tissue. 
 
Participants will undertake a medical screening and have their fitness measured on the first visit.  
On a separate day the intensity corresponding to 40% and 80% of their maximal fitness will be 
determined during a short exercise session. 
 
Participants will be divided into two groups, one training at 40% of their maximal ability for 
approximately 60-mins and the other at 80% for approximately 30-mins.  Training will take place 
each day for 14 days. In order to measure the changes in the function of muscle cells, muscle 
biopsies will be taken on selected days during the training period. 
 
 
2.2 AIMS OF AND JUSTIFICATION FOR THE RESEARCH (see Guidelines) 
 
 Aims of Research 
To determine the impact of the intensity/effort of exercise on gene expression (the initial step in 
making new proteins) and protein content in response to short-term exercise training in human 
skeletal muscle. 
 
Significance 
There is very little known about the impact of exercise training on gene expression in muscle 
cells.  Determining the influence of intensity/effort of exercise training on the regulation of gene 
expression would help further our understanding of the benefits of exercise and the mechanism 
of its effects. 
 
Brief description of current research 
Research studies have shown that 16 hours following an exercise session there is an increase in 
the expression of GLUT-4 (Neufer & Dohm, 1993), a key protein in glucose transport into muscle 
cells.  It has also been shown that exercise training will lead to an increase in the amount of this 
protein in muscle cells (Kraniou et al., 2004), and helps to reduce blood glucose levels in patients 
with type 2 diabetes and those who are overweight and insulin resistant (common before 
diabetes). We have previously shown an increase in GLUT4 protein following short-term exercise 
training in type 2 diabetics  (O’Gorman et al., 2006). However, it is not known how exercise 
results in this increase in expression. We have also shown that key cellular proteins are regulated 
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to a greater or lesser extent depending on the intensity of exercise (Egan et al., 2007). A 
transcriptional co-activator, PGC-1, is involved in the regulation of a number of key proteins in 
glucose and fat metabolism (Puigserver & Spiegelman, 2003).  Acute exercise and exercise 
training both lead to an increase in PGC-1 and is thought to play a role in the exercise-related 
training adaptation (Pilegaard et al., 2003). Important enzymes activated by exercise (i.e. AMPK 
and CaMK) are also activated in an intensity-dependent manner (Rose et al., 2006; Sriwijitkamol 
et al., 2007, Egan et al., 2007), with a greater degree of activation evident at higher exercise 
intensities even when the energy cost of exercise is the same.  We want to further our research 
findings from one exercise session, to determine the impact on changes in muscle proteins 
following short term exercise training. 
 
Hypothesis to be tested 
Stated as a null hypothesis, no difference will exist in the time-course or magnitude of the 
exercise training-induced response to exercise at two different intensities when energy 
expenditure is the same. 
 
Implications of this Research 
While there may not be any direct benefits to society from this study, the results will contribute to 
our knowledge of the regulation of gene expression following exercise.  This has implications for 
the prescription of exercise training, particularly whether the intensity of each exercise bout is an 
important determinant in the positive outcomes associated with such training programmes. It is 
possible that this research will identify novel mechanisms for understanding energy regulation in 
response to exercise training. 
 
 
 Egan B, Carson BP, Garcia-Roves PM, Sarsfield FM, Chibalin AV, Monedero J, 
O’Connor P, Moyna NM, McCaffrey N, Zierath JR, O’Gorman DJ (2007) Intensity-
dependent effect of exercise on contraction-mediated signalling and metabolic gene 
expression in human skeletal muscle. Nuclear Receptor Pathways to Metabolic 
Regulation. Keystone Symposia, Steamboat Springs, CO. (Abstract) 
 
 Kraniou GN, Cameron-Smith D, Hargreaves M (2004) Effect of short-term training on 
GLUT-4 mRNA and protein expression in human skeletal muscle. Experimental 
Physiology. 89:559-63 
 
 Neufer PD, Dohm GL (1993) Exercise induces a transient increase in transcription of the 
GLUT-4 gene in skeletal muscle. American Journal of Physiology (Cell Physiology). 
265:C1597-603 
 
 O'Gorman DJ, Karlsson HK, McQuaid S, Yousif O, Rahman Y, Gasparro D, Glund S, 
Chibalin AV, Zierath JR, Nolan JJ (2006) Exercise training increases insulin-stimulated 
glucose disposal and GLUT4 (SLC2A4) protein content in patients with type 2 diabetes. 
Diabetologia. 49:2983-2992 
 
 Pilegaard H, Saltin B, Neufer PD (2003) Exercise induces transient transcriptional 
activation of the PGC-1alpha gene in human skeletal muscle. Journal of Physiology. 
546:851-8 
 
 Puigserver P, Spiegelman BM (2003) Peroxisome proliferator-activated receptor-gamma 
coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. 
Endocrine Reviews. 24:78-90 
 
 Rose AJ, Kiens B, Richter EA (2006) Ca2+-calmodulin-dependent protein kinase 
expression and signalling in skeletal muscle during exercise. Journal of Physiology. 
574:889-903. 
 
 Sriwijitkamol A, Coletta DK, Wajcberg E, Balbontin GB, Reyna SM, Barrientes J, Eagan 
PA, Jenkinson CP, Cersosimo E, Defronzo RA, Sakamoto K, Musi N (2007) Effect of 
acute exercise on AMPK signaling in skeletal muscle of participants with type 2 
diabetes: a time-course and dose-response study. Diabetes. 56:836-48 
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2.3  PROPOSED METHOD (see Guidelines) 
 
 Participants 
The study will take place in the Metabolic Physiology Research Unit (MPRU) in the School of 
Health and Human Performance. The nature and risks of the study will be explained, and any 
questions will be answered to the satisfaction of the participants before obtaining written informed 
consent.  Participants will complete a medical history questionnaire and be interviewed by the 
study physician to determine eligibility.  Participant height, weight blood pressure and body 
composition, as well as resting 12 lead ECG and a blood sample will be evaluated as part of the 
physical examination and medical clearance. The blood sample (3 ml) will be used to ensure that 
the immune system is not fighting infection and that the proportion of red blood cells is normal.  
Participants will have a normal body mass index and will be excluded if they exercise regularly, 
smoke, have diabetes, suffer from other acute or chronic diseases or use drugs that the 
physician and investigators decide would interfere with the normal adaptation to the proposed 
intervention.  Participants will be asked to keep a food diary for 3 days prior to starting exercise 
and then to maintain a similar diet throughout the study.  Participants will abstain from caffeine for 
24 hours prior to each biopsy (see below) and from alcohol for the duration of the training 
programme. 
 
 
 
Research procedures 
Stage 1 - Maximal oxygen consumption:  This test follows the standard operating procedure for 
all similar trials submitted to the Research Ethics Committee.  Participants will exercise on a 
stationary cycle ergometer to volitional fatigue.  After 5 minutes at an easy pace the resistance to 
pedalling will increase every 2 minutes until it is not possible for the participant to maintain cycling 
cadence.  During the test the participant will have a mouthpiece, similar to a snorkel in their 
mouth.  This is connected to an oxygen analyser that will determine the amount of oxygen 
consumed by the body.  Generally the more oxygen someone is capable of consuming the higher 
the fitness level. The participant will have their heart rate and rate of perceived exertion (a 
subjective measure of the degree of effort involved) monitored throughout the test. This test takes 
approximately 15 minutes. 
 
Stage 2 – Verification of exercise intensity:  On a separate day, participants will exercise to 
determine the workload that corresponds to either 40% or 80% of their maximal oxygen uptake 
(determined from the maximal test) depending on which training group each participant is 
randomly assigned to.  The exercise intensity/effort will be verified by oxygen consumption, heart 
rate and perceived exertion and will take approximately 30 minutes.   
 
Verification of 
training intensity
~30 minutes to verify workload at either 
40% or 80% of maximal exercise ability
14 days of exercise training
GROUP 1
Low Intensity 
40% of maximal 
exercise ability
GROUP 2
High Intensity 
80% of maximal 
exercise ability
Each session will continue until 400 kcal of 
energy is used (~30-60 minutes)
Informed consent 
and physical 
screening
~15 minutes of progressively 
increasing exercise intensity
Maximal 
exercise 
tests
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Stage 3 – Exercise training phase:  Five to seven days after the verification test, participants will 
begin the exercise training phase of the study. Participants will be required to exercise on 14 
consecutive days. One group will train at an intensity corresponding to 40% of their maximum 
ability for approximately 60 minutes and the other group will train at an intensity corresponding to 
80% of their maximum ability for approximately 30 minutes. They will use the exact same amount 
of energy (400 kcal) in each training session. This magnitude of training load is consistent with 
that employed in similar designs and is well tolerated by sedentary individuals (Spina et al., 1996; 
Gibala et al., 2006). All exercise training sessions will take place in the MPRU on a stationary 
bicycle under supervision by one of the study’s investigators. Training sessions will take place in 
the late afternoon to early evening depending on the participants’ availability. 
On the morning of the first day of training, participants will report to the MPRU between 0800h 
and 0900h after an overnight fast. They will rest for 15 minutes and then have a blood sample (6 
ml) using venepuncture and a muscle biopsy taken from m. vastus lateralis.  They will then be 
free to leave the lab before returning that afternoon to complete the first exercise training session. 
On the morning following the 1
st
, 3
rd
, 7
th
, 10
th
, and 14
th
 training sessions, participants will report to 
the MPRU under the same conditions for subsequent blood and muscle sample collection. 
Participants will have additional blood samples taken immediately prior to and immediately after 
the exercise sessions prior to a muscle biopsy. 
 
 
 
 
Meals 
Participants will be required to record their daily food intake in the three days leading up to the 
beginning of the exercise training phase. They will be advised to maintain a similar level of 
dietary intake throughout the two week training period. Each participant will be weighed 
immediately prior to and immediately after each training session to determine the volume of fluid 
loss through sweating that has occurred. They will be advised to replace this loss with the 
appropriate amount of fluid based on established recommendations. However, water will be 
available ad libitum throughout the training sessions. Body mass will be monitored on a daily 
basis as a surrogate measure of both hydration and energy balance. At 3 day intervals, dietary 
intake will be assessed as per the days prior to beginning of the exercise programme to ensure 
an appropriate number of calories is being taken and to monitor any dietary changes that may 
have inadvertently occurred since the beginning of training.   
 
Rationale for muscle biopsy samples 
A total of six biopsies will be taken from each participant. This number is not uncommon in this 
type of research (Pilegaard et al., 2003). A biopsy is needed prior to the start of the training 
programme in order to establish a baseline value to which subsequent changes can be 
compared. We intend to track the rate of change in muscle function in response to training per se 
and measure the effect of exercise intensity on this rate of change. In order to complete a time-
course study we will require muscle samples at regular intervals during the 14 day training 
programme.  
 Gibala MJ, Little JP, van Essen M, Wilkin GP, Burgomaster KA, Safdar A, Raha S, 
Tarnopolsky MA. Short-term sprint interval versus traditional endurance training: similar 
initial adaptations in human skeletal muscle and exercise performance. Journal of 
Physiology 15: 901-11, 2006. 
 Pilegaard H, Saltin B, Neufer PD (2003) Exercise induces transient transcriptional 
activation of the PGC-1alpha gene in human skeletal muscle. Journal of Physiology. 
546:851-8 
 Spina RJ, Chi MM, Hopkins MG, Nemeth PM, Lowry OH, Holloszy JO. Mitochondrial 
enzymes increase in muscle in response to 7-10 days of cycle exercise. Journal of 
Applied Physiology 80: 2250-2254, 1996. 
Day
Time AM PM AM PM AM PM AM PM AM PM AM PM AM PM AM PM AM PM AM PM AM PM AM PM AM PM AM PM AM PM
Training
Biopsy
Blood sample
Dietary assesment
1 2 3 4 5 6 7 8 13 14 159 10 11 12
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2.4 PARTICIPANT PROFILE (see Guidelines) 
  
Sixteen healthy (no current illness or history of clinical conditions that may preclude them from 
exercise) but untrained males, aged 18-35, will volunteer to participate in the study.   
 
Sample size calculations from citrate synthase activity in two studies with a similar design 
indicate that 7 (Spina et al. 1996) to 13 (Scarritt et al. 1999) subjects are required to significantly 
increase mitochondrial enzyme activity (a key outcome for this study).  These calculations are 
based on an alpha level of 0.05 and a beta level of 0.2. We propose to recruit 8 subjects in each 
group. 
 
 Spina RJ, Chi MM, Hopkins MG, Nemeth PM, Lowry OH, Holloszy JO. Mitochondrial 
enzymes increase in muscle in response to 7-10 days of cycle exercise. Journal of 
Applied Physiology 80: 2250-2254, 1996. 
 Starritt EC, Angus D, Hargreaves M. Effect of short-term training on mitochondrial ATP 
production rate in human skeletal muscle.  Journal of Applied Physiology 86: 450-454, 
1999. 
 
 
2.5 MEANS BY WHICH PARTICIPANTS ARE TO BE RECRUITED (see Guidelines) 
 
Volunteers will be recruited from the general population, including students and staff at Dublin 
City University.  The study will be advertised by e-mail (below) to provide individuals with 
information about the study and contact details.  Potential participants will be asked to come to 
the School of Health and Human Performance where they will have the study explained to them.  
They will have an opportunity to ask questions and, before leaving, will be provided with a blank 
medical history form, an explanation of the study and a blank informed consent for them to 
review.  If they wish to participate in the study they will have to provide written informed consent, 
which will be witnessed, on their next visit to the School of Health and Human Performance. 
Contact details will be provided to ensure all queries or concerns of the participant can be dealt 
with immediately. 
 
E-mail to be sent to staff and students 
The School of Health and Human Performance at DCU are conducting a research study to 
investigate the influence of the intensity of exercise training on changes in skeletal muscle that 
occur with training.  The purpose of this project is to look at the impact of training at two different 
exercise intensities for 14 days on muscle function. One group will exercise at a low intensity for 
60 minutes each day and another group will exercise at a high intensity for 30 minutes each day.  
 
We are looking for healthy males between 18-35 years, who have not been involved in regular 
exercise for the last 6 months and do not smoke.  The study would involve a fitness test on a 
bicycle followed by two weeks of exercise training.  To determine the impact of exercise on the 
muscle cells, we would take muscle biopsies from the leg at different points during the training 
programme. 
 
If you would like to hear more about this study or would consider participating, please contact 
Brendan Egan (Tel: 7008472; e-mail: brendan.egan6@mail.dcu.ie) 
 
2.6 PLEASE EXPLAIN WHEN, HOW, WHERE, AND TO WHOM RESULTS WILL BE 
DISSEMINATED, INCLUDING WHETHER PARTICIPANTS WILL BE PROVIDED WITH ANY 
INFORMATION AS TO THE FINDINGS OR OUTCOMES OF THE PROJECT? 
 
Participants will be provided with a report, which will summarise their fitness characteristics on 
the bicycle ergometer and all other relevant information such as percentage body fat and blood 
profile.  The results will form the basis for a postgraduate thesis and will be presented at scientific 
meetings or published in a scientific journal. The identity of individual participants will not be 
divulged and will only be presented as part of a group. 
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2.7 OTHER APPROVALS REQUIRED Has permission to gain access to another location, 
organisation etc. been obtained?.  Copies of letters of approval to be provided when available. 
  
 YES  NO  NOT APPLICABLE 
 
 (If YES, please specify from whom and attach a copy.  If NO, please explain when this will be 
obtained.) 
      
 
2.8 HAS A SIMILAR PROPOSAL BEEN PREVIOUSLY APPROVED BY THE REC? 
 
 YES  NO 
 
(If YES, please state both the REC Application Number and Project Title) 
 
1. The influence of exercise intensity on skeletal muscle gene expression. REC 
 
2. The influence of contraction frequency on skeletal muscle gene expression. 
REC/2006/20 
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3. RISK AND RISK MANAGEMENT 
 
3.1 ARE THE RISKS TO PARTICIPANTS AND/OR RESEARCHERS ASSOCIATED WITH YOUR 
PROJECT GREATER THAN THOSE ENCOUNTERED IN EVERYDAY LIFE? 
 
 YES  NO If YES, this proposal will be participant to full REC review 
If NO, this proposal may be processed by expedited 
administrative review 
 
3.2 DOES THE RESEARCH INVOLVE: 
 YES NO 
 use of a questionnaire? (attach copy)?   
 interviews (attach interview questions)?   
 observation of participants without their knowledge?   
 participant observation (provide details in section 2)?   
 audio- or video-taping interviewees or events?   
 access to personal and/or confidential data (including student, patient or client data) 
without the participant’s specific consent? 
  
 administration of any stimuli, tasks, investigations or procedures which may be 
experienced by participants as physically or mentally painful, stressful or unpleasant 
during or after the research process? 
  
 performance of any acts which might diminish the self-esteem of participants or cause 
them to experience embarrassment, regret or depression? 
  
 investigation of participants involved in illegal activities?   
 procedures that involve deception of participants?   
 administration of any substance or agent?   
 use of non-treatment of placebo control conditions?   
 collection of body tissues or fluid samples?   
 collection and/or testing of DNA samples?   
 participation in a clinical trial?   
 administration of ionising radiation to participants?   
 
3.3 POTENTIAL RISKS TO PARTICIPANTS AND RISK MANAGEMENT PROCEDURES (see 
Guidelines) 
 
Muscle biopsy.  There may be discomfort during the muscle biopsy with some pain and delayed 
soreness afterward.  There is a risk of bleeding, bruising, infection and scaring of the skin.  
Temporary numbness of the skin near the biopsy site may occur. 
Blood draws.  There may be discomfort during the insertion of a needle in a vein and the 
development of a small bruise at the site of puncture. 
Exercise. There is a risk of delayed muscle soreness following an exercise session in a group of 
untrained individuals.  The risk of sudden death during exercise for healthy men is 1:15000-
18000.   
  
We will take all possible precautions to avoid infection during these procedures.  Blood samples 
will be taken with sterile disposable needles, drapes, and gauze.  Reusable biopsy needles are 
cleaned and sterilized prior to use.  Sterile techniques are used during blood sampling and 
muscle biopsy procedures. 
  
Alternatives to the risks 
All of the procedures described in the methodology section of the study are standard procedures 
for the evaluation of blood and muscle tissue.  These procedures are currently the best methods 
for the questions being addressed.  The investigators are very experienced in the implementation 
of these techniques from previously published studies 
 
3.4 ARE THERE LIKELY TO BE ANY BENEFITS (DIRECT OR INDIRECT) TO PARTICIPANTS 
FROM THIS RESEARCH? 
 
 YES  NO (If YES, provide details.) 
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Participants will receive a copy of their personal results, 
body fat and fitness measurements after the study. The 
will also be provided with feedback on their responses 
to the exercise sessions and be provided with 
recommendations for exercise training. As such they 
will already have begun a regular exercise training 
programme, which if continued will result in health 
benefits in both the present and future.  
 
3.5 ARE THERE ANY SPECIFIC RISKS TO RESEARCHERS? (e.g. risk of infection or where 
research is undertaken at an off-campus location) 
  
 YES  NO (If YES, please describe.) 
 
The exposure to blood and muscle tissue and needles 
are minimal but the School of Health and Human 
Performance has standard operating procedures for the 
handling of biological products.  
 
3.6 ADVERSE/UNEXPECTED OUTCOMES (see Guidelines) 
 
The School of Health and Human Performance has the facilities to deal with all aspects of this 
study and an emergency plan for adverse events.  The laboratory is equipped with an emergency 
crash cart and defibrillator. An individual trained in Advanced Cardiac Life Support (ACLS) will be 
present during each test.  In the unlikely event of a major adverse outcome, an ambulance will be 
called and the participant will immediately be sent to Beaumont Hospital. In the unlikely event of 
a minor adverse outcome, the situation will be dealt with by the attending study physician with 
subsequent attention at the on-campus VHI SwiftCare clinic if required.  
 
3.7 MONITORING (see Guidelines) 
 
The principal investigator will be involved in all aspects of the research, including participant 
recruitment and data collection.  The research team have weekly meeting to update on all 
aspects of the study. The School of Health and Human Performance has a detailed list of 
Standard Operating Procedures for each of the protocols in this study.  All researchers, including 
students, must be familiar with the procedures and the Safety Statement before beginning data 
collection. 
 
3.8 SUPPORT FOR PARTICIPANTS (see Guidelines) 
 
This project does not require additional support for participants. 
 
3.9 DO YOU PROPOSE TO OFFER PAYMENTS OR INCENTIVES TO PARTICIPANTS? 
 
 YES  NO (If YES, please provide further details.) 
 
 
 
3.10 EXPENSE ALLOWANCE 
 
Participants will not be paid to participate in this study but we will cover any expenses associated 
with participation in this study to a maximum value of €150 
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4. INVESTIGATORS’ QUALIFICATIONS, EXPERIENCE AND SKILLS (Approx. 200 words – 
see Guidelines) 
 
Donal O’Gorman is a Lecturer in Exercise Physiology at the School of Health and Human 
Performance at Dublin City University.  Donal has been involved in the publication of numerous 
papers investigating the role of exercise in the regulation of metabolism for general health and in 
Type 2 diabetes. 
Brendan Egan is a PhD student at the School of Health and Human Performance.  Brendan 
completed an MSc in Sport Nutrition and has a wide range of experience in exercise metabolism. 
He recently completed a similar project looking at the effect of acute exercise on skeletal muscle 
gene expression. 
Paul O’Connor is a technical officer at the School of Health and Human Performance who is 
pursuing a Masters degree part-time. He has several years of experience in all aspects of 
exercise testing and research implementation  
Professor Niall Moyna is Head of Department at the School of Health and Human Performance. 
Niall has over 10 years of research experience, both in Ireland and abroad, in many aspects of 
exercise training, exercise metabolism, cardiovascular metabolism and has had over 20 research 
communications published in peer-reviewed journals.  
Brian Carson is a PhD student at the School of Health and Human Performance. Brian graduated 
from the Sport Science and Health programme at DCU with 1st class honours in 2005. He is 
currently active in similar project looking at the effect of altering the contraction frequency of 
acute exercise on skeletal muscle gene expression. 
David Ashley is a PhD student at the School of Health and Human Performance. David 
graduated from the Sport Science and Health programme at DCU with 2nd class honours in 
2005. 
Dr. Noel McCaffrey will act as the study physician.  He is a sports medicine physician with an 
adjunct position in the Faculty of Science and Health. 
Dr. Gavin McHugh will act as study physician.  He is a specialist registrar in orthopaedics and has 
been taking muscle biopsies as part of his own research. 
Dr. Ray Walls will also act as the study physician.  He is a specialist registrar in orthopaedics and 
has been taking muscle biopsies as part of his own research 
 
 
5. CONFIDENTIALITY/ANONYMITY 
 
5.1 WILL THE IDENTITY OF THE PARTICIPANTS BE PROTECTED? 
 
 YES  NO (If NO, please explain) 
      
 
 
IF YOU ANSWERED YES TO 5.1, PLEASE ANSWER THE FOLLOWING QUESTIONS: 
 
5.2 HOW WILL THE ANONYMITY OF THE PARTICIPANTS BE RESPECTED? (see Guidelines) 
 
Confidentiality is an important issue during data collection. Participant’s identity, or other personal 
information, will not be revealed or published.  Participants will be assigned an ID number under 
which all personal information will be stored in a secure file and saved in password protected file 
in a computer at DCU.  The principal investigator, graduate student and study physicians will 
have access to the data. 
 
5.3 LEGAL LIMITATIONS TO DATA CONFIDENTIALITY: (Have you included appropriate 
information in the plain language statement and consent form?  See Guidelines) 
 
 YES  NO (If NO, please advise how participants will be advised .) 
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6 DATA/SAMPLE STORAGE, SECURITY AND DISPOSAL (see Guidelines) 
 
 
6.1 HOW WILL THE DATA/SAMPLES BE STORED? (The REC recommends that all data be stored 
on campus) 
 
Stored at DCU      
Stored at another site     (Please explain where and for what 
purpose) 
      
 
6.2 WHO WILL HAVE ACCESS TO DATA/SAMPLES? 
 
Access by named researchers only       
  
Access by people other than named researcher(s)  (Please explain who and for what 
purpose) 
Other  :     (Please explain) 
       
 
6.3 IF DATA/SAMPLES ARE TO BE DISPOSED OF, PLEASE EXPLAIN HOW, WHEN AND BY 
WHOM THIS WILL BE DONE? 
 
Data will be shredded after 5 years by Dr. Donal O’Gorman. At the same time biological samples 
will be disposed of by a technician at the School of Health and Human Performance consistent 
with standard protocols for the treatment of biohazard materials. 
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7. FUNDING 
 
 
7.1 HOW IS THIS WORK BEING FUNDED? 
 This work is being funded by a grant from the Targeted Research Initiative Fund from the Faculty 
of Science & Health and postgraduate IRSCET funding. 
 
7.2 PROJECT GRANT NUMBER (If relevant and/or known) 
 N/A 
 
7.3 DOES THE PROJECT REQUIRE APPROVAL BEFORE CONSIDERATION FOR FUNDING BY 
A GRANTING BODY?  
 
 YES  NO  
 
 
7.4HOW WILL PARTICIPANTS BE INFORMED OF THE SOURCE OF THE FUNDING? 
The source of funding will be included in the plain language statement and the informed consent 
document. 
 
 
 
8. PLAIN LANGUAGE STATEMENT (Approx. 400 words – see Guidelines) 
 
Title:  The influence of training intensity on adaptations to exercise training in human skeletal muscle 
 
Principal investigators: 
Dr. Donal O’Gorman  - donal.ogorman@dcu.ie  01-7008060 
Mr. Brendan Egan  - brendan.egan6@mail.dcu.ie 01-7008472 
Metabolic Physiology Research Unit, School of Health and Human Performance, Dublin City University 
 
It is well known that exercise training has many health benefits, including weight loss and the 
prevention of diabetes and cardiovascular disease.  Despite the known benefits, we don’t fully 
understanding what changes occur in the body, especially skeletal muscle. Learning more about 
these changes would have important implications for (i) future treatments of these diseases and (ii) 
more specific exercise recommendations. 
 
The purpose of this project is to look at how the intensity/effort of exercise influences the adaptations 
to training. You will be asked to make several visits to the lab.   
 On the first visit you will have a medical examination from the doctor, to make sure you are 
suitable for the study.  You will then exercise on a bicycle for approximately 15 minutes to 
determine your fitness level. 
 On the second visit to the lab you will cycle at either 40% or 80% of your maximal ability to 
verify the intensity that you will train at.  This will take approximately 30 minutes.   
 After a week, you will begin an exercise training program lasting 14 days. You will be required 
to train every day at either 40% of your maximal ability for approximately 60-mins or 80% for 
approximately 30-mins. Your training will be supervised at all times.   
 A muscle biopsy will be taken from your leg before you start the training programme and 
following 1-, 3-, 7-, 10- and 14-days of training. A blood sample will also be taken at this time, 
and at the exercise session the previous evening. 
 For three days prior to the commencement of training you will be asked to record your daily 
food intake. You will be advised to continue this pattern of intake for the duration of the 
program. 
 
Exercise does carry a risk of injury, such as a pulled muscle, muscle soreness or in extreme cases 
abnormal heart rhythm, heart attack or death.  The benefits of being involved in this study include a 
detailed assessment of your fitness, your response to exercise and your energy use.  All information 
we gather will be stored in a secure filing cabinet.  The results of the study will be used for a 
postgraduate thesis and may be published in academic journals.  You will not be identified, as your 
information will be presented as part of a group.  Confidentiality of information provided can only be 
protected within the limitations of the law.  It is possible for data to be participant to subpoena, freedom 
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of information claim or mandated reporting by some professions.  All data will be destroyed after 5 
years. Your participation in this research project is voluntary and you may withdraw your consent at 
any time.  There will not be any penalty nor will your rights as a student or staff member of DCU be 
affected in any way.   
 
This research project is being funded from a grant awarded within DCU and the funding of a 
postgraduate student by the Irish Research Council for Science, Engineering and Technology 
(IRSCET). 
 
If participants have concerns about this study and wish to contact an independent person, 
please contact: 
The Secretary, Dublin City University Research Ethics Committee, c/o Office of the Vice-
President for Research, Dublin City University, Dublin 9.  Tel 01-7008000 
 
 
9. INFORMED CONSENT FORM (Approx. 300 words – see Guidelines) 
 
Title: The influence of training intensity on adaptations to exercise training in human skeletal muscle 
 
Principal investigators: Dr. Donal O’Gorman, and Mr. Brendan Egan: School of Health and Human 
Performance 
 
Other investigators: Brian Carson, David Ashley, Dr. Gavin McHugh, Dr. Ray Walls, Prof. Niall Moyna, 
Paul O’Connor 
 
Purpose 
The purpose of this project is to look at the impact of changing the intensity of exercise training on 
changes that occur in muscle proteins in response to 14 days of exercise training. 
 
This is what will happen during the research study 
5. I will have the purpose of the study, each of the steps involved and the risks of participating in the 
study explained to me. I will have the opportunity to ask any questions and if I am happy with the 
answers I will:  
a. Provide written informed consent for participation in the research project.  
b. I will then complete a medical history form, which will ask questions about my general 
health, personal and family health history, smoking, exercise, and dietary habits.   
c. I will talk with a medical doctor about the information I have provided and I understand, 
based on the information provided, the medical doctor may exclude me from 
participating in the research project. 
d. I will be provided with dietary advice, which I will follow for three days prior to each visit 
to the laboratory.  I will not consume caffeine or alcohol during this period. 
6. Pre-test evaluation 
a. I will have a number of measurements of my body size and shape.  Firstly, my blood 
pressure will be measured.  I will have an electrocardiogram (ECG) done to evaluate my 
heart.  This is a painless, 5 minute procedure that involves lying down and having adhesive 
pads attached to my arms, legs and chest.  My height and weight will be measured in light 
clothing, and without shoes.  My percentage body fat will be measured by the thickness of 
skin and fat on 7 sites around the body including the chest, leg, arm, back and side of the 
body. I will provide a blood sample to check some health indicators. 
b. I understand that any of these procedures or tests may be waived at the discretion of the 
doctor for the following reasons: (i) I have completed the same or similar step in the past 6 
months as part of another research protocol at the School of Health and Human 
Performance; (ii) It has been determined that I am not eligible to participate in this research 
project; and thus completion of the entire screening process will not be necessary. 
7. Exercise capacity and determination of exercise intensity 
a. I will undergo an exercise test designed to measure my fitness, and to evaluate my current 
physical condition.  I understand that I will pedal on a stationary bicycle, with the pedal 
resistance getting more difficult every 2 minutes until, fatigue, breathlessness, chest pain 
and/or symptoms that indicate to the doctor or myself that I should stop exercise.  To assess 
my fitness I will have a mouthpiece similar to a snorkel in my mouth to measure the amount 
of air I breathe in and out. 
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b. At least 4 days later, I will cycle on a stationary bike for 30 minutes to determine the 
resistance that corresponds to either 40% or 80% of my exercise capacity (depending on the 
training group that I will be assigned to).  During this time I will also wear the mouthpiece to 
determine oxygen use 
8. Impact of training on muscle cell function 
a. Approximately one week later I will begin the exercise training phase of the study. I will 
exercise on consecutive days for 14 days. 
b. I will be assigned to one of two training groups and as such will train at an intensity 
corresponding to either 40% of my maximum ability for approximately 60 minutes or at an 
intensity corresponding to 80% of my maximum ability for approximately 30 minutes 
depending on my group. I understand that I will be breathing more often, and will sweat, but 
that I will be able to maintain a conversation. 
c. I understand that all my exercise training sessions will take place in the MPRU on a 
stationary bicycle under supervision by one of the study’s investigators and that training 
sessions will take place in the late afternoon to early evening. 
d. On the morning of the first day of training, I will come to the MPRU between 0800h and 
0900h after an overnight fast, with only water taken for the previous 10 hours. After resting 
for 15 minutes, I will have a blood sample taken from my arm and a muscle biopsy taken 
from my thigh. For the biopsy I will have the area anaesthetised with local anaesthetic, then 
a small 0.5 cm incision will be made in the skin and a needle inserted briefly into the muscle.  
A small piece of muscle, less that 0.15 of a gram, will be taken from my leg.  The incision is 
pulled close with sterile strips and my leg will be wrapped snugly with an elastic bandage to 
maintain pressure. Before I leave I will be given contact information and supplies to change 
the dressing around the biopsy sites. 
e. I will then leave the lab before returning that afternoon to complete the first exercise training 
session. On the morning following the 1
st
, 3
rd
, 7
th
, 10
th
, and 14
th
 training sessions, I will report 
to the MPRU under the same fasting conditions for subsequent blood and muscle sample 
collection. I will have additional blood samples taken immediately prior to and immediately 
after the 1
st
, 3
rd
, 7
th
, 10
th
, and 14
th
 training sessions. This will complete my participation in 
the study. 
f. In preparation for the training phase I will be required to record my daily food intake in the 
three days leading up to the commencement of training. I will maintain a similar level of 
dietary intake throughout the two week training period. 
g. I will be weighed immediately prior to and immediately after each training session to 
determine the volume of fluid loss through sweating that has occurred. I will be advised to 
replace this loss with the appropriate amount of fluid based on established 
recommendations. However, I understand that water will be available ad libitum throughout 
the training sessions. 
 
Sometimes there are side effects from performing exercise tests. These side effects are often 
called risks, and for this project, the risks are: 
4. Exercise testing carries with it a very small risk of exercise induced asthma, abnormal heart 
rhythms, heart attack, or death in less than one in 30,000 patients.  The risk of sudden death 
during exercise for healthy men is 1:15000-18000.  Because I will be asked to give a maximum 
effort, I may experience some muscle soreness in my arms and legs or nausea following the 
maximal exercise test. It should be noted that if the experimental protocol is adhered to that the 
likelihood of these risks occurring is minimal. 
5. I understand that the insertion of a needle into a superficial arm vein (to take blood samples) 
should be minimally painful but a slight ache may be felt and a small bruise may appear on my 
arm.  There is also a small risk of infection, but by using the appropriate techniques this risk is 
minimal. 
6. I understand that there may be discomfort during the muscle biopsy with some pain and delayed 
soreness afterward.  There is a risk of bleeding, bruising, infection and scaring of the skin.  After 
the biopsy, my leg may feel stiff and sore.  Temporary numbness of the skin near the biopsy may 
also occur. 
 
There may be benefits from my participation in this study.  These are: 
4. I will receive a copy of my personal results, body fat and fitness measurements and energy use 
during exercise when the study is finished. 
5. I will be given guidelines to maintain or increase my physical activity/training program if I feel I 
would like to continue to exercise after the study. 
6. I understand that no other benefits have been promised me. 
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Costs associated with the study 
I understand that there will not be any payment for participation in this study but legitimate expenses to a 
maximum value of €150 will be recompensed. 
 
Participant – please complete the following (Circle Yes or No for each question) 
I have read the Plain Language Statement     Yes/No 
I understand the information provided     Yes/No 
I have had an opportunity to ask questions and discuss this study   Yes/No 
I have received satisfactory answers to all my questions    Yes/No 
 
My confidentiality will be guarded: 
Dublin City University will protect all the information about me, and my part in this study, within the 
limitations of the law.  My identity or personal information will not be revealed or published. All records 
associated with my participation in the study will be participant to the usual confidentiality standards 
applicable to medical records.  In addition, the study findings may be presented at scientific meetings and 
published in a scientific journal and/or as part of a postgraduate thesis, but my identity will not be divulged 
and only presented as part of a group.   
 
If I have questions about the research project, I am free to call Donal O’Gorman at 01-7008060.   
 
Taking part in this study is my decision.   
I understand that my participation in this study is voluntary and that I may withdraw my consent at any time 
by notifying any of the investigators.  I may also ask that the information gathered about me be removed 
from the database, or storage, and destroyed.  My withdrawal from this study, or my refusal to participate, 
will in no way affect my relationship with Dublin City University or my entitlements as a student or staff 
member.  I understand that my participation in this research may be terminated by the investigator without 
regard to my consent if I am unable or unwilling to comply with the guidelines and procedures explained to 
me.  
 
Project Funding 
This research project is being funded from an award to Dr. Donal O’Gorman from the Faculty of Science 
and Health at Dublin City University and funding for a postgraduate student from the Irish Research 
Council on Science, Engineering and Technology. 
 
Signature: 
I have read and understood the information in this form.  My questions and concerns have been answered 
by the researchers, and I have a copy of this consent form.  Therefore, I consent to take part in this 
research project 
 
Participants Signature:         
 
Name in Block Capitals:         
 
Witness:             
 
Date:                 
 
 
 
 
10. CHECKLIST 
 
Please check that all supplementary information is attached to your application (in both hard and 
soft copy). If questionnaire or interview questions are submitted in draft form, a copy of the final 
documentation must be submitted for final approval when available. 
 
 ATTACHED NOT 
APPLICABLE 
Bibliography    
Recruitment advertisement    
Plain language statement/Information Statement    
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Informed Consent form    
Evidence of external approvals related to the research    
Questionnaire  draft  final  
Interview Schedule  draft  final  
Debriefing material     
Other    
 
 
Please note: 
 
1. Any amendments to the original approved proposal must receive prior REC approval. 
 
2. As a condition of approval investigators are required to document and report immediately to the 
Secretary of the Research Ethics Committee any adverse events, any issues which might 
negatively impact on the conduct of the research and/or any complaint from a participant relating 
to their participation in the study 
 
 
Please submit the signed original, plus an electronic copy of your completed application to:  
Ms. Fiona Brennan, Research Officer, Office of the Vice-President for Research  
(fiona.brennan@dcu.ie, Ph. 01-7007816) 
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Appendix J 
 
Submission to Ethics Committee 
 
 
Dublin City University 
RESEARCH ETHICS COMMITTEE 
APPLICATION FOR APPROVAL OF A PROJECT INVOLVING HUMAN 
PARTICIPANTS 
Application No. (office use only)  DCUREC/2010/   
Period of Approval (office use only) ....../....../......to....../....../.... 
 
This application form is to be used by researchers seeking ethics approval for 
individual projects and studies. The signed original and an electronic copy of your 
completed application must be submitted to the DCU Research Ethics Committee.   
 
NB - The hard copy must be signed by the PI.  The electronic copy should consist of 
one file only, which incorporates all supplementary documentation.  The completed 
application must be proofread and spellchecked before submission to the REC.  All 
sections of the application form should be completed.  Applications which do not 
adhere to these requirements will not be accepted for review and will be returned 
directly to the applicant. 
 
Applications must be completed on the form; answers in the form of attachments will 
not be accepted, except where indicated.  No handwritten applications will be 
accepted.  Research must not commence until written approval has been received 
from the Research Ethics Committee. 
 
 
PROJECT TITLE Comparisons of two Exercise Training Programmes on 
Vascular Health in Patients with Cardiovascular Disease 
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PRINCIPAL 
INVESTIGATOR(S) 
Prof. Niall M. Moyna 
 
 
Please confirm that all supplementary information is included in your application (in 
both signed original and electronic copy). If questionnaire or interview questions are 
submitted in draft form, a copy of the final documentation must be submitted for final 
approval when available. 
 
 INCLUDED NOT 
APPLICABLE 
Bibliography    
Recruitment advertisement    
Plain language statement/Information Statement    
Informed Consent form    
Evidence of external approvals related to the 
research 
   
Questionnaire  
draft 
 
final 
 
Interview Schedule  
draft 
 
final 
 
Debriefing material     
Other    
 
 
Please note: 
 
3. Any amendments to the original approved proposal must receive prior REC 
approval. 
 
4. As a condition of approval investigators are required to document and report 
immediately to the Secretary of the Research Ethics Committee any adverse 
events, any issues which might negatively impact on the conduct of the 
research and/or any complaint from a participant relating to their participation 
in the study 
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Please submit the signed original, plus the electronic copy of your completed 
application to:  
Ms. Fiona Brennan, Research Officer, Office of the Vice-President for Research  
(fiona.brennan@dcu.ie, Ph. 01-7007816) 
 
Guidelines to Applicants 
 
1.1 PRINCIPAL INVESTIGATOR(S):  The named Principal Investigator is the person with 
primary responsibility for the research project. Doctoral researchers and Research 
Masters or their supervisors may be listed as Principal Investigators, depending on the 
conventions of the discipline and on the individual case. It should be made clear, in 
subsequent sections of this application, who is carrying out the research procedures. In 
the case of Taught Masters and undergraduate student projects the supervisors are 
Principal Investigators. 
 
2.0 PROJECT OUTLINE:  Provide a brief outline of the project, aims, methods, duration, 
funding, profile of participants and proposed interaction with them. This description 
must be in everyday language that is free from jargon.  Please explain any technical 
terms or discipline-specific phrases.  
 
2.1 LAY DESCRIPTION:  Provide a brief outline of the project, including what 
participants will be required to do.  This description must be in everyday language 
which is free from jargon.  Please explain any technical terms or discipline-specific 
phrases. (No more than 300 words). 
 
2.2 AIMS OF AND JUSTIFICATION FOR THE RESEARCH:  State the aims and significance 
of the project (approx. 400 words). Where relevant, state the specific hypothesis to be 
tested. Also please provide a brief description of current research, a justification as to 
why this research should proceed and an explanation of any expected benefits to the 
community. NB – all references cited should be listed in an attached bibliography. 
 
2.3 PROPOSED METHOD:  Provide an outline of the proposed method, including details 
of data collection techniques, tasks participants will be asked to do, the estimated time 
commitment involved, and how data will be analysed. If the project includes any 
procedure which is beyond already established and accepted techniques please include 
a description of it.  (No more than 400 words.) 
2.4 PARTICIPANT PROFILE:  Provide number, age range and source of participants.  
Please provide a justification of your proposed sample size.  Please provide a 
justification for selecting a specific gender. 
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2.5 MEANS BY WHICH PARTICIPANTS ARE TO BE RECRUITED:  Please provide specific 
details as to how you will be recruiting participants. How will people be told you are 
doing this research? How will they be approached and asked if they are willing to 
participate? If you are mailing to or phoning people, please explain how you have 
obtained their names and contact details. This information will need to be included in 
the plain language statement. If a recruitment advertisement is to be used, please 
ensure you attach a copy to this application. 
 
3.3 POTENTIAL RISKS TO PARTICIPANTS AND RISK MANAGEMENT PROCEDURES:  
Identify, as far as possible, all potential risks to participants (physical, psychological, 
social, legal or economic etc.), associated with the proposed research. Please explain 
what risk management procedures will be put in place. 
 
3.6 ADVERSE/UNEXPECTED OUTCOMES:  Please describe what measures you have in 
place in the event that there are any unexpected outcomes or adverse effects to 
participants arising from involvement in the project. 
 
3.7 MONITORING:  Please explain how you propose to monitor the conduct of the 
project (especially where several people are involved in recruiting or interviewing, 
administering procedures) to ensure that it conforms with the procedures set out in this 
application.  In the case of student projects please give details of how the supervisor(s) 
will monitor the conduct of the project. 
 
3.8 SUPPORT FOR PARTICIPANTS:  Depending on risks to participants you may need to 
consider having additional support for participants during/after the study.  Consider 
whether your project would require additional support, e.g., external counselling 
available to participants.  Please advise what support will be available. 
 
4.0 IN ESTIGATORS’ QUALIFICATIONS, EXPERIENCE AND SKILLS:  List the academic 
qualifications and outline the experience and skills relevant to this project that the 
researchers and any supporting staff have in carrying out the research and in dealing 
with any emergencies, unexpected outcomes, or contingencies that may arise. 
 
5.2 HOW WILL THE ANONYMITY OF THE PARTICIPANTS BE RESPECTED?  Please bear 
in mind that where the sample size is very small, it may be impossible to guarantee 
anonymity/confidentiality of participant identity.  Participants involved in such projects 
need to be advised of this limitation. 
 
5.3 LEGAL LIMITATIONS TO DATA CONFIDENTIALITY:  Participants need to be aware 
that confidentiality of information provided can only be protected within the 
limitations of the law - i.e., it is possible for data to be subject to subpoena, freedom of 
information claim or mandated reporting by some professions. Depending on the 
research proposal you may need to specifically state these limitations.   
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6.0 DATA/SAMPLE STORAGE, SECURITY AND DISPOSAL: For the purpose of this 
section, “Data” includes that in a raw or processed state (e.g. interview audiotape, 
transcript or analysis).  “Samples” include body fluids or tissue samples. 
 
8.0 PLAIN LANGUAGE STATEMENT:  Written information in plain language that you 
will be providing to participants, outlining the phases and nature of their involvement 
in the project and inviting their participation.  Please note that the language used must 
reflect the participant age group and corresponding comprehension level. 
 
9.0 INFORMED CONSENT FORM:  This is a very important document that should be 
addressed by participants to researchers, requiring participants to indicate their 
consent to specific statements, and give their signature. 
 
FOR FURTHER INFORMATION AND NOTES ON THE DEVELOPMENT OF PLAIN 
LANGUAGE STATEMENTS AND INFORMED CONSENT FORMS, PLEASE CONSULT THE 
DCU REC WEBSITE: WWW.DCU.IE/RESEARCH/ETHICS 
 
. ADMINISTRATIVE DETAILS 
 
 
THIS PROJECT IS:  Research Project  Funded Consultancy 
(tick as many as 
apply) 
 Practical Class  Clinical Trial 
  Student Research Project  
(please give details) 
 Other  - Please Describe:       
  Resear
chMast
ers 
 Taught Masters 
  PhD  Undergraduate 
 
Project Start 
Date: 
01/02/11 Project End 
date: 
01/06/11 
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1.1 INVESTIGATOR CONTACT DETAILS (see Guidelines) 
 
PRINCIPAL INVESTIGATOR(S):  
 
TITLE SURNAME FIRST NAME PHONE FAX EMAIL 
Prof Moyna Niall 01 7008802 01 7008888 niall.moyna@dcu.ie 
 
OTHER INVESTIGATORS: 
 
TITLE SURNAME FIRST 
NAME 
PHONE FAX EMAIL 
Dr. Mc Caffrey Noel      087 2797597 
 
01 7008888 
 
noel.mccaffrey@dcu.i
e 
 
Dr.      Woods Catherine      01 7008008 
 
01 7008888 
 
catherine.woods@dc
u.ie 
 
Dr. Murphy Ronan 01 7008824 
 
01 7008888 
 
ronan.murphy@dcu.i
e 
 
Ms.      Hughes Sarah      086 8673608      01 7008888 
 
sarah.hughes3@mail.
dcu.ie 
 
Ms. Furlong Bróna 086 3687961 
 
01 7008888 
 
brona.furlong2@mail
.dcu.ie 
 
Ms. Gray Cleona 01 8034478 01 8034252 cgray@mater.ie 
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FACULTY/DEPARTMENT/SCHOOL/ 
CENTRE: 
(NB – if Nursing, please note all students 
including PhD’s must attach the letter from 
the Nursing Ethics Advisory Committee to 
this application) 
      
 
 
1.2 WILL THE RESEARCH BE UNDERTAKEN ON-SITE AT DUBLIN CITY UNIVERSITY? 
 
 YES  NO (If NO, give details of off-campus location.) 
      
 
1.3 IS THIS PROTOCOL BEING SUBMITTED TO ANOTHER ETHICS COMMITTEE, OR 
HAS IT BEEN PREVIOUSLY SUBMITTED TO AN ETHICS COMMITTEE?) 
 
 YES  NO (If YES, please provide details and copies of 
approval(s) received etc.)   
 
 
DECLARATION BY INVESTIGATORS 
The information contained herein is, to the best of my knowledge and belief, accurate.  
I have read the University’s current research ethics guidelines, and accept responsibility 
for the conduct of the procedures set out in the attached application in accordance 
with the guidelines, the University’s policy on Conflict of Interest and any other 
condition laid down by the Dublin City University Research Ethics Committee or its Sub-
Committees.  I have attempted to identify all risks related to the research that may 
arise in conducting this research and acknowledge my obligations and the rights of the 
participants. 
 
If there any affiliation or financial interest for researcher(s) in this research or its 
outcomes or any other circumstances which might represent a perceived, potential or 
actual conflict of interest this should be declared in accordance with Dublin City 
University policy on Conflicts of Interest.  
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I and my co-investigators or supporting staff have the appropriate qualifications, 
experience and facilities to conduct the research set out in the attached application 
and to deal with any emergencies and contingencies related to the research that may 
arise. 
Signature(s): 
Principal investigator(s):      
 
Print name(s) in block letters:   Niall M. Moyna 
Date:    2 December 2010 
2. PROJECT OUTLINE  
 
5. LAY DESCRIPTION 
 Cardiac Rehabilitation is a structured exercise and education programme 
designed to help patients recover from their heart event.  It is a multi-
disciplinary approach to improve short-term recovery and to promote long-
term changes in lifestyle. Patients in Ireland currently enter an 8-10 week 
hospital-based cardiac rehabilitation programme (Phase III) after discharge 
from hospital.  This involves a gradual increase in physical activity, continuation 
of risk-factor modifications and development of maintenance programs.  This is 
followed by a community based Phase IV Cardiac Rehabilitation that aims to 
assist patients who have successfully completed a hospital based phase III 
programme.  
In 2006, DCU established a community-based phase IV Cardiac Rehabilitation 
programme (HeartSmart) in collaboration with Beaumont Hospital, The Mater 
Misericordiae University Hospital and Connolly Memorial Hospital.  The 
HeartSmart programme is located in the DCU Sport Centre.  Patients, who 
meet the inclusion criteria, are referred to the programme by the cardiac 
rehabilitation teams at the three partner hospitals.  Individuals normally attend 
2 classes per week.  The classes are normally 60 minutes in duration and 
involve primarily aerobic exercise to stress the cardiovascular system and some 
form of resistance training.  Participants exercise in small groups and rotate 
between the various exercises during a class.  Substantial improvements in 
physical fitness, psychological well being and quality of life are evident after 3-6 
months.  Further improvements in fitness levels and cardiovascular health may 
require participants to exercise at higher intensities under supervision.  
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The purpose of this study is to compare the effect of a traditional 4 week 
community based cardiac rehabilitation exercise programme (HeartSmart) and 
an individualized 4 week high intensity intermittent exercise programme on 
vascular health in individuals who have participated in HeartSmart for at least 6 
months.   Aerobic fitness and the health of the arteries (Figure 1 and 2) will be 
assessed before and at the end of the 4 weeks.  In addition blood samples will 
be taken at the same time points.  The electrical activity of the heart will be 
continuously monitored during each class. 
  
                                                    
Figure 1: Carotid artery ultrasound   Figure 2: Brachial artery 
reactivity 
2.2 AIMS OF AND JUSTIFICATION FOR THE RESEARCH  
 Cardiovascular disease (CVD) collectively refers to diseases of the heart and 
circulatory system, and typically includes coronary heart disease (CHD), stroke, 
and peripheral vascular diseases (e.g. atherosclerosis, deep vein thrombosis, 
hypertension).  Ireland has the highest mortality rate from CVD in the EU 
(40%).  The socio-economic impact of C D to Ireland and the EU is €169 
billion/year.  Physical activity plays a critical role in both the primary and 
secondary prevention of CVD.  In individuals with documented CVD, physical 
activity is an established, inexpensive, and generally safe secondary 
intervention that is associated with a 31% reduction in cardiovascular-related 
mortality.  The beneficial effects of physical activity are multifactorial and are 
related to direct and indirect protective mechanisms that impact blood vessel 
health (endothelium function, inflammation, vessel remodeling), blood clotting 
processes (platelet activation and fibrinolysis), and cardiac performance.  
Substantial improvements in physical fitness, psychological well being and 
quality of life are evident after 3-6 months.  Further improvements in fitness 
levels and cardiovascular health may require participants to exercise at higher 
intensities under supervision. 
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This study will compare the effect of a 4 week community based exercise 
programme (HeartSmart) and an individualized 4 week high intensity 
intermittent exercise programme on aerobic fitness and circulating endothelial 
cells (CEC), endothelial progenitor cells (EPC) and microparticles (MP) in 
individuals with CVD.  CEC, EPC and MP are released by a damaged 
endothelium (innermost layer of blood vessel walls), and currently little is 
known about the effect of exercise on their number and function.  Carotid 
intima media thickness (CIMT) will be used to estimate CVD.  Endothelial 
function will be assessed using flow mediated dilation (endothelial dependent) 
and endothelial independent dilation (this involves the administration of 
vasodilator, glyceryl trinitrate). 
The aim of this study is to compare the effect of a traditional 4 week 
community based exercise programme (HeartSmart) and an individualized 4 
week high intensity intermittent exercise programme on vascular health in 
patients with CVD who have participated in a community based phase IV 
Cardiac Rehabilitation programme for at least 6 months. 
The purpose of this study is to 
1. Compare the effect of a traditional 4 week community based cardiac 
rehabilitation exercise programme and an individualized 4 week high 
intensity intermittent exercise programme on vascular health in 
patients with CVD.   
2. Compare the effect of a traditional 4 week community based cardiac 
rehabilitation exercise programme and an individualized 4 week high 
intensity intermittent exercise programme on aerobic fitness in patients 
with CVD.   
3. Compare the effect of a traditional 4 week community based cardiac 
rehabilitation exercise programme and an individualized 4 week high 
intensity intermittent exercise programme on CECs, EPCs and MPs in 
patients with CVD.   
2.3  PROPOSED METHOD  
 Overview 
Subjects participating in HeartSmart for more than 6 months will be recruited.  
The study will take place in the Vascular Research Unit in the School of Health 
and Human Performance.  Subjects will be randomly assigned to a traditional 
cardiac rehabilitation (TCR) group or to an individually tailored high intensity 
intermittent exercise (HIT) training group.  Subjects in the TCR will continue to 
attend HeartSmart twice a week for the duration of the 4 week study.  Subjects 
in training group will attend 2 supervised exercise sessions per week in the 
Vascular Research Unit.  Subjects in the training group will wear electrodes on 
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their chest to monitor the electrical activity of their heart throughout the 
exercise sessions. 
Subjects will visit the laboratory for testing sessions on 2 occasions before and 
2 occasions after the 4 week exercise programme.  The first testing session will 
be used to further explain the requirements of the study, obtain informed 
consent, take a blood sample, measure CIMT and to assess endothelial 
function.  During the second testing session aerobic fitness (VO2peak) will be 
measured.  At the end of the 4 week programme the third testing session will 
be a repeat of the tests carried out during testing session 1, and similarly 
testing session 4 will consist of the same tests as carried out during testing 
session 2. . 
Traditional Cardiac Rehab Group: Subjects will attend HeartSmart twice per 
week.  They will wear a heart rate monitor during these classes each week.   
Training Group: Subjects will attend a high intensity intermittent exercise 
programme in the Vascular Research Unit twice a week.  They will wear an ECG 
during every class.  These exercise sessions will be supervised and include a 15 
min warm-up.  The sessions will involve individually prescribed programmes 
based on each subjects symptom-limited graded exercise test.  Subjects will 
perform bouts of high intensity exercise at 60-100% HRmax interspersed with 
periods of recovery.  The total duration of the high intensity intermittent 
exercise will increase from 5 min at week 1 up to 15 min at week 4.  Each 
session will take place on a treadmill.  Subjects will finish with a 10 min cool 
down and stretch.  Before and after the final interval exercise session (Session 
8) a blood sample will be drawn and endothelial function will be assessed. 
Testing Session 1:  Approximately 1.5 hour in duration.  Subjects will read and 
sign the informed consent, have their CIMT measured and their endothelial 
function assessed.  Approximately 25 ml of blood will be taken from a vein in 
the arm.  
 Testing Session 2:  Approximately 1 hour in duration.  Aerobic fitness level 
(VO2peak) will be assessed and 10 L of blood will be taken using a lancing 
device to prick the earlobe. 
Testing Session 3:  Approximately 1.5 hour in duration.  The testing procedures 
that were carried out during testing session 1 will be repeated. 
Testing Session 4:  Approximately 1 hour in duration. The testing procedures 
that were carried out during testing session 2 will be repeated. 
Carotid Intima Media Thickness (CIMT):  Thickness of the carotid intima-media 
will be assessed using a 12.0 MHz linear-array transducer (SonoSite, 
MicroMaxx).  Recordings will be obtained with the subject resting in a supine 
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position, with the head turned slightly to the contralateral side.  The common 
carotid artery, including the carotid bulb, will be visualized, and 2 longitudinal 
B-mode images of the left and the right common carotid arteries at end 
diastole will be recorded and electronically stored.  Measurements of CIMT will 
be conducted in the 10-mm linear segment proximal to the carotid bulb at 2 
plaque-free sites twice in the near wall and twice in the far wall on both sides 
and combined as mean CIMT.  The combination of readings from the near and 
far walls yields the strongest association with cardiovascular disease.  The 
artery will be scanned longitudinally without colour flow to assess the grey 
scale image, and with colour flow to identify difficult anatomy and delineate 
irregularities in plaque.  
Brachial Artery Reactivity (BAR): Endothelial dependent dilation will be 
determined in response to reactive hyperemia following 5 min of lower arm 
occlusion.  A blood pressure cuff will be placed on the left arm for blood 
pressure monitoring and another on the right lower arm for occlusion.  ECG 
leads will be attached to monitor heart rate.  Subjects will rest for 10 min in a 
supine position.  Blood pressure will be determined during the final 2 minutes 
of the rest period.  Baseline blood flow and brachial artery diameter (SonoSite, 
MicroMaxx) will be recorded.  The right arm blood pressure cuff will then be 
inflated to approximately 220-230 mmHg and maintained at that pressure for 5 
minutes.  The cuff will then be rapidly deflated after 5 min of occlusion.  
Doppler blood flow measurement will be obtained during the first minute 
following cuff deflation.  Brachial artery diameter will be assessed at one and 
three minutes post occlusion.  Subjects will then rest for 15 minutes to 
eliminate endothelium dependent effects on brachial artery diameter.  After 
this period, endothelial independent dilation will be assessed.  Baseline blood 
flow and brachial artery diameter will be recorded and used as a baseline prior 
to sublingual glyceryl trinitrate administration.  Glyceryl trinitrate (0.4mg) will 
be placed under the subjects tongue.  Doppler blood flow measurement will be 
obtained three minutes following the sublingual glyceryl trinitrate 
administration and brachial artery diameter measurements will be assessed 3 
and 5 minutes post glyceryl trinitrate administration.   
Peak Aerobic Capacity (VO2peak) Assessment:  Peak aerobic 
capacity will be determined on a treadmill using open circuit spirometry.  
During this assessment subjects will be fitted with a mouthpiece or facemask.  
ECG will be continuously monitored using a 12 lead ECG, and a physician will be 
present. 
2.4 PARTICIPANT PROFILE  
A total of 20 men aged 40-65 yr, enrolled in HeartSmart in DCU Sport’s complex 
for at least 6 months, will be recruited.  The subjects will be referred from 
Beaumont Hospital, The Mater Hospital and Connolly Memorial Hospital phase 
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III cardiac rehabilitation programme.  Subjects will have documented CVD, will 
have passed a medical and physical examination that permits them to exercise.  
Each participant’s cardiologist will be informed of his/her participation in the 
study 
Inclusion Criteria: 
 Male 
 Involved in HeartSmart programme for more than 6 months 
 Referred from Beaumont Hospital, The Mater Hospital and Connolly 
Memorial Hospital phase III cardiac rehabilitation programme 
 Stable angina 
 Able to achieve 30 min of continuous walking without symptoms 
(cardiac chest pain/discomfort, severe breathlessness, dizziness or 
palpitations) or be able to undertake activities of at least 5 METS 
(manually washing a car, digging/turning over soil, walking/jogging a 
mile in less than 15 minutes) without symptoms   
 Clinically stable and in good health for a minimum of 2 weeks prior to 
beginning the study 
Exclusion Criteria:   
Potential subjects will be excluded if 
 Current smoker  
 Unstable angina 
 Systolic blood pressure >180 mmHg and/or diastolic blood pressure 
> 100 mmHg   
 Resting tachycardia   
 Unstable or acute heart failure 
 Ventricular arrhythmias during maximal exercise test 
 Prolonged ST-segment depression (> 2mm) during maximal exercise 
test 
 Severe angina during maximal exercise test 
2.5 MEANS BY WHICH PARTICIPANTS ARE TO BE RECRUITED  
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 Men enrolled in the HeartSmart cardiac rehabilitation programme in DCU Sport 
for at least 6 months will be informed of the research study.  A brief summary 
of the study and contact details will be provided to patients enrolling in 
HeartSmart.  Following an expression of interest, potential subjects will be 
asked to visit the Vascular Research Laboratory in the School of Health and 
Human Performance.  They will be told that by agreeing to visit the laboratory 
they are not obligated to participate in the study.  The nature, benefits, risks 
and discomforts of the study will be explained.  In addition, they will be 
provided with a plain language statement, and the informed consent will be 
explained.  They will be encouraged to ask questions.  Individuals who wish to 
participate in the study will have to provide written informed consent.   
2.6 PLEASE EXPLAIN WHEN, HOW, WHERE, AND TO WHOM RESULTS WILL BE 
DISSEMINATED, INCLUDING WHETHER PARTICIPANTS WILL BE PROVIDED 
WITH ANY INFORMATION AS TO THE FINDINGS OR OUTCOMES OF THE 
PROJECT? 
 The results will form the basis for a postgraduate thesis and will be presented 
at scientific meetings and published in scientific journals.  The identity of 
individual participants will not be divulged.  Group information will only be 
presented.  Participants will be provided with a copy of their results, 
summarising information such as body mass index, blood pressure and 
cholesterol levels. 
2.7 OTHER APPROVALS REQUIRED Has permission to gain access to another 
location, organisation etc. been obtained?  Copies of letters of approval to be 
provided when available. 
  
 YES  NO  NOT APPLICABLE 
(If YES, please specify from whom and attach a copy.  If NO, please explain 
when this will be  obtained.) 
      
2.8 HAS A SIMILAR PROPOSAL BEEN PREVIOUSLY APPROVED BY THE REC? 
 
 YES  NO 
 
(If YES, please state both the REC Application Number and Project Title) 
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 REC/2010/49 EFFECT OF AN 8 WEEK COMMUNITY BASED CARDIAC EXERCISE 
REHABILIATION PROGRAMME ON  VASCULAR HEALTH IN PATIENTS WITH CARDIOVASCULAR 
DISEASE 
3. RISK AND RISK MANAGEMENT 
3.1 ARE THE RISKS TO SUBJECTS AND/OR RESEARCHERS ASSOCIATED WITH YOUR 
PROJECT GREATER THAN THOSE ENCOUNTERED IN EVERYDAY LIFE? 
 
 YES  NO If YES, this proposal will be subject to full REC review 
If NO, this proposal may be processed by expedited 
administrative review 
 
3.2 DOES THE RESEARCH INVOLVE: 
 YES NO 
 use of a questionnaire? (attach copy)?   
 interviews (attach interview questions)?   
 observation of participants without their knowledge?   
 participant observation (provide details in section 2)?   
 audio- or video-taping interviewees or events?   
 access to personal and/or confidential data (including student, 
patient or client data) without the participant’s specific consent? 
  
 administration of any stimuli, tasks, investigations or procedures 
which may be experienced by participants as physically or 
mentally painful, stressful or unpleasant during or after the 
research process? 
  
 performance of any acts which might diminish the self-esteem 
of participants or cause them to experience embarrassment, 
regret or depression? 
  
 investigation of participants involved in illegal activities?   
 procedures that involve deception of participants?   
 administration of any substance or agent?   
 use of non-treatment of placebo control conditions?   
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 collection of body tissues or fluid samples?   
 collection and/or testing of DNA samples?   
 participation in a clinical trial?   
 administration of ionising radiation to participants?   
3.3 POTENTIAL RISKS TO PARTICIPANTS AND RISK MANAGEMENT PROCEDURES  
1. Exercise testing carries with it a very small risk of abnormal heart 
rhythms, heart attack, or death in less than one in 30,000 patients.  
Subjects will be continuously monitored using a 12 lead ECG and a 
physician will be present. 
2. Drawing blood may cause a slight pain where the needle is inserted and 
can leave a bruise.  A person trained to take blood will be used to 
decrease these risks.  The amount of blood drawn is not harmful. 
3. Assessment of endothelial dependent and independent dilation will 
require restriction of blood flow for 5 minutes.  This may cause slight 
discomfort in the arm, which will go away after the blood pressure cuff 
in deflated.  The glyceryl trinitrate used may induce a headache that 
may last 5 - 10 minutes. 
Alternatives to the risks  
It is not possible to assess endothelial dependent and independent dilation 
without the use of brachial artery reactivity and the administration of glyceryl 
trinitrate.  Subjects will be informed that they must refrain from Viagra, PDE5 
inhibitors and all other sexual enhancers (herbal or otherwise) 48 hours prior to 
participation in the study.   
Analysis of cardiovascular biomarkers cannot be undertaken without a sample 
of blood.  The investigators are certified and experienced in phlebotomy and 
ultrasonography. 
3.4 ARE THERE LIKELY TO BE ANY BENEFITS (DIRECT OR INDIRECT) TO 
PARTICIPANTS FROM THIS RESEARCH? 
 
 YES  NO Participants will be provided with a copy of their 
results, summarising information such as blood 
pressure and fitness levels       
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3.5 ARE THERE ANY SPECIFIC RISKS TO RESEARCHERS? (e.g. risk of infection or 
where research is undertaken at an off-campus location) 
  
 YES  NO Working with blood and needles carries risks, 
however the exposure to blood and needles is 
minimal and the School of Health and Human 
Performance has standard operating procedures for 
the handling of biological products. 
3.6 ADVERSE/UNEXPECTED OUTCOMES  
 The School of Health and Human Performance has the facilities to implement 
all aspects of this study and has an emergency plan for adverse events.  In the 
unlikely event of a major adverse outcome, an ambulance will be called and the 
participant will immediately be sent to Beaumont Hospital. In the unlikely 
event of a minor adverse outcome, the situation will be dealt with by the 
attending study physician with subsequent attention at the Mater Smithfield 
Rapid Injury Clinic if required.   
3.7 MONITORING 
 The principal investigator will be involved in all aspects of the research, 
including participant recruitment and data collection.  The research team will 
have weekly meetings to update on all aspects of the study. The School of 
Health and Human Performance has a detailed list of Standard Operating 
Procedures for each of the protocols in this study.  All researchers, including 
students, must be familiar with the procedures and the Safety Statement 
before beginning data collection. 
3.8 SUPPORT FOR PARTICIPANTS  
This project does not require additional support for participants 
3.9 DO YOU PROPOSE TO OFFER PAYMENTS OR INCENTIVES TO PARTICIPANTS? 
 
 YES  NO (If YES, please provide further details.)      
4. IN ESTIGATORS’ QUALIFICATIONS, EXPERIENCE AND SKILLS (Approx. 200 
words – see Guidelines) 
Prof. Moyna is an exercise physiologist and has extensive experience in 
cardiovascular research. 
Dr. Noel McCaffrey is a physician with extensive experience in exercise related 
research 
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Ms. Sarah Hughes is a graduate student in the School of Health and Human 
Performance, DCU.  She has extensive experience in studies involving human 
experimentation, and has undertaken extensive training in ultrasonography 
under the guidance of Cleona Gray, Chief Vascular Technologist in the 
Department of Vascular Surgery in the Mater Hospital, Dublin.  Sarah is also a 
certified phlebotomist. 
Dr Ronan Murphy has 12 years of post PhD experience and training in cell and 
molecular biology, vascular biology, and thrombosis & haemostasis. He 
received his undergraduate degree and Ph.D. with NUI Galway. Following this 
he worked for two years as a Clinical Research Scientist in the field of 
Pharmacogenomics. He was awarded a Fellowship from the HRB to work on 
bleeding disorders.  Thereafter, he went to work for Prof. S.J. Shattil, at The 
Scripps Research Institute, San Diego (2000-2003). He has also been a visiting 
scientist to the Blood Research Institute, Milwaukee, USA. 
Dr. Catherine Woods is Head of the School of Health and Human Performance, 
Catherine and Dr. Noel McCaffrey established the community based 
HeartSmart cardiac rehabilitation program in DCU.  Dr Woods is actively 
involved in the co-ordination of the HeartSmart classes. 
Brona Furlong has recently graduated first in her class with a 1st class honours 
degree in Sports Science and Health.  She is currently enrolled as a PhD student 
in the School of Health and Human Performance.  She has extensive experience 
in blood sampling and research involving human subjects.  Brona will assist 
with data collection and supervising classes. 
Cleona Gray is Senior Vascular Technologist in the Vascular Lab in the Mater 
Hospital.  Cleona has trained Sarah Hughes and Brona Furlong in 
Ultrasonography.  Cleona’s involvement in the research project will continue in 
the form of a supervisory and troubleshooting role.  She will provide technical 
support in performing carotid and brachial ultrasound scanning 
5. CONFIDENTIALITY/ANONYMITY 
5.1 WILL THE IDENTITY OF THE PARTICIPANTS BE PROTECTED? 
 
 YES  NO (If NO, please explain) 
      
IF YOU ANSWERED YES TO 5.1, PLEASE ANSWER THE FOLLOWING QUESTIONS: 
5.2 HOW WILL THE ANONYMITY OF THE PARTICIPANTS BE RESPECTED?  
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Confidentiality is an important issue during data collection.  Participant’s 
identity and other personal information will not be revealed, published or used 
in further studies.  Subjects will be assigned an ID number under which all 
personal information will be stored in a secure locked cabinet and saved in a 
password-protected file in a computer at DCU.  The principal investigator, and 
collaborators listed on this ethics application will have access to the data. 
5.3 LEGAL LIMITATIONS TO DATA CONFIDENTIALITY: (Have you included 
appropriate information in the plain language statement and consent form?  
See Guidelines) 
 
 YES  NO (If NO, please advise how participants will be 
advised.) 
      
6 DATA/SAMPLE STORAGE, SECURITY AND DISPOSAL (see Guidelines) 
6.1 HOW WILL THE DATA/SAMPLES BE STORED?  (The REC recommends that 
all data be stored on        campus) 
 
Stored at DCU      
Stored at another site     (Please explain where 
and for what purpose) 
6.2 WHO WILL HAVE ACCESS TO DATA/SAMPLES? 
Access by named researchers only       
  
Access by people other than named researcher(s)  (Please explain who and 
for what purpose)  
Other  :     (Please explain) 
       
6.3 IF DATA/SAMPLES ARE TO BE DISPOSED OF, PLEASE EXPLAIN HOW, WHEN 
AND BY WHOM THIS WILL BE DONE? 
The principal investigator will be responsible for security of the data.  The data 
will be kept in locked cabinet in the Cardiovascular Research Unit in the School 
of Health and Human Performance in DCU. Access to the data will only be 
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attainable by the named researchers.  Data will be kept for a minimum of five 
years from the date of publication of the research.  Aside from the named 
researchers, no others will have access to the raw data.  Data will be shredded 
by Prof. Moyna after 5 years. 
7. FUNDING 
7.1 HOW IS THIS WORK BEING FUNDED? 
 School of Health and Human Performance/CLARITY – SFI 
7.2 PROJECT GRANT NUMBER (If relevant and/or known) 
 P07625 - SFI  07/CE/I1147 
7.3 DOES THE PROJECT REQUIRE APPROVAL BEFORE CONSIDERATION FOR 
FUNDING BY A GRANTING BODY? 
 
 YES  NO  
7.5 HOW WILL PARTICIPANTS BE INFORMED OF THE SOURCE OF THE FUNDING? 
 Participants will be informed of the source of funding in the Plain Language 
Statement. 
7.5 DO ANY OF THE RESEARCHERS, SUPERVISORS OR FUNDERS OF THIS PROJECT 
HAVE A PERSONAL, FINANCIAL OR COMMERCIAL INTEREST IN ITS OUTCOME 
THAT MIGHT COMPROMISE THE INDEPENDENCE AND INTEGRITY OF THE 
RESEARCH, OR BIAS THE CONDUCT OR RESULTS OF THE RESEARCH, OR 
UNDULY DELAY OR OTHERWISE AFFECT THEIR PUBLICATION? 
 
 YES  NO (If Yes, please specify how this conflict of 
interest will be addressed.) 
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Plain Language Statement 
Dublin City University 
Project Title: Comparisons of two Exercise Training Programmes on Vascular 
Health in Patients with Cardiovascular Disease 
The Research Study will take place in the School of Health and Human 
Performance, DCU. 
The principal investigator is:  Prof. Niall M. Moyna, (Tel:  7008802, Fax: 7008888, 
Email: niall.moyna@dcu.ie) 
I. Disease of the heart and blood vessels is called cardiovascular disease 
(CVD), and is the main cause of death in Ireland.  CVD increases the 
thickness of blood vessels, and also reduces the ability of blood vessel 
to dilate (get bigger).  We can use a simple ultrasound procedure to 
measure the health of your blood vessel.  Tiny pieces of the damaged 
blood vessel wall break off into the blood and these can be measured 
by taking a blood sample.  People who exercise regularly have less 
chance of getting CVD.  People who have CVD also can reduce their risk 
of having a heart attack or stroke by exercising regularly).  The purpose 
of this study is to compare the effect of a traditional cardiac 
rehabilitation exercise programme and the effect of a high intensity 
exercise programme on your fitness level and the health of your blood 
vessels over the course of 4 weeks.  You will be allowed to take part in 
the study if you meet the entry criteria and sign the informed consent.  
II. If you agree to take part in the study you will attend exercise sessions in 
the Vascular Research Unit in the School of Health and Human 
Performance in DCU twice a week for 4 weeks.  In addition to this you 
will have 2 testing sessions carried out before you begin this training 
programme and 2 at the end (Testing Session 1, 2, 3 and 4).  You will 
not be allowed to exercise for at least 24 hours before each of these 
Testing Sessions.   
III. Before the study begins you will be assigned by chance to either a 
traditional cardiac rehabilitation exercise group, which is called the 
Control Group or an Interval Training Group. 
Control Group:  If you are assigned to the traditional cardiac 
rehabilitation group, you will be asked to visit the School of Health and 
Human Performance in DCU on 2 occasions before the 4 weeks begin 
and on 2 occasions at the end of the 4 weeks.  You will continue 
participating in the HeartSmart classes two days per week.  During each 
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class you will wear a strap around your chest to monitor your heart 
rate.  
Intermittent Exercise Group: If you are assigned to the interval training 
group, you will visit to the Vascular Research Unit in the School of 
Health and Human Performance in DCU for the first 2 Testing Sessions 
before the 4 week programme begins and for the second 2 Testing 
Sessions at the end of the 8 weeks.   You will attend exercise sessions in 
the Vascular Research Unit, DCU 2s days per week for 4 weeks.  During 
each exercise session you will wear small pads (ECG) and a  strap 
around your chest to monitor your heart rate.  
Testing Session 1:   
 The first Testing Session will take place in the Vascular Research 
Unit in the School of Health and Human Performance in DCU 
and will last approximately 1.5 hours 
 You will sign an informed consent and an ultrasound picture will 
be taken of a blood vessel in your neck   
 You will have a blood sample taken (about 2 tablespoons) 
 The health of a blood vessel in your arm will be measured using 
an ultrasound to take an image of your blood vessel. This will 
involve blocking the blood flow to your arm for 5 minutes using 
a blood pressure cuff and taking one spray of glyceryl trinitrate 
under your tongue.  You will be fasting before this test 
 If you are taking Viagra, other PDE5 inhibitors or any herbal 
sexual enhancers you will not take any of these for at least 48 
hours before this testing visit 
Testing Session 2 
 This session will last about 1 hour 
 Your fitness level will be measured 
 During your fitness assessment you will wear a mouthpiece and 
exercise on a treadmill  
 You will wear small pads on your chest (ECG) to monitor your 
heart throughout exercise   
 A small droplet of blood will be taken from the earlobe before 
and after the exercise test  
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Testing Session 3   
 The third Testing Session will take place at the end of the 4 
weeks again in the Vascular Research Unit in DCU and will last 
approximately 1.5 hour   
 You will undergo the same tests as you did during Testing 
Session 1   
 If you are taking Viagra, other PDE5 inhibitors or any herbal 
sexual enhancers you will not take any of these for at least 48 
hours before this testing visit 
Testing Session 4 
 The fourth testing session will also take place at the end of the 4 
weeks again in the Vascular Research Unit in DCU and will last 
approximately 1 hour 
 Your fitness will be assessed in the same way as Testing Session 
2 
Interval Exercise sessions    
 The Interval Exercise Sessions will be monitored in the Vascular 
Research Unit   
 You will wear small pads (ECG) and a strap around on your chest 
to monitor your heart throughout exercise  
 During the second and eighth interval sessions you will wear a 
mouthpiece or a facemask during the exercise  
 You will have the health of your arteries assessed and blood 
samples drawn before and after the final (eighth) session 
 If you are taking Viagra, other PDE5 inhibitors or any herbal 
sexual enhancers you will not take any of these for at least 48 
hours before interval session 8. 
 You will fast for at least 10 hours prior to interval session 8. 
III.  1.  Exercise testing carries with it a very small risk of abnormal heart 
rhythms, heart attack, or death in less than one in 30,000 patients.  
Your heart will be continuously monitored using a 12 lead 
electrocardiogram (ECG) and a physician will be present.  A 12 lead ECG 
is a special machine that takes 12 different views of your heart (like 
photographs) while you are exercising.  You will have electrodes placed 
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on your chest to allow the researchers observe the electrical activity of 
your heart during exercise. 
2.  Drawing blood may cause a slight pain where the needle is inserted 
and may leave a bruise.  A person trained to take blood will be used to 
decrease these risks.   
3.  Taking an ultrasound image of your arm requires blocking the blood 
flow to your arm for 5 minutes using a blood pressure cuff.  This may 
cause slight discomfort in your arm, which will go away after the blood 
pressure cuff in deflated.  The glyceryl trinitrate spray used in this study 
may cause a headache that could last 5 to 10 min. 
IV. Your confidentiality will be guarded.  All information we gather will be 
stored in a secure filing cabinet.  The results of the study will be used 
for a postgraduate project and may be published in academic journals. 
You will not be identified, as your information will be presented as part 
of a group.  You will be assigned an ID number under which all personal 
information will be stored in the secure locked filing cabinet and saved 
in a password protected file in a computer at DCU.  You need to be 
aware that confidentiality of information provided can only be 
protected within the limitations of the law.  It is possible for data to be 
subject to subpoena, freedom of information claim or mandated 
reporting by some professions.  
VI. Involvement in this study is completely voluntary.  You may withdraw 
from the Research Study at any point.  Withdrawal from this study will 
not affect your participation in the HeartSmart programme or the 
medical treatment of your condition. 
VII. This research is funded by Science Foundation Ireland. 
VIII. If you have concerns about this study and wish to contact an 
independent person, please contact: The Secretary, Dublin City 
University Research Ethics Committee, c/o Office of the Vice-President 
for Research, Dublin City University, Dublin 9.  Tel 01-7008000 
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Informed Consent 
Dublin City University 
Project Title Comparisons of two Exercise Training Programmes on Vascular 
Health in Patients with Cardiovascular Disease 
Principal Investigator Prof. Niall M. Moyna 
Introduction to this study 
Disease of the heart and blood vessels is called cardiovascular disease (CVD), and 
is the main cause of death in Ireland.  Measuring the thickness of the carotid 
artery in your neck using ultrasound can indentify CVD.  CVD damages blood 
vessels and reduces their ability to dilate (get bigger).  We can also use a simple 
ultrasound procedure to measure how much the blood vessels can dilate.  
Damaged blood vessels release cells into the blood, which can be measured by 
taking a blood sample.  Regular physical activity improves the health of blood 
vessels, and also has a beneficial effect on many of the risk factors for CVD.  This 
study will measure the health of your blood vessels.  In addition, we will compare 
the effect of a traditional 4 week cardiac rehabilitation programme and the effect 
of a high intensity intermittent exercise programme on your fitness level and the 
health of your blood vessels. 
Participants Requirements 
1. I will take part in a 4 week exercise programme in the Vascular Research Unit 
in the School of Health and Human Performance in DCU.  I will visit DCU for a 2 
Testing Sessions before and 2 at the end of the 4 weeks.  
Traditional Cardiac Rehab Group:  If I am assigned to this group, after Testing 
Sessions 1 and 2, I will continue participation in the HeartSmart classes twice 
per week.  During each class I will wear a strap around my chest to monitor my 
heart rate.  After 4 weeks of HeartSmart I will return to the Vascular Research 
Unit for my 3rd and 4th exercise testing visit. 
Intermittent Training Group: If I am assigned to the Intermittent 
training group I will attend 2 supervised exercise sessions per week in the 
Vascular Research Unit, DCU. During every session I will wear small pads on 
my chest and a strap around my chest to monitor my heart.  After 4 weeks of 
intermittent training I will return to the Vascular Research Unit for Testing 
Session 3 and 4. 
2. During my first Testing Session (which lasts approximately 1.5 hour), I will have 
a blood sample taken and an ultrasound measurement will be taken of my 
neck to measure my carotid artery (See Figure 1).  This test is painless and lasts 
about 15 min.  I will also have a blood sample taken from a vein in my arm.  
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The total amount of blood drawn will be 2 tablespoons.  The health of an 
artery in my arm will also be measured. If I am taking Viagra, other PDE5 
inhibitors or any herbal sexual enhancers I will not take any of these for at 
least 48 hours before this testing visit. 
3. My second Testing Session will last about 1 hour and I will have my fitness 
assessed.  During this test the electrical activity of my heart will be assessed by 
a 12 lead electrocardiogram (ECG).  This is a special machine that takes 12 
different views of my heart (like photographs).  I will have electrodes (small 
pads) placed on my chest and a heart rate monitor to allow the researchers 
observe the electrical activity of my heart during exercise. I will be fitted with a 
mouthpiece and will undergo a treadmill exercise test to assess my fitness 
level.   
4. At the end of the 4 week programme, I will return to the Vascular Research 
Unit in the School of Health and Human Performance DCU for my third Testing 
Session.  This will be a repeat of the tests carried out during Testing Session 1.  
If I am taking Viagra, other PDE5 inhibitors or any herbal sexual enhancers I 
will not take any of these for at least 48 hours before this testing visit. 
5. Testing Session 4 will be a repeat of the test carried out during during Testing 
Session 2. 
6. During the 4 week exercise programme, all training sessions will take place in 
the Vascular Research Unit in DCU.   
- During these sessions I will wear a mouthpiece and walk on a treadmill 
-  I will have a small droplet of blood taken from my earlobe at the end 
of each session  
- I will wear electrodes and a strap on my chest to monitor my heart 
throughout the exercise 
- Before and after the last exercise session I will have a blood sample 
taken and the  health of a blood vessel in my arm will be measured.  I 
will fast for 10 hour before this session.  If I am taking Viagra, other 
PDE5 inhibitors or any herbal sexual enhancers I will not take any of 
these for at least 48 hours before the last exercies sessions (Session 8). 
7. I will not exercise for at least 24 hours before each visit to the Vascular 
Research Unit. 
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6. To test the health of the arteries in my neck (testing session 1) I will lie on my 
back and an ultrasound will be placed on my neck and a number of 
photographs of the artery will be taken. 
7. To test the health of the arteries in my arm (exercise session 2 and 3, and 
testing session 2) I will lie on my back, and an ultrasound will be placed on my 
upper arm to create an image of my artery.  After the first image is recorded, a 
blood pressure cuff will be inflated on my forearm to block blood flow for five 
minutes.  This may be uncomfortable.  The cuff will be released and the images 
of my arteries repeated.  I will rest for 15 minutes and then have one spray of 
glyceryl trinitrate under my tongue.  The glyceryl trinitrate will cause my arm 
arteries to enlarge and how much they enlarge will again be documented by 
taking a third set of pictures.  
                                     
Potential risks to participants from involvement in the Research Study  
1.  Exercise testing carries with it a very small risk of abnormal heart rhythms, heart 
attack, or death in less than one in 30,000 patients. Your heart will be continuously 
monitored using a 12 lead ECG and a physician will be present. 
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2.  Drawing blood may cause a slight pain where the needle is inserted and can 
leave a bruise.  A person trained to take blood will be used to decrease these risks. 
3.  The amount of blood drawn is not harmful, however, if I have a history of 
anaemia, I should inform the investigator. 
4.  The pictures of my arm arteries require blocking the blood flow to my arm for 5 
minutes.  This may cause slight discomfort in the arm, which will go away after the 
blood pressure cuff in deflated.  The glyceryl trinitrate used in this study may 
induce a headache that could last 5 to 10 min.   
Benefits (direct or indirect) to participants from involvement in the Research 
Study 
After completing the study I will be provided with a copy of my results, 
summarising information such as my body mass index, blood pressure and 
cholesterol levels.  There are no other direct benefits to me. 
Participant – please complete the following (circle Yes or No for each question) 
Have you read or had read to you the Plain Language Statement?        Yes  No 
 
Do you understand the information provided?    Yes  No 
 
Have you had an opportunity to ask questions and discuss this study? Yes  No 
 
Have you received satisfactory answers to all your questions?  Yes  No 
 
Advice as to arrangements to be made to protect confidentiality of data, 
including that confidentiality of information provided is subject to legal 
limitations. 
Your identity and other personal information will not be revealed, published or 
used in further studies.  You will be assigned an ID number under which all 
personal information will be stored in a secure locked cabinet and saved in a 
password protected file in a computer at DCU.  The named investigators will have 
access to the data.  Data will be shredded after 5 years by Prof. Moyna. 
Confidentiality is insured, but you must be aware that confidentiality of 
information provided can only be protected within the limitations of the law.  It is 
possible for data to be subject to subpoena, freedom of information claim or 
mandated reporting by some professions. 
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If you are in a dependent relationship with any of the researchers their 
involvement in the project will not affect ongoing assessment/grades/management 
or treatment of health at DCU. Withdrawal from this study will not affect your 
participation in the HeartSmart programme or the medical treatment of your 
condition. 
Signature: 
I have read and understood the information in this form.  The researchers have 
answered my questions and concerns, and I have a copy of this consent form.  
Therefore, I (print name) ______________________ consent to take part in this 
research project entitled Comparisons of two Exercise Training Programmes on 
Vascular Health in Patients with Cardiovascular Disease.  
Participants Signature:  ____________________________________ 
Name in Block Capitals       
Witness:          
Date:          
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Appendix L 
VO2max Protocol 1 
Stage Time Speed Slope 
Warm Up 2:00 3.4 0.0 
1 2:00 4.0 2.5 
2 2:00 4.0 5.0 
3 2:00 4.0 7.5 
4 2:00 4.0 10.0 
5 2:00 4.0 12.5 
6 2:00 4.0 15.0 
7 2:00 4.0 17.5 
8 2:00 4.0 20.0 
9 2:00 4.0 22.5 
10 2:00 4.0 22.5 
11 99:00 4.0 22.5 
Recovery 5:00 3.2 0.0 
 
VO2max Protocol 2 
Stage Time Speed Slope 
Warm Up 2:00 4.0 0.0 
1 2:00 4.8 2.5 
2 2:00 4.8 5.0 
3 2:00 4.8 7.5 
4 2:00 4.8 10.0 
5 2:00 4.8 12.5 
6 2:00 4.8 15.0 
7 2:00 4.8 17.5 
8 2:00 4.8 20.0 
9 2:00 4.8 22.5 
10 2:00 4.8 22.5 
11 99:00 4.8 22.5 
Recovery 5:00 3.2 0.0 
 
  
247 
 
VO2max Protocol 3 
Stage Time Speed Slope 
Warm Up 2:00 3.4 0.0 
1 2:00 5.5 2.5 
2 2:00 5.5 5.0 
3 2:00 5.5 7.5 
4 2:00 5.5 10.0 
5 2:00 5.5 12.5 
6 2:00 5.5 15.0 
7 2:00 5.5 17.5 
8 2:00 5.5 20.0 
9 2:00 5.5 22.5 
10 2:00 5.5 22.5 
11 99:00 5.5 22.5 
Recovery 5:00 3.2 0.0 
 
VO2max Protocol 4 
Stage Time Speed Slope 
Warm Up 2:00 6.0 0.0 
1 2:00 6.0 2.5 
2 2:00 6.0 5.0 
3 2:00 6.0 7.5 
4 2:00 6.0 10.0 
5 2:00 6.0 12.5 
6 2:00 6.0 15.0 
7 2:00 6.0 17.5 
8 2:00 6.0 20.0 
9 2:00 6.0 22.5 
10 2:00 6.0 22.5 
11 99:00 6.0 22.5 
Recovery 5:00 3.2 0.0 
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VO2max Protocol 5 
Stage Time Speed Slope 
Warm Up 2:00 7.0 0.0 
1 2:00 9.0 2.5 
2 2:00 9.0 5.0 
3 2:00 9.0 7.5 
4 2:00 9.0 10.0 
5 2:00 9.0 12.5 
6 2:00 9.0 15.0 
7 2:00 9.0 17.5 
8 2:00 9.0 20.0 
9 2:00 9.0 22.5 
10 2:00 9.0 22.5 
11 99:00 9.0 22.5 
Recovery 5:00 3.2 0.0 
 
 
